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Lihua Ye 
THE ROLES OF PANCREATIC HORMONES IN REGULATING PANCREAS 
DEVELOPMENT AND ΒETA CELL REGENERATION 
 
Diabetes mellitus is a group of related metabolic diseases that share a common 
pathological mechanism: insufficient insulin signaling. Insulin is a hormone secreted 
from pancreatic β cells that promotes energy storage and consequently lowers blood 
glucose. In contrast, the hormone glucagon, released by pancreatic α cells, plays a critical 
complementary role in metabolic homeostasis by releasing energy stores and increasing 
blood glucose. Restoration of β cell mass in diabetic patients via β cell regeneration is a 
conceptually proven approach to finally curing diabetes. Moreover, in situ regeneration 
of β cells from endogenous sources would circumvent many of the obstacles encountered 
by surgical restoration of β cell mass via islet transplantation. Regeneration may occur 
both by β cell self-duplication and by neogenesis from non-β cell sources. Although the 
mechanisms regulating the β cell replication pathway have been highly investigated, the 
signals that regulate β cell neogenesis are relatively unknown. In this dissertation, I have 
used zebrafish as a genetic model system to investigate the process of β cell neogenesis 
following insulin signaling depletion by various modes. Specifically, I have found that 
after their ablation, β cells primarily regenerate from two discrete cellular sources: 
differentiation from uncommitted pancreatic progenitors and transdifferentiation from α 
cells. Importantly, I have found that insulin and glucagon play crucial roles in controlling 
β cell regeneration from both sources. As with metabolic regulation, insulin and glucagon 
play counter-balancing roles in directing endocrine cell fate specification. These studies 
have revealed that glucagon signaling promotes β cell formation by increasing 
differentiation of pancreas progenitors and by destabilizing α cell identity to promote α to 
β cell transdifferentiation. In contrast, insulin signaling maintains pancreatic progenitors 
in an undifferentiated state and stabilizes α cell identity. Finally, I have shown that 
insulin also regulates pancreatic exocrine cell development. Insufficient insulin signaling 
destabilized acinar cell fate and impairs exocrine pancreas development. By 
understanding the roles of pancreatic hormones during pancreas development and 
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regeneration can provide new therapeutic targets for in vivo β cell regeneration to 
remediate the devastating consequences of diabetes.  
 
Ryan M. Anderson, Ph.D., Chair 
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CHAPTER ONE: Introduction 
 
I.A. Diabetes Mellitus and β Cell Regeneration 
Diabetes Mellitus is a group of metabolic diseases characterized by hyperglycemia 
that results from insufficient insulin secretion, insulin action, or both. Due to different 
mechanisms of pathology, diabetes can be mainly classified into two types: Type 1 
diabetes Mellitus (T1DM) and Type 2 diabetes Mellitus (T2DM) (3). The development of 
T1DM is mainly due to the destruction of β cells by autoimmune attack which leads to 
absolute insulin deficiency. Severe hyperglycemia and appearance of auto-immunity 
antibodies are usually found in T1DM patients (4). In contrast, patients with T2DM 
usually have elevated blood glucose levels, but normal or elevated insulin levels. T2DM 
is strongly associated with genetic disposition and results from the progressive 
impairment of β cell function and loss of β cell mass in the setting of insulin resistance 
(5). In addition to these two main types of diabetes, the prevalance of gestational diabetes 
mellitus (GDM), the induction of maternal insulin resistance and hyperglycemia during 
pregnancy, has been increasing over time, and is associated with long term impact on the 
metablic profiles of the child (6) 
 
i. Current therapeutic approaches for diabetes treatment 
The pathological differences between T1DM and T2DM require different therapeutic 
interventions. Currently, insulin or insulin analogue treatments are the main approach for 
T1DM. The administration of exogenous insulin is essential for glycemic control and 
survival of people with T1DM (7), and although such therapies have dramatically 
reduced its mortality, several disadvantages limit this approach. First, the requirement for 
frequent insulin injection not only decreases quality of life, but also imposes huge long-
term financial burdens, both at a personal level, and upon the public health system (8). 
Secondly, exogenous insulin administration cannot perfectly mimic endogenous β cell 
function, and chronically high levels of peripheral insulin resulting from insulin 
injections will exacerbate insulin resistance in the peripheral tissues (9,10). Finally, and 
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most importantly, exogenous insulin administration does not cure the disease. Whether 
patients are using manual insulin injections or an insulin pump, hyperglycemia will return 
upon cessation of insulin therapy (11). 
As compared with T1DM, more therapeutic options have been developed for patients 
with T2DM. For most T2DM patients, therapy starts with lifestyle changes including 
weight loss and exercise (12). When these changes alone cannot achieve the goal of 
glycemic control, metformin is usually selected as the first-line treatment due to its 
efficacy, safety, and low cost (13). Eventually for most T2DM patients, metformin must 
be combined with other pharmaceutical treatments that target various physiological 
processes including insulin secretion, peripheral tissue insulin uptake, renal glucose 
retention, and intestinal glucose absorption (14). Besides these, bariatric by-pass surgery 
has also been used to improve the metabolic profile and glycemic control of T2DM 
patients with severe obesity (15).  However, in most cases, these treatments can only 
temporarily decrease hyperglycemia, and are not able to permanently reverse T2DM (16). 
Due to the progressive nature of T2DM and the decline of β cell function and mass over 
time, many patients with T2DM eventually require insulin therapy to achieve glycemic 
control (14). In summary, although current therapeutic strategies have enhanced glycemic 
control and reduced mortality for patients with diabetes, none of these therapies 
represents a permanent cure. Exogenous insulin administration is required for both 
T1DM and T2DM at late stages that present with severe β cell deterioration. Thus, in 
spite of the etiological differences between T1DM and T2DM, loss of β cell quantity and 
function underlie the pathology and development of both forms of the disease. 
Therefore, understanding how to restore β cell function and increase β cell mass and 
thereby provide a permanent cure to diabetes through recovery of endogenous 
insulin secretion has become a primary goal of metabolic research (17).  
 
ii. β cell regeneration: a pathway toward curing diabetes 
In theory, restoration of sufficient β cell mass could be achieved by augmentation of β 
cell number from either endogenous or exogenous sources. The former includes the 
stimulation of endogenous repair mechanisms, while the latter includes transplantation of 
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islets, differentiated β cells, or undifferentiated β cell progenitors. The first clinical 
attempt at islet transplantation in T1DM patients was carried out in the 1980s; this 
transplantation protocol has significantly advanced in recent years, which has brought 
hope for the cure of diabetes (18). In the most successful studies, about 60% of patients 
remained insulin independent for one year after islet transplantation, and that 10% 
remained insulin independent at 5 years (18). Besides T1DM, increasing evidence has 
also demonstrated the efficiency of pancreas transplantation in the treatment of T2DM 
(19). In fact, pancreas transplantation in Type 2 diabetics complicated with end-stage 
renal disease results in outcomes as successful as those patients with T1DM (20). These 
encouraging results have bolstered the hypothesis that replenishment of pancreatic β cells 
reverses the course of diabetes, and is so far the closest approximation to a cure.  
However, there are still great challenges with the islet transplantation strategy (21). 
First, there is a great shortage of donor islets. Second, immunosuppression is required to 
prevent allogenic rejection-induced islet cell death and to block the triggering of 
autoimmunity. This prolonged immunosuppression not only increases the risk of 
infection and cancer, but also dampens endogenous β cell regeneration in mouse models 
(22), which may actually worsen diabetes progression. In the past decade, researchers 
have focused on stem cells as a source for generating unlimited β cells in vitro to 
overcome these obstacles, and great progress has been achieved towards this goal. By 
mimicking events of embryonic pancreas development, human embryonic stem (hES) 
cells or induced human pluripotent stem cells (hiPS) can be directed to differentiate into 
definitive endodermal cells (23). These cells can be further differentiated into pancreatic 
endodermal cells, the progenitors of β cells. When transplanted into mice, these 
pancreatic endodermal cells efficiently differentiate into functional β cells (24). Moreover 
the implantation of these hES derived pancreatic endodermal cells can fully reverse 
diabetes in a mouse model (24). Clinical trials using hES-derived pancreatic endodermal 
cells and an immuno-protective delivery system are underway to evaluate the efficiency 
and safety of this approach in humans (25). More recent findings have further pushed the 
differentiation of pancreatic endodermal cells toward mature β cells in vitro (26).  These 
in vitro differentiated β cells express markers of endogenous β cells, secrete insulin in a 
glucose-regulated manner, and critically, transplantation of these cells ameliorated 
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hyperglycemia in diabetic mice (26). Altogether, these findings have generated great 
optimism for the future of diabetes therapies that restore β cell mass via generation and 
transplantation of functional insulin-producing cells. 
Despite these advances, significant challenges remain. These include surgical risks, 
immune suppression, the risk of tumor formation from stem cells, and the ethical hurdles 
associated with acquiring human embryonic stem cells (27). Moreover, transplantation to 
the liver through the portal vein is currently the most common site for islet 
transplantation; however, this location does not provide the same innate pancreatic islet 
environment necessary to restore accurate regulation of blood glucose (28,29). For all of 
these reasons, promoting endogenous β cell regeneration in the pancreas will have many 
advantages over in vitro artificial β cell generation and transplantation.  
 
iii. Evidence for the existence of endogenous β cell regeneration in humans 
Multiple studies have shown that the majority of long-duration T1DM patients have 
detectable C-peptide levels and endogenous insulin secretion (30-32). Further, the 
secretion of C-peptide increases after a meal, indicating the presence of functional β cells 
in these patients (30).  These observations imply that a small percentage of β cells escape 
from autoimmune destruction, and/or that continuous, low-level β cell regeneration occur 
in these T1DM patients. The latter hypothesis of endogenous β cell regeneration is also 
supported by indirect evidence that β cells are present in long-duration T1DM patients, in 
spite of on-going apoptosis (33). However, the frequency of residual C-peptide decreases 
with time, indicating that the endogenous β cell regeneration may eventually become 
exhausted (32). In support of the hypothesis that endogenous β cell regeneration occurs 
early in disease progression, the replication rate of β cells is significantly higher in on-set 
T1DM patients than in age-matched controls and β cell replication rates decline with the 
progression of disease (34). However, even though these studies support the hypothesis 
that endogenous β cell regeneration exists in human T1DM patients, clearly regeneration 
is very limited as it is incapable of preventing diabetes progression (35). 
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In T2DM, it is also well recognized that β cells can regenerate and compensate for 
increased physical demands in early stages following the on-set of insulin resistance (36). 
However, for those who proceed to develop frank diabetes, this β cell adaption is 
temporary and β cell mass ultimately degenerates (36,37). While the ability to regenerate 
persists after the onset of T2DM, continual metabolic or physiologic stresses may inhibit 
endogenous β cell regeneration (38). This insufficiency of β cell regeneration may 
therefore be a tipping point for T2DM development.  
Therefore, in both T1DM and T2DM patients, the ability to regenerate new β cells 
exists at early disease stages; however, as this capacity becomes exhausted, the disease 
progresses. For decades, it has been believed that β cell depletion is due to a mechanism 
of increased β cell death triggered by intolerable environmental and intracellular stresses. 
However, recent findings suggest that this may not be the only cause. Studies from two 
independent groups have shown that when β cells lack critical metabolic sensors, e.g. 
FoxO transcription factors or the KATP channel Kir6.2, β cells undergo dedifferentiation 
rather than apoptosis (39,40). These β cells degranulate and begin to express a gene 
expression profile similar to pancreatic progenitors. These observations indicate that β 
cell fate is not rigidly fixed, and that endocrine cells actively adapt to environmental 
stress to prevent further cellular metabolic stress (39,40). If this mechanism is translatable 
to human diabetes, novel therapeutic strategies will be needed to coax these 
dedifferentiated β cells back to a differentiated state. Nevertheless, finding mechanisms 
to augment endogenous β cell regeneration or awaken new cellular sources will 
provide promising future directions for both T1DM and T2DM treatments.  
 
I.B. Pancreas development: from progenitor to endocrine and exocrine lineages 
It is clear that many aspects of tissue regeneration mirror embryonic development 
(41-43). Therefore, understanding the cellular and molecular mechanisms of β cell 
formation during embryonic development is critical for developing new therapies that 
promote endogenous β cell regeneration in children and adults with diabetes. In 
vertebrates, insulin-secreting β cells and other hormone secreting endocrine cells, 
including glucagon-secreting α cells, somatostatin-secreting δ cells, pancreatic 
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polypeptide-secreting PP cells and ghrelin-secreting ε cells, cluster together to form islet-
like structures scattered within the pancreatic exocrine tissues (44). Among all the 
pancreatic endocrine cells, β cells and α cells are the two most plentiful endocrine cell 
types and together they make up ~95% of islet cell mass (44). The exocrine pancreatic 
compartment comprises acinar cells and duct epithelium cells, and is responsible for the 
synthesis and secretion of digestive enzymes into the duodenum (44). 
Although the pancreas is a complex organ composed of different cell types that 
perform different physiology functions, all of these cells originate from one group of 
progenitors in the foregut endoderm during the early organogenesis. Therefore, β cell 
formation during development is studied within the scope of whole pancreas 
differentiation program.    
 
i. The morphological aspects of pancreas development  
The morphology of pancreas development is represented in Figure 1-1. A series of 
signals released from nearby mesoderm and ectoderm imposes patterning on the foregut 
endoderm, which gives rise to stomach, duodenum, and accessory gut tissue like liver and 
pancreas. In mammals, pancreatic progenitors bud out from two discrete areas of the 
foregut endoderm, and are termed the dorsal and ventral pancreatic buds. The ventral 
pancreas progenitors arise from the posterior ventral foregut, which also gives rise to the 
liver and gall bladder, while dorsal progenitors evaginate from the dorsal foregut adjacent 
to duodenum and stomach progenitors (45,46). Although the signals that initiate these 
two pancreatic buds are different, the progenitor cells themselves have similar gene 
expression profiles, and both can differentiate into endocrine and exocrine pancreatic 
cells (44). In successive developmental stages, the closure and rotation of the endodermal 
tube, together with the uneven growth of the duodenum wall, leads to fusion of the 
ventral and dorsal pancreatic buds (47). 
After evagination from the main endoderm tube, the pancreatic buds undergo 
extensive proliferation and expansion. Continuous tubular structures develop in the 
pancreatic progenitor domain, followed by the specification and patterning of pancreatic 
progenitors, resulting in formation of a bipotent “trunk” domain and multipotent “tip” 
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domain (48). The cells located at the trunks exhibit bipotency, and can give rise to 
pancreatic ductal cells or endocrine islet cells at later stages. The cells residing at the tips 
of the branches exhibit multipotency, and can differentiate into all the pancreatic cellular 
linages including acinar cells, duct cells, and the endocrine cell lineages (48). This 
specification of different early pancreatic progenitor domain is also referred as “primary 
transition”.  In the mouse pancreatic development, the primary transition spans from 
embryonic day (e)9.5 to e12.5 (49). 
Following the primary transition, the progenitor cells continue branching into 
surrounding mesenchymal tissues, which provide cues for their growth and 
differentiation. The differentiation of pancreatic progenitor cells into acinar cells, duct 
cells, and endocrine cells is referred to as the “secondary transition” (49). The period of 
the secondary transition in mouse spans from e12.5 to birth. Although the trunk cells 
remain bipotent for duct and endocrine through the rest of pancreatogenesis, the tip cells 
lose their mutipotency during the secondary transition and become limited to acinar cell 
differentiation (50). During this process, endocrine progenitors delaminate from the trunk 
region, then migrate, replicate, and differentiate into specific endocrine subtypes, and 
finally they aggregate into islet structures (51,52). Interestingly, for the endocrine cells, 
the differentiation program is not completely synchronous with exocrine pancreas 
development, as there is an early wave of endocrine differentiation during the primary 
transition stage. These early-differentiated endocrine cells primarily consist of glucagon 
and insulin expressing cells (53-55). Although great understanding of endocrine 
differentiation has been achieved within last few decades, the programing and biological 
functions of these early-differentiated endocrine cells still remain unknown.  
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 Figure 1-1. Pancreas development in the mouse. Dorsal and ventral pancreatic progenitor 
domains initiate in the endodermal sheet at e8.5. Signals secreted from the notochord and 
dorsal aorta promote dorsal pancreas formation. Signals secreted from cardiac and 
septum transversum mesoderm promote liver cell fate, but inhibit ventral pancreas cell 
fate. At e9.5 early pancreatic progenitors continue to to bud from the endoderm. First 
wave α cells differentiate in the progenitor domain. At e10.5, the pancreatic progenitor 
domain continues to expand. First wave α and β cells can be detected. At e12.5, the 
pancreatic progenitors start to branch into the surrounding mesenchymal tissues and two 
distinct domains, the “tip domain” and “trunk domain,” are formed. Later (>e13.5), 
pancreatic progenitors start to differentiate. Acinar cells differentiate from progenitors 
located at the tips of the branches. Endocrine progenitors differentiate from duct 
structures and the five endocrine cell lineages migrate and cluster into islets.  Modified 
from Kim, S. K. and MacDonald R.J. 2002 (56) and Zaret, K. S. 2008 (57). 
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From the perspective of β cell regeneration, the study of pancreas development can 
provide insight into the following questions: (1) which cells have the potential to become 
β cells and (2) how can this process be facilitated for therapeutic treatment? In general, β 
cells can be generated from stem cells or from β cell relatives, including the closely 
related endocrine cells or more distant exocrine relatives. Revealing the innate genetic 
programing of different pancreatic cell linages and the extracellular signaling guiding 
them during pancreas development will facilitate the in vitro differentiation of stem cells 
and the in vivo reprograming of β cell relatives.  
 
ii. Innate genetic programing during pancreas development 
Each differentiated cell expresses its identity through the expression of a unique 
genetic program (58). The transition of progenitor cells into mature differentiated 
pancreatic cell types is a dynamic process that encompasses the active evolution of 
cellular identities.  Through the use of varied powerful genetic tools including gene 
knock-out, gene knock-in and genetic lineage tracing, this dynamic process during 
pancreas development has been largely revealed. During pancreatogenesis, the key 
transcription factors described in sections below play important roles in defining cell 
identity, and loss of these results in selective impairment of pancreas maturation.  
 
Pdx1 and Ptf1a: “master regulators” of the pancreas 
Pancreas and duodenal homeobox 1 (Pdx1) is considered one of the key master genes 
initiating the pancreas differentiation program as well as regulating mature β cell identity. 
Pdx1 is expressed in the early dorsal and ventral pancreatic progenitor domains, as well 
as in the duodenum and lower parts of the stomach (59).  Although Pdx1 is continually 
expressed throughout pancreas development, its expression subsides in all but the trunk 
branches, which give rise to the pancreatic duct and to endocrine cells (48). High levels 
of Pdx1 are limited to islet β cells in adult pancreas (60).  Knockout of Pdx1 results in 
complete absence of adult pancreas tissues (59).  Further, in the absence of Pdx1, 
pancreatic progenitor expansion is arrested, and only a small number of short-lived β-like 
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cells and clusters of α-like cells are evident (61). This indicates that Pdx1 is not required 
for the differentiation of early wave endocrine cells.  The importance of Pdx1 in pancreas 
development has also demonstrated in human studies: mutation of PDX1 in humans 
causes permanent neonatal diabetes due to pancreas agenesis (62). 
Pdx1 is also crucial for β cell function and maintenance β cell identity.  Conditional 
knockout of Pdx1 in β cells impairs essential β cell gene expression, and leads to 
depletion of β cells and the development of diabetes (63).  Molecular analyses indicate 
that Pdx1 binds to the promoter regions of key β cell functional genes where it promotes 
gene expression (64).  Interestingly, loss of Pdx1 in β cells results in an increased 
expansion of islet α cells and δ cells at the expense of β cell quantity (63).  On the other 
hand, enforcing Pdx1 expression in pancreatic endocrine progenitors results in 
destabilized α cell fate and reprograming of α cells into β cells (65,66).  All these data 
indicate that in addition to regulating the Glucose Stimulated Insulin Secretion (GSIS) 
machinery in β cells, Pdx1 also plays a role in guiding and stabilizing pancreatic 
endocrine lineages during development.  
Besides the important role of Pdx1, Pancreas transcription factor 1a (Ptf1a) is a 
second key gene that coordinates with Pdx1 to regulate pancreas progenitor fates (67,68).  
In contrast to Pdx1, the endodermal expression of Ptf1a is limited to the pancreatic 
progenitor domain.  Lineage tracing experiments indicate that like Pdx1+ cells, Ptf1a+ 
cells in the early pancreatic progenitor domain give rise all the pancreatic cell types 
including acinar, duct and endocrine cells; this suggests that the expression of Ptf1a is 
important to maintain the multipotency of pancreatic progenitors (67). Indeed, loss of 
Ptf1a via gene knockout in mouse model results in severe impairment of pancreas 
development including complete absence of acinar cells (67). Furthermore, mutation of 
PTF1A in humans also causes pancreatic agenesis, which results in permanent neonatal 
diabetes (69).  
Besides its important role in pancreatic progenitors, Ptf1a also acts as a master gene 
for maintaining acinar cell function. During the primary transition, global pancreatic 
Ptf1a is eventually restricted to the tip region of the pancreatic branches from which the 
mature acinar cells arise.  In adult pancreas, the expression of Ptf1a is limited to acinar 
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cells, where it directs the transcriptional activity of secretory digestive enzyme genes 
(48,70).  Interestingly, suppression of Ptf1a activity in differentiated pancreatic acinar 
cells facilitates reprogramming of acinar cells into insulin+ cells (71). This evidence 
illustrates a level of plasticity in pancreatic cells and hints at how certain key 
transcription factors may play critical roles in maintaining the stability of individual 
pancreatic fates. As with Pdx1, the roles of Ptf1a in regulating pancreas development and 
acinar cellular function are highly conserved among different species (72,73).  
 
Ngn3 and Neurod1: Triggers for endocrine cell differentiation 
In contrast to Pdx1 and Ptf1a, the basic helix-loop-helix (bHLH) transcription factor 
neurongenin3 (Ngn3) is only transiently expressed in endocrine progenitors, when they 
exit the cell cycle and begin differentiating into endocrine cells (74,75). Ngn3 marks all 
precursors of pancreatic endocrine cells, and mice lacking Ngn3 fail to generate any 
pancreatic endocrine cells and die postnatal from diabetes (74).  However, although there 
is a complete endocrine absence in Ngn3 knockouts, the exocrine pancreas including duct 
and acinar cells is relatively normal, indicating that Ngn3 plays a specific role in 
pancreatic endocrine lineages.  Importantly, as Ngn3 knockouts lack expression of all 
characteristic pancreatic endocrine genes, this indicates that Ngn3 has an important role 
in the initial specification of endocrine lineages from the progenitor pool (74,76).  
Furthermore, lineage tracing with Ngn3-creER has indicated that Ngn3+ early progenitor 
cells give rise to all the endocrine lineages, but not to acinar or duct cells. This provides 
direct evidence that Ngn3+ cells are islet progenitors (75).  In mouse, there are two waves 
of pancreatic Ngn3 expression.  In the first, Ngn3 is expressed from e8.5 to e11 and in the 
second wave, Ngn3 expression starts at ~e12.5, the initial phase of the secondary 
transition (53).  These two waves of Ngn3 expression coincide with the two waves of 
pancreatic endocrine cell formation.  Although it is clear that the second wave endocrine 
cell formation requires Ngn3, the primary endocrine cells still form in the absence of 
Ngn3, indicating that Ngn3 by itself is not necessary for the first wave of pancreatic 
endocrine differentiation.  Interestingly, although Ngn3 has a crucial role in determining 
endocrine lineage in mouse models, mutation of NGN3 in humans results in a much 
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milder phenotype (77).  While NGN3 is expressed in human early pancreatic endocrine 
progenitors, persons with NGN3 mutations are not diabetic, and present all the pancreatic 
endocrine cell types.  This indicates that the role of NGN3 in the regulation pancreatic 
endocrine cell linages is not conserved among all vertebrates.  
The Neurogenic differentiation factor 1 (Neurod1) is widely expressed during 
development. It is first detectable in early pancreatic progenitors during the primary 
transition, and continues to be expressed in pancreatic β cells throughout development.  
Genetic lineage tracing has demonstrated that these early Neurod1+ cells give rise to all 
the β cells and part of the α cell population, but not to δ cells or PP cells (78,79).  
Accordingly, knockout of Neurod1 in mouse results in a significant reduction in the 
number of insulin producing β cells, failure to develop mature islets, and death shortly 
after birth due to severe diabetes (80).  In addition, α cell quantity is also reduced in 
Neurod1 null mice (81).  Conditional knockout of Neurod1 in differentiated β cells 
results in a reduction of insulin gene expression and mis-expression of other pancreatic 
hormones; this indicates that Neurod1 is required for β cells to achieve and maintain 
functional maturity (82).  The critical role of Neurod1 in β cell formation and 
maintenance is also conserved in humans.  Homozygous mutation of NEUROD1 results 
in permanent neonatal diabetes, and heterozygous mutations are strongly associated with 
T2DM (83,84).  Interestingly, although Neurod1 is a critical transcription factor 
regulating endocrine pancreas development, and it is not expressed in the exocrine 
pancreas, Neurod1 null mouse models show impairment of exocrine pancreas and loss of 
acinar granules (80).  These observations indicate that the development of endocrine and 
exocrine pancreas are connected, and that the change in the endocrine component can 
influence the exocrine component structure. 
 
Arx and Pax4: Antagonistic determinants of endocrine cell fate determination. 
The homeobox-containing transcription factor Aristaless related homeobox (Arx) is 
expressed throughout the genesis of the pancreas, and is subsequently expressed in islet 
cells. Knockout of Arx leads to progressive hypoglycemia, and mice die shortly after 
birth. Histological analysis has indicated that Arx mutant mice show a loss of α cells and 
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PP cells and concomitantly, increased quantities of β and δ cells; this suggests that Arx 
plays an important role in specifying α cell fate during endocrine progenitor 
differentiation (85).  Further, the forced expression of Arx in pancreatic progenitors, 
endocrine progenitors, or differentiated β cells drives α and PP cell fates by conversion of 
β cells (86), indicating that Arx is necessary and sufficient for α cell differentiation and 
inhibition of β cell fate.  This is interpretation is further supported by the observations 
that suppression of endogenous Arx is necessary to maintain β cell identity (87).  Lastly, 
humans ARX null mutations lead to deficiency of α and PP cell types, demonstrating that 
ARX has a conserved role in vertebrate pancreas development (88). 
Next, the gene Paired Box 4 (Pax4) is expressed in the early pancreatic domain, but is 
later restricted to β cells.  Pax4 knockout results in the absence of β and δ cells, but an 
increase of α and PP cell quantity, which is opposite to Arx mutants (89).  Further, Arx 
and Pax4 inhibit each other at the transcriptional level, suggesting a model for early islet 
cell specification in which endocrine progenitors are confronted with the choice of 
becoming precursors of either β -/δ-cells or α-/PP-cells.  These fates are are promoted by 
Pax4 and Arx, respectively (85,90).  Finally, the heterozygous mutation of Pax4 gene 
leads to early on-set diabetes, indicating that PAX4 has a conserved role in human β cell 
development (91).  
The preceding sections summarize data that have uncovered roles for certain crucial 
transcription factors in the determination of specific pancreatic cellular lineages. The 
development of the pancreas is highly regulated by the expression of these integrated 
transcription factor cascades.  However, the delineation of this complex gene network 
prompts this question: how is this complex network regulated by developmental signals 
and changing physiological demands?  
 
iii. Extracellular signals direct pancreas development 
When pancreatic progenitors bud from the endoderm, they have a multitude of 
differentiation potentials.  During the process of pancreas development, each of these 
progenitor cells receives guidance from neighboring cells and in turn provides its own 
environmental cues.  In addition to these local factors, pancreas development also 
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requires the integration of many systemic factors, including circulating and neuronal 
factors, and this environment milieu influences cellular programing.  At the same time, 
the evolving internal programing alters cellular responses to the environmental cues. 
Moreover, environmental signals will continue to maintain the final differentiated 
identities of constituent cells so they may integratively fulfill the pancreatic functions. 
During gastrulation, the embryo generates three primary germ layers: endoderm, 
mesoderm and ectoderm.  After gastrulation, a series of morphologic movements 
transform the endoderm into a primitive gut tube surrounded by mesoderm.  After this is 
established, induction of the dorsal pancreatic bud requires Fibroblast Growth Factor 
(Fgf) secreted from the notochord.  This suppresses SHH in the endoderm and initiates 
Pdx1 expression in the dorsal pancreatic progenitor domain (92,93).  In addition to the 
notochord, transient interaction of the dorsal aorta with the pancreatic progenitor domain 
is crucial for the early steps of pancreas development (94). However, the molecular cues 
emanating from the dorsal aorta are still unclear.  In contrast to dorsal pancreas induction, 
the induction of ventral pancreas initiation is less understood.  The ventral pancreas is 
derived from a precursor population in a ventral endodermal region that lies near the 
developing heart (95).  Using embryo tissue explant culture experiments, it was found 
that the ventral foregut endoderm defaults to a pancreatic program.  However, FGF 
signaling from cardiac and septum transversum mesoderm diverts these progenitor to 
express liver genes instead of pancreas, and this occurs partially through activation of 
SHH signaling (95). 
After the induction of the pancreatic progenitor fields, the differentiation of these 
cells requires signals from the surrounding mesenchymal tissues, neurons, blood vessels, 
and the autocrine or paracrine signals secreted from the developing pancreatic epithelium.  
The early interaction between pancreatic epithelium cells and surrounding mesenchymal 
tissues is crucial for exocrine pancreatic differentiation.  The mesenchyme secretes 
growth factors like Fgf that induce pro-exocrine effects, and depletion of mesenchyme 
reveals a “default” endocrine differentiation program (96-99).  Besides mesenchymal 
tissues, the signals secreted from islet innervating neurons also play a part in endocrine 
differentiation and islet architecture.  For example, islet maturation and islet clustering 
are impaired when parasympathetic neuron innervation is blocked during development 
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(100).  Interestingly, blood vessel invasion also influences pancreas development not 
only via nutrient supply, but also by endothelial signals.  For example, VEGF-induced 
hyper-vascularization inhibits pancreas tip progenitor differentiation and decreases 
pancreas size (101,102).  Lastly, it is clear that during development, pancreatic epithelial 
cells themselves secrete growth factors to self-regulate their differentiation and 
proliferation.  For instance, TGF-β is necessary for pancreatic duct development and 
restricts the progenitor differentiation toward endocrine lineages.  Inhibition of TGF-β 
signaling promotes endocrine cell differentiation (103,104).  In constrast, EGF secreted 
from pancreatic epithelia promotes β cell formation.  EGF receptor agonists in pancreatic 
organ cultures expand Pdx1 expression and promote β cell formation at the expense of 
acinar cells (105).  In addition to soluble growth factors, pancreatic progenitor fates are 
regulated through direct cellular interactions.  Notch signaling, the best understood of 
these, mediates multiple steps of pancreas development.  Mutation of Notch ligand or its 
downstream effectors in mice resulted in an accelerated and over-abundant commitment 
of the embryonic pancreatic epithelium into the endocrine lineage, suggesting that notch 
signaling prevents endocrine differentiation of these progenitors (106,107) and permits 
expansion of progenitor domain (108).  Consistent with these data, Notch signaling 
represses Ngn3 and Ptf1a, two transcription factors that determine endocrine and 
exocrine lineages (see above).  Additionally, repression Notch signaling is thought to be 
required for both endocrine and exocrine pancreas differentiation (109-111) .  Although 
the Notch target gene Hes1 is rarely expressed in adult pancreas, in certain injury models 
Notch signaling is reactivated, and this appears crucial for pancreas regeneration 
mechanisms (112-114). 
 
I.C. The role of Glucagon/GLP-1 and Insulin hormones in pancreas development  
The question of how of the quantities of each endocrine cell subtype are determined 
during development, and maintained in maturity in the face of physiological flux, is of 
obvious importance to understanding metabolic disease.  While the final pancreas size is 
directly determined by the number of pancreatic progenitor cells (115), this observation 
still does not answer the question of how the ratio of different cell types within the 
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pancreas is determined. Developmental genetics studies have shown how certain 
transcription factors influence the balance of different endocrine subtypes, revealing that 
competitive expression of these transcription factors within progenitor cells may 
determine the final islet endocrine distribution.  Yet, it still does not answer the question 
of how the transcription factor levels are controlled.  One mechanism that balances 
hormone levels within the mature, functioning endocrine system is negative feedback 
regulation.  Multiple examples of feedback regulation also happen during development, 
and this opens the question of whether hormonal feedback mechanisms are present during 
pancreatic endocrine cell development.  In the following section, I focus on the two most 
important counterbalancing pancreatic hormones, glucagon and insulin, and discuss the 
current understanding of their influence on pancreas development.  
 
i. glucagon gene products and signaling  
Activation of the proglucagon gene leads to the transcription of proglucagon mRNA 
which can then be translated into proglucagon peptides.  In mature islet α cells, this 
proglucagon peptide is chiefly processed into glucagon and other fragments via the 
activation of prohormone processing enzyme Proprotein Convertase 2 (PC2). Besides the 
α cells, proglucagon mRNA is also expressed in intestinal enteroendocrine L cells and 
certain neurons.  However, in these non-α cells, the preproglucagon peptide is processed 
by different prohormone processing enzyme PC1. Processing of preproglucagon by PC1 
leads to the production of glucagon-like peptide 1 (GLP-1), but not glucagon. 
Previous studies have shown that glucagon and GLP-1 selectively bind to the 
Glucagon receptor (Gcgr) and GLP-1 receptor (GLP-1r), respectively, and that this 
activates divergent physiological functions.  Affinity binding analysis indicates that high 
levels of Gcgr are found in the liver, adipocytes, cardiac muscle (116,117).  In addition, 
Gcgr is expressed abundantly in β cells.  Activation of Gcgr can stimulate multiple 
downstream signaling pathways including the cAMP-PKA pathway, elevated 
intracellular calcium signals, and the AMPK signaling pathway (118).  Glucagon can act 
as local signal to regulate insulin secretion and β cell functions (118).  Knock-out of Gcgr 
in mice results in reduced insulin secretion in response to glucose (119).  Conversely, 
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over-expression of Gcgr in β cells promotes insulin secretion and increased β cell mass, 
indicating that glucagon signaling exhibits a positive role in β cell function (120).  
GLP-1 belongs to the incretin class of hormones that lower glucose and stimulate 
insulin secretion (121) and the physiological functions of GLP-1 are quite different from 
glucagon.  In some regards, it elicits physiological actions opposite to glucagon.  The 
biological functions of GLP-1 include GSIS stimulation, increase of insulin biosynthesis, 
and inhibition of glucagon secretion, (121).  Within in the pancreas, GLP-1r is highly 
expressed in β cells and duct tissues (122).  In α cells, GLP-1r is highly expressed during 
fetal development, but is decreased by adulthood (123), though a subpopulation of α cells 
may retain weak expression of GLP-1r in adults (122).  Besides the endocrine pancreas, 
GLP-1r is also weakly expressed in acinar cells.  The direct effects of GLP-1 on β cell 
insulin secretion are unclear, despite much study (124).  As with the Gcgr, GLP-1r is a G-
protein coupled receptor.  Activation of GLP-1r drives cAMP production and activates 
the downstream PKA signaling pathway. PKA then directly acts on insulin secretory 
machinery, or indirectly promotes insulin secretion by elevating intracellular calcium 
levels.  In addition, treatment with the GLP-1r agonist Exendin-4 in adults can increase β 
cell mass (125).  Finally, activation of the GLP-1r stimulates the PI3K and PKA 
pathways to drive proliferative and anti-apoptotic effects in β cells (126,127). 
 
ii. Insulin gene products and signaling  
As with GLP-1, insulin is also processed by the prohormone peptide preproinsulin by 
protein convertase 1 (PC1).  In all vertebrates, insulin is mainly produced by the β cells, 
with some neural production as well (128,129).  Insulin secreted from the β cells is 
critical for maintaining metabolic homeostasis.  Insulin receptor (Insr) is ubiquitously 
expressed in most cell types, but exhibits highest levels in metabolically active tissues 
like liver, muscle and adipocytes (130).  In peripheral metabolic tissues, activation of Insr 
stimulates glucose uptake and energy storage (131). Insulin signaling also plays crucial 
roles in regulating embryonic development and tissue growth.  Activation of Insr induces 
phosphorylation of its major substrates Insulin Receptor Substrate 1 (IRS1) and -2 
(IRS2), which then stimulate downstream pathways.  These include PI3K-Akt and Ras-
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Raf-MAPK pathways (132).  Insulin signaling regulates gene expression through Foxo 
proteins, a subclass of the fork-head transcription factor family.  Activation of PI3K-Akt 
via insulin stimulation can shuttle Foxo out of the nucleus, thus relieving Foxo-mediated 
repression of insulin target genes (133). 
Within the pancreas, Insr is expressed in islet cells, and Insulin signaling has crucial 
roles in regulating islet hormone secretion.  Both in vitro and in vivo studies have shown 
that glucose-regulated glucagon secretion requires Insr expression in α cells (134,135).  
Moreover, knockout of Insr in β cells impairs insulin secretion in response to glucose 
stimulation, and leads to progressive loss of glucose tolerance (136).  These data indicate 
that insulin acts as an autocrine and paracrine factor to regulate islet functions.  Besides 
endocrine components, it is also shown that insulin receptor also expressed in pancreatic 
duct cells and acinar cells (137).  Activation of Insr is important for acinar cell functions: 
it regulates digestive enzyme biosynthesis and secretion (138).  
 
iii. Glucagon/GLP-1 and Insulin regulate pancreas development  
Although the vast majority of Glucagon/GLP-1 and Insulin signaling research has 
focused on their physiological roles in metabolism, some limited data have shown that 
these two signals may also have important roles in pancreas development.  In rodents, 
disruption of glucagon signaling not only results in hypoglycemia as expected, but also 
induced significant changes in pancreas and islet phenotypes.  Loss of glucagon signaling 
produces a dramatic expansion of α cell mass, but no significant change in β cells (139).  
Interestingly, many α cells that develop in the absence of Glucagon mis-express β cell-
specific markers, like Pdx1 and Glut2.  Although there is no significant change of β cell 
quantity in Gcgr-/- adult mice, β cell functions and expression of key β cell genes is 
significantly reduced (140).  This indicates that Glucagon is involved in β cell 
maturation.  Moreover, studies using in vitro pancreatic explant cultures have indicated 
that Glucagon signaling is required for the induction of early β cells (141).  These 
findings indicate that Glucagon can stimulate β cell differentiation and insulin expression.  
Moreover, increased calcium influx also increases insulin promoter activity, which may 
also partially explain Glucagon-induced insulin gene transcription (142).  Together, these 
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results indicate that Glucagon exhibits β cell-promoting activities during development.  
However, the mechanisms of glucagon-regulated β cell generation are still unclear. 
There is accumulating evidence that GLP-1 signaling protects against β cell injury 
and promotes β cell regeneration, but there is little evidence for a role for GLP-1 during 
pancreas and β cell development.  Knockout GLP-1r in mice results in impaired glucose 
responses in β cells, but no significant morphological changes in the pancreas and islet 
(143).  However, studies of in vitro β cell differentiation show that exendin-4 treatment 
promotes early induction of β cells from pancreatic progenitors (144).  In adult pancreas, 
GLP-1r is highly expressed in β cells and a subpopulation of pancreatic duct cells (122).  
However, the expression pattern of GLP-1r in fetal pancreas is not clear.  Furthermore, 
previous studies have identified a population of adult pancreatic duct cells that exhibit a 
potential for β cell differentiation, and this can be accelerated by GLP-1r activation (125).  
This suggests that GLP-1 acts locally to regulate β cell development, and this is 
underscored by the GLP-1r knockout studies (145).  
In spite of the clear evidence for insulin signaling in regulating metabolism, little is 
known about the role of Insulin in regulating pancreas development and β cell 
neogenesis.  It has been shown that in embryonic stem cells (ESC), insulin signaling is 
need for self-maintenance; blocking insulin signaling promotes differentiation of ESC 
(146).  Similar phenomena have been seen in hematopoietic stem cells and adult 
intestinal stem cells (147,148).  Together, these studies indicate that the organ 
development is tightly linked with metabolism.  Thus, pancreatic progenitor expansion 
and differentiation are likely to be regulated by Insulin, as it is a key nutrient sensor.  
Indeed, abundant evidence shows that Insulin signaling is required for β cell 
compensation and glucose homeostasis in adults.  Insr is globally expressed in both 
endocrine and exocrine pancreatic compartments, and much interest has focused on the 
autocrine effects of insulin signaling in regulating β cell proliferation.  For instance, 
knockout of Insr in β cells impairs glucagon tolerance and results in failure of β cell 
compensation due to the blockage of β cell proliferation (136). 
The autocrine stimulation of insulin signaling in β cells plays an important role in 
facilitating Pdx1 expression and normal β cell function by controlling Foxo transcription 
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factor localization (149).  Interestingly, knockout of Foxo genes in β cells leads to loss of 
β cell character and induces dedifferentiation of β cells (150).  Further, although Pdx1 is 
inhibited by Foxo expression, expression of other β cell transcription factors such as 
Neurod and Mafa are enhanced upon Foxo activation (151).  The complex role of Foxo 
genes in regulating metabolism and β cell fate may reflect the mixed role of insulin 
signaling in regulating β cell differentiation and growth. 
In addition to its autocrine effects, insulin signaling also acts as important paracrine 
regulator, mediating other islet cell functions, such as α cells (135).  Moreover, it can 
stimulate increased proliferation of pancreatic duct cells (152).  During embryonic 
development, pancreatic duct epithelial cells exhibit a potency to differentiate into 
endocrine cells, including β cells.  Thus, understanding the roles of insulin signaling in 
pancreatic development will likely have a strong impact on research into mechanism of β 
cell regeneration. 
 
I.D. In vivo β cell regeneration from endogenous reservoirs 
From discussion above, we have shown that studies of pancreas development have 
revealed genes and signals that promote specific pancreatic cell lineages, and these have 
been effectively manipulated to promote both in vitro and in vivo β cell regeneration. 
Recent breakthroughs have been made in this field for producing glucose responsive 
insulin secreting β cells in vitro from human stem cells. Transplantation of these in-vitro 
differentiated β cells are able protect against hyperglycemia in Diabetic mouse models 
(24,26). Although great advances have been made in the research of in vitro β cell 
production, there are still great ethical and social hurdles to be overcome before these 
stem cell therapies can move forward for the treatment of diabetic patients.  However, 
previous human and animal studies have shown evidence for the existence of 
spontaneous endogenous β cell regeneration in vivo.  Moreover, recent studies have 
shown that besides proliferation of exixting β cells, β cell can also regenerate from non-β 
cell sources, and has suggested that there are great reservoirs for endogenous β cell 
regeneration via neogenesis.  However, much remains to be learned about the molecular 
mechanisms that regulate β neogenesis. 
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i. Cellular sources of endogenous β cell neogenesis 
The study of pancreas development has revealed how internal and external signals 
direct the progenitors to their final differentiated cell fates.  Recent findings indicate that 
alteration of these internal or external cues can dramatically influence progenitor cell fate 
specification or even transform one differentiated cellular fate into another.  Excitingly, 
the plasticity of pancreatic cells, revealed from developmental studies, has opened new 
directions for study in the in vivo β cell regeneration field, as it is possible for many other 
pancreatic cell types to be transformed into β cells.  So far, the pancreatic α cells, δ cells, 
acinar cells, and duct cells all have been shown to have some potential to serve as new 
cellular sources for in vivo β cell regeneration. 
 
The intertwined fates of α and β cells 
From a physiological perspective, glucagon-secreting α cells and insulin-secreting β 
cells execute opposite, complementary biological functions.  β cells clear blood glucose 
and promote energy storage while glucagon mobilizes the stored nutrition into useable 
energy forms (131).  This yin-yang balance between α and β cells is crucial to maintain 
balanced metabolism. Pancreas developmental studies have revealed that these two cell 
lineages are derived from the same progenitors (TrPCs), and can interconvert under 
certain conditions.  This inter-conversion can be mediated by the loss or gain of any of 
several key transcription factors.  For instance, over-expression of Pax4 in pancreatic or 
endocrine progenitors drives conversion of α cells into β cells; this in turn drives new α 
cell differentiation to replace the lost cells.  These newly formed α cells are also 
eventually transformed into β cells, resulting in β cell hyperplasia and hypoglycemia 
(153).  In addition, mis-expression of Pdx1 in endocrine progenitors induces the 
transformation of α cells into β cells during a developmental window (65). This α to β 
cell reprograming can also be induced by loss of key α cell transcription factors, like Arx. 
Knockdown of Arx results in a complete loss α cells together with increased β cell 
populations (85).  Specific deletion of Arx in α cells triggers their transformation into β 
cells (154).  On the other hand, enforcing expression of Arx in endocrine progenitor 
results in a drastic loss of β cells and concurrently increases α cells (86).  The 
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transformation between α cells and β cells is likely due to their close developmental 
relationship in that they share a common ancestor. 
Using different approaches, the epigenetic and transcriptional landscape of human 
pancreatic α cells, β cells, and exocrine cells have been analyzed by large-scale ChIP 
sequencing and RNA sequencing.  These studies showed that many β cell specific genes 
are not fully repressed in α cells, but rather are epigenetically marked as “bivalent” , 
meaning that these genes can be rapidly induced, permitting α to β cell transformations 
under certain conditions (155).  However, neither β cells, nor exocrine cells exhibit this 
pattern of bivalent epigenetic markers.  This evidence indicates that α cells have special 
character, and that the barriers for α to β cell reprogramming may be lower than 
reprograming from other pancreatic cell types.  It also suggests that α cells exhibit certain 
β-progenitor characteristics.  This hypothesis is also supported by the evidence that dual 
hormone-expressing cells, which co-express insulin and glucagon, can be broadly 
detected in the fetal pancreas, but are rarely detected in adults (156-158).  However, this 
hypothesis is challenged by linage tracing experiments, which indicated that β cells never 
arise from α cells, and vise-versa (159).  Thus, whether β cells are derived α-like 
progenitors during development is controversial. 
Transformation of α cells to β cells has also been shown to occur during β cell 
regeneration. In a mouse model permitting specific, extreme β cell ablation (>99%), β 
cells regeneration was observed.  Further, genetic linage tracing showed that a portion of 
the newly regenerated β cells were derived from pre-existing glucagon+ α cells (160).  
The α to β cell transformation was also detected in another rodent study using a 
combination of genetic and chemically-induced β cell ablation (161).  Interestingly, in 
other β cell ablation mouse models, in which less severe β cell ablation was performed, β 
cell regeneration was mediated by self-replication rather than neogenesis (162).  Thus it 
is clear that the injury model influences the mode of β cell regeneration, but the 
mechanisms regulating this are unknown.  Furthermore, it is completely unknown which 
endogenous cues might control β cell regeneration from different cellular sources.  
Unveiling these endogenous factors will certainly lead to new drug targets for diabetes 
treatments that aim to restore functional β cell mass. 
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Interestingly, when compared with β cells, α cells exhibit a much greater regenerative 
potential.  When α to β cell transformation was induced by either Pax4 mis-expression or 
Arx knockout, the converted α cells were rapidly replenished by α cell neogenesis from 
pancreatic duct cells (153,154).  Conversely, no analogous β cell neogenesis was detected 
after Arx expression in endocrine progenitors was used to drive β-to-α transformation 
(86).  Furthermore, α cell hyperplasia, via increased α cell proliferation and neogenesis, 
has been observed after knockdown of glucagon receptor or PC2 (139,163).  The 
molecular signaling cues that drive α cell hyperplasia under conditions of glucagon 
signaling deficiency are unknown, but circulating factor(s) derived from the liver may be 
involved (164).  During the progression of both Type 1 and Type 2 diabetes, increased α 
cell proliferation has been observed together with the decrease of β cell mass (165).  
Thus, understanding the relationships between α and β cells under normal and 
pathological conditions, and uncovering the molecular cues that regulate α to β 
transformation, may help to re-establish metabolic homeostasis in diabetic patients. 
 
A new appreciation for δ cells 
In addition to α cells, the somatostatin+ delta (δ) cells exhibit some plasticity.  
Somatostatin plays an important role as a local inhibitory factor to repress insulin and 
glucagon secretion in the islet (166).  Besides this local action, release of somatostatin 
from the islet plays an important role in regulating exocrine pancreas and GI tract 
functions (167).  δ cells share expression of some transcription factors with β cells, 
including Pax4 and Pdx1 (168,169), implying a relationship β cells and δ cells that is 
supported by some genetic studies.  For instance, knockout of Arx in the pancreas 
increases both β and δ cell populations (85), while misexpression of Arx induces loss of 
both β and δ cells (153).  However, the mechanisms mediating differential specification 
of δ and β cells is still unclear. 
Recently, it was found that β cell injury in young mice triggered δ cell, but not α cell, 
transdifferentiation into β cells.  However, this capacity for conversion was lost with 
aging, while age only increased α cell plasticity (170).  The transformation of δ to β cells 
involves first the proliferation of δ cells, and then dedifferentiation. This proceeds to 
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Ngn3 re-expression and re-differentiate into Insulin+ cells and Somatostain+ cells.  As 
such, it is likely that δ cell characteristics, and their response to β cell loss, are very 
different at juvenile and adult stages.  Uncovering the molecular mechanisms that are 
involved in juvenile δ cell adaptability will shed further light on islet cell plasticity and β 
cell regeneration. 
 
Duct cells: Progenitors hiding in plain sight? 
The potential of pancreatic ductal cells as sources of β cell regeneration has been a 
long-debated and controversial topic.  This debate has centered on the questions of 1) 
Whether pancreatic progenitor cells exist in or adjacent to the adult pancreatic duct, and 
2) Whether this cellular source is relevant to islet regeneration. 
During development, duct-like epithelial cells in the trunk of the pancreatic arbor 
(trunk progenitor cells; TrPCs) are the precursors of endocrine cells. Ngn3+ TrPCs 
delaminate from the epithelium and subsequently differentiate into endocrine cells (44).  
However, it is unclear whether pancreatic duct remains competent for endocrine 
neogenesis in the adult pancreas.  Largely circumstantial evidence suggests that it does. 
For instance, histological analyses of adult pancreatic tissues in both human and rodent 
samples show Insulin+ cells within the duct epithelium, and small clusters of endocrine 
cells budding from it (171).  Furthermore, budding of β cells from duct epithelium region 
and proliferation of pancreatic duct cells were found to be increased in certain β cell 
injury models such as partial pancreatectomy (172).  Moreover, the long-half life and 
slow turn-over of β cells suggest β cell replication may not be sufficient to explain the β 
cell expansion seen after birth or during β cell compensation (173,174).  In certain human 
pathologies, diffuse islet cell hyperplasia called nesidioblasotosis apparently arises from 
the duct epithelium and is associated with hyperinsulinemia and hypoglycemia; this is 
often diagnosed in children but also reported in adults (175). 
The hypothesis that duct cells can serve as an adult β cell progenitor pool is further 
supported by some genetic evidence. First, β cell regeneration studies that use the partial 
duct ligation (PDL) model in rodents (176) showed that Ngn3 was expressed in ducts 
following PDL in adult mice, and linage tracing and transplantation assays showed that 
24 
 
these Ngn3+ cells could differentiate into Insulin+ β cells.  Secondly, lineage tracing 
results using the pancreatic duct-specific promoter carbonic anhydrase II (cpaII) showed 
that pancreatic progenitor cells residing in the pancreatic ducts give rise to both endocrine 
and exocrine components after birth (177). These exciting studies suggest that pancreatic 
duct cells retain a “developmental memory” that can be replayed for new β cell 
generation; However, some conclusions derived from these studies have been 
subsequently challenged.  Multiple studies using β cell-specific and duct-specific genetic 
linage tracing tools failed to detect significant β cell neogenesis from the duct or any 
other sources (178-180).  These studies support the conclusion that duct cells give rise to 
β cells only during pancreatogenesis.  However, it is important to recognize that these 
studies underscore the difficulty in detecting neogenesis against a background of pre-
existing β cells and substantially altered exocrine pancreatic mass. Therefore, it is still 
controversial whether the pancreatic duct cells can serve as a significant reservoir for β 
cell generation in adults. 
 
Acinar cells: how to shorten the distance to β cells? 
From a developmental perspective, the acinar cells are perhaps the most distant 
pancreatic relative of β cells.  Acinar cell differentiation is initiated at the tip of the 
branched pancreatic arbor by signals from adjacent mesenchyme during the primary 
transition (181).  Interestingly, the tip progenitor cells (TipPCs) remain multipotent 
throughout early embryonic stages, retaining the ability to differentiate into duct and 
endocrine cells as well as acinar cells (48).  Whether acinar cells can be experimentally 
converted into β cells has been the focus of much research. 
The first successful attempts to transform acinar cells into β cells proceeded to 
activate β cell fate through the expression of three key β cell developmental regulators. 
Using adenovirus transfection, the combination of Ngn3, Mafa and Pdx1 in acinar cells 
transformed them into insulin-expressing cells, which could ameliorate STZ-induced 
hyperglycemia (182).  Besides over-expression of β cell regulators, the loss of Ptf1a 
activity is also sufficient to transform acinar cells into β cells (183).  Despite these limited 
successes, the potential of acinar to β cell transformation has only been detected in cases 
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of genetic manipulation; no spontaneous examples of regenerative transdifferentiation 
have been reported in vivo.  Even so, in some pathologies, such as pancreatic cancer 
acinar cells are well known to transdifferentiate into duct epithelium cells, and this 
process may involve the dedifferentiation of acinar cells (184).  Thus, understanding the 
mechanism of acinar-to-duct transformation may help reveal a path from acinar cells to β 
cells.  
 
ii. Signals regulating pancreatic β cell development promote in vivo β cell 
regeneration 
β cell regeneration may recapitulate certain aspects of development, using similar 
signals and mechanisms to drive the regeneration process.  For example, Activin, an 
important extracellular signal that regulates pancreatic progenitor initiation and endocrine 
cell development was found to be up-regulated in adult pancreatic ducts upon STZ-
induced β cell ablation (185).  Administration of Activin in neonatal STZ-treated rats can 
increase β cell regeneration and improve glucose homeostasis (186).  Besides Activin, 
other growth factors, including EGF, FGF, and growth hormone, which regulate β cell 
development also play positive roles promoting β cell regeneration in vivo through β cell 
proliferation (187). 
In addition to growth factors and hormones, cytokines and inflammatory factors also 
contribute to β cell regeneration (188-190).  After β cell injury, the induction of an 
immune response to remove dead cells promotes the remodeling of existing pancreas/islet 
tissue.  This immune response is highly dependent on the injury mechanism, and is likely 
to affect the mode of β cell regeneration in different animal models.  For example, 
surgical injury, i.e., partial pancreatectomy, induces β cell proliferation and some 
potentially some neogenesis from pancreatic ducts (171).  However, after PDL, severe 
pancreas remodeling occurs, together with a more robust immune response.  The unique 
inflammatory environment resulting from PDL is an essential trigger for pancreatic duct 
cells to activate Ngn3 expression.  Lastly, the transient induction of vascular endothelial 
growth factor-A (VEGF-A) expression in β cells increases intra-islet endothelial cells and 
induces β cell loss.  Return to basal intra-islet VEGF levels promotes β cell regeneration, 
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and bone marrow derived macrophage cells are shown to be critical for this process 
(191). 
Although these studies contribute much to the understanding of β cell regeneration, 
the complete extracellular milleu of signaling cues that guide different cellular sources 
during their responses to β cell injury is not known.  Additionally, despite the fact that 
spontaneous transformations of cellular identity are observed in some β cell injury 
models, the endogenous triggers of this transformation are wholly unknown.  Moreover, 
two or more cellular sources may contribute new β cells in a given injury model.  It is not 
clear how these different cellular sources are coordinated.  Certainly, a clearer 
understanding of the extracellular signaling pathways controlling in vivo β cell 
regeneration will provide new drug targets for innovative diabetes treatments. 
 
iii. Mammalian models used to study endogenous β cell regeneration 
In order to find therapeutic targets to stimulate in vivo β cell regeneration, numerous 
animal models have been developed to mimic human diabetes.  These animal studies can 
facilitate understanding of the mechanisms of innate β cell regeneration and how diabetic 
pathology influences β cell regeneration.  Results from these animal studies have 
revealed that there are two modes of β cell regeneration: β cell replication and β cell 
neogenesis (192,193). The latter involves the formation of new β cells from cellular 
sources that do not express insulin, including facultative progenitor cells or differentiated 
non-β cells. Furthermore, the regeneration mode is dependent on age, injury types, 
genetic background and animal species.  Importantly, the mode of pancreatic injury 
strongly influences the mode of pancreatic repair.  The animal models used to study β cell 
regeneration can be classified into four categories based on injury type: (1) chemically-
induced β cell injury, (2) surgical pancreatic injury, (3) transgene-mediated β cell injury 
and (4) induction of insulin resistance. Although the majority of β cell regeneration 
studies have been performed in rodent models, recent studies, including those in this 
dissertation, have revealed that zebrafish can also be used as a powerful model for 
diabetes and β cell regeneration.  
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Chemically-induced β cell injury model 
Alloxan and streptozotocin (STZ) are two chemical compounds that are commonly 
used to induce β cell ablation.  Both are glucose analogs, and specifically accumulate in β 
cells after entering via the Glut2 transporter.  Alloxan induces β cell apoptosis/necrosis 
through a localized increase in reactive oxygen species (ROS), while STZ induces β cell 
apoptosis through DNA alkylation (194).  Due to its less toxic side effects, STZ is more 
widely used.  It was first reported in the 1970s that STZ induced β cell destruction and 
could be used to mimic T1DM.  Since that publication, myriad publications have 
investigated β cell regeneration after STZ-induced β cell loss (195).  The detailed 
mechanism of β cell destruction after STZ treatment is still a matter of debate, but is 
dependent on the dose of STZ and age of treated animal.  Both β cell replication and β 
cell neogenesis mechanisms have been reported during islet recovery using this model 
(196,197). 
 
Surgical injury models 
Two main surgical models have been commonly used for β cell regeneration studies: 
pancreatecotomy (PX), in which portions of the pancreas are removed, and partial duct 
ligation (PDL), in which a portion of the pancreatic duct is ligated to trigger acinar cell 
autolysis.  After 50%-70% PX, rodents can maintain normal unchallenged blood glucose 
levels, but exhibit impaired glucose tolerance; obvious fasting hyperglycemia develops 
only after >90% PX (198).  Interestingly, increased β cell replication and β cell 
neogenesis are found to be initiated at 50% PX, indicating hyperglycemia itself is not 
solely the β cell regenerating trigger (199,200).  Interestingly, although obvious β cell 
regeneration happens in rodent models, PX in adult humans does not provoke β cell 
replication, but it does induce hyperglycemia and diabetes (201).  These data indicate that 
rodents exhibit greater adaptation to their physiological environment than humans, and 
also a greater β cell regeneration capacity.  In contrast to PX, an aggressive inflammatory 
response is induced following PDL, together with substantial acinar cell apoptosis and 
depletion (202,203).  It has been proposed that the infiltration of immune cells and the 
inflammatory environment influence cellular behavior of surviving exocrine ductal tissue 
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and endocrine cells.  Further, PDL can activate the pancreatic progenitor program in duct 
cells and these progenitor cells can further differentiated into β cells (see above) 
(172,176). 
 
Transgenic models of β cell injury and regeneration 
In order to more specifically induce β cell destruction in a temporally-controllable 
manner, several transgenic rodent models have been developed.  In these, expression of 
toxi-genes is induced in β cells via the control of either the Insulin or Pdx1 promoter.  
The first transgenic model that was derived by this strategy was Tg(ins:INF-γ), which 
was shown to mimic the islet destruction and lymphocyte infiltration observed in Type 1 
diabetes (204).  Increased duct epithelial cell proliferation was observed in this model, 
and new islets were formed near the ducts.  In a second model, temporally-controlled 
repression of β cell function was exerted via suppression of Pdx1 in β cells (205).  In this 
system, Tg(Pdx1tTA)Tg(Tet-Pdx1), Pdx1 was specifically dampened by administration of 
doxycycline; withdraw of doxycycline drove β cell formation adjacent to pancreatic 
ducts.  In a third approach, diphtheria toxin A (DTA) was used to induce specific β cell 
death.  In these Tg(Ins:rtTA ,Tet:DTA ) mice, about 50%-70% β cells were destroyed 
following administration of doxycycline (162).  Lineage tracing revealed that β cell 
replication provided all of the regenerated β cells observed in this model.  However, in 
another transgenic model based on misexpression of the human diphtheria toxin receptor, 
Tg(Ins:DTR) mice can present with destruction of 99% β cells after diphtheria toxin 
administration, and β cell regeneration can be observed afterward it's clearance (160).  
Lineage tracing demonstrated that most regenerated β cells in this model arise by α cell 
transdifferentiation.  Fourthly, the inducible and reversible ablation of pancreatic β cells 
can be achieved in the PANIC-ATTAC model, whereby efficient β cell apoptosis can be 
driven via conditional misexpression of Caspase 8 (206).  Finally, β cell regeneration 
studies have been carried in mutant mice that mimic the development of both T1DM and 
T2DM, such as AKITA and NOD mice and ZDF rats (207,208).  Together, these rodent 
models have shown that β cells regenerate from multiple cellular sources, and that the 
mode of β cell regeneration is highly dependent on the injury mode.  However, the 
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triggering factor(s) that activate and coordinate the different cellular contributions to new 
β cell regeneration are entirely unknown. 
 
Regeneration by β cell compensation in models of insulin resistance 
Insulin resistance in T2DM can result increased β cell mass (209).  Although the 
mechanisms mediating this expansion are still unclear, it has been proposed to involve a 
reduced response to insulin in target tissues and and in the islet itself.  However, 
knockout of Insulin Receptor (Insr) in most energy reservoirs like adipose or skeletal 
muscle does not increase β cell mass, and compensatory β cell regeneration is only 
observed in liver-specific Insr knockout mice (210-214).  The fact that only liver-Insr 
knockouts induce compensatory β cell mass expansion suggests a feedback regulatory 
mechanism between liver and pancreatic endocrine cells.  Subsequent studies showed that 
this feedback regulation was mediated by circulating factors derived from the liver, 
which are suppressed by insulin signaling (215). 
 
I.E. Zebrafish as a model for pancreas development and β cell regeneration 
Although the vast majority of animal models used to study pancreas development and 
β cell regeneration are rodents, other organisms have emerged as suitable alternative 
systems, and are actively being used.  The zebrafish (Danio rerio), a tropical fish 
originally from the Ganges flood plains of India, has become a powerful alternative for 
biomedical and genetic studies (216).  One advantage of this system is that zebrafish are 
especially genetically amenable, which makes in vivo large-scale mutagenesis and 
screening strategies possible.  Importantly, zebrafish share a considerable amount of 
genetic identity with humans, with almost 70% of human genes having at least one 
zebrafish orthologue (217).  In addition, its transparent body makes zebrafish an excellent 
tool for in vivo, noninvasive, imaging studies.  Thus, this small vertebrate model 
represents a valuable tool in many areas of investigation (218).  Crucially, the pancreatic 
developmental program and metabolic profile are highly conserved between mammals 
and zebrafish (216,219-221).  In this dissertation, I have used varied cellular and genetic 
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approaches in zebrafish to investigate the hormonal control of pancreas development as 
well as β cell regeneration. 
 
i. Pancreas development in zebrafish 
The zebrafish pancreas comprises both endocrine and exocrine components.  There 
are four types of endocrine cells known in zebrafish pancreas, including insulin-secreting 
β cells, glucagon-secreting α cells, somatostatin-secreting δ cells, and rare ghrelin-
secreting ε cells.  Moreover, the zebrafish exocrine pancreas is composed of acinar cells, 
pancreatic duct cells, and centroacinar cells.  Digestive enzymes, including elastase and 
carboxypeptidases, are secreted from acinar cells and enter the intestinal bulb via the 
pancreatic ductal system (220). 
A diagram of zebrafish pancreas development is shown in Figure1-2.  As in 
mammals, the zebrafish pancreas is generated from dorsal and ventral pancreatic 
progenitor domains (220).  Specification of the dorsal bud, which gives rise only to 
endocrine cells (222), occurs at gastrulation, commensurate with endoderm formation.  
At 14 hours post fertilization (hpf), the dorsal progenitors differentiation: the first 
endocrine cells to appear are β cells, followed by α cells then δ cells.  These early 
differentiated endocrine cells aggregate to form an islet by 24 hpf.  Interestingly, it is 
likely that these early derived zebrafish dorsal endocrine cells represent a conserved 
population analogous to the mammalian first wave endocrine cells.  The ventral pancreas 
progenitors are specified from ventral endoderm around 31 hpf.  After evaginating, these 
progenitors migrate toward, and then engulf, the dorsal endocrine cells.  The ventral bud 
differentiates into both endocrine and exocrine cells.  During the later larval period (>5 
dpf), endocrine cells continually differentiate from endocrine progenitors that reside 
throughout the pancreatic duct network.  These ventral bud-derived endocrine cells 
migrate to join the dorsal bud-derived endocrine cells and form one “principal islet”, 
which is located in the pancreatic head, as well as nucleating new islets at late larval and 
juvenile stages (222).  The zebrafish exocrine pancreas cytodifferentiation begins around 
3 dpf, and clear zymogen granules are evident in acinar cells by 84 hpf (223).  Formation 
of the functional exocrine pancreatic digestive system is necessary for the transition from 
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embryonic to larval stages, since after 5 dpf, the maternally provided yolk is exhausted 
and the larva requires external feeding.  Switching nutrient supply stimulates secondary 
islets to form in body of the pancreas (2,224), which differentiate from intra-pancreatic 
duct associated progenitor cells (225).   
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Figure 1-2. Pancreas development in zebrafish. (A) Pancreatogenesis shown within the 
time frame of embryogenesis and pancreas development. β cells are represented by green, 
α cells by red, and exocrine pancreas by blue. (B) Morphology of zebrafish pancreas 
development. At 14 hpf, pancreatic dorsal bud begins differentiation into endocrine cells; 
these cluster into the principal islet by 24 hpf. At 32 hpf, ventral pancreatic progenitors 
initiate in endoderm. By 42 hpf, ventral progenitors have fused with the islet. Endocrine 
cells continually differentiate from ventral progenitors and migrate to the principal islet. 
By 72 hpf, the growing pancreas has formed a head and tail region. Acinar cells begin 
cytodifferentiation. By 120 hpf, secondary islets start to form in the pancreas tail. 
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Lineage tracing has shown that the progenitor cells in pancreatic duct region are 
multipotent, and give rise to endocrine and acinar cell lineages.  Moreover, these 
progenitors exist throughout adult stages in zebrafish, indicating that zebrafish pancreas 
may exhibit higher regeneration capacity compared with mammals (2). 
 
ii. Conserved genetic programing in zebrafish pancreas development 
Not only are the key steps in the pancreas development conserved between zebrafish 
and mammals, but the genetic developmental program is conserved as well. The key 
transcription factors in zebrafish pancreatic development are shown in Figure 1-3.  
 
Figure 1-3. Diagram of key transcription factors in regulating zebrafish pancreas 
development. EP/DP: bi-potent progenitors which gives rise to both endocrine cells and 
duct cells. Hes1: target genes involved in regulating Notch signaling pathway. 
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As in mammals, Pdx1 and Ptf1a play important roles in defining zebrafish pancreatic 
progenitors, as well as in regulating pancreatic progenitor differentiation.  The expression 
of pdx1 can be detected in the dorsal bud progenitors at 12 hpf.  At 24 hpf, pdx1 is mainly 
expressed in β cells, and upon the onset of ventral bud specification, pdx1 is found 
throughout the ventral pancreatic domain and in the intestinal bulb (226).  pdx1 
knockdown results in impaired endocrine differentiation from ventral progenitors and 
impaired exocrine pancreas development, indicating that pdx1 is essential for proper 
development of the ventral bud (227).  However, the dorsal bud is essentially unaffected, 
which is consistent with the mouse observation that Pdx1 may not be required for early 
wave endocrine cell differentiation (227).  In addition, ptf1a is expressed in the ventral 
progenitors.  These ptf1a+ cells co-express other progenitor markers, supporting a state of 
mutipotency in early ventral bud cells (183).  Fate mapping of these ptf1a+ cells showed 
that they give rise to all pancreatic linages (228).  After the ventral bud progenitor 
domain completes its expansion, the expression of ptf1a becomes limited to acinar cells, 
where it is critical to maintain acinar cell identity.  Suppression of Ptf1a activity in 
differentiated zebrafish pancreatic acinar cells promotes their reprogramming into 
insulin+ cells (71).  This finding clearly demonstrates the plasticity of pancreas tissues 
and exemplifies how key transcription factors play crucial roles in maintaining the 
stability of each cell fate. 
Similar to mammals, the bHLH transcription factor Neurod1 is also critical for the 
induction of endocrine cell fates (229-231).  Interestingly, Although neurod1 is expressed 
in endocrine progenitors and maintained in all nascent endocrine cell types, knockdown 
of neurod1 in zebrafish results in an absence of α cells and a significant reduction of δ 
cells and ghrelin cells, but no significant change in β cell number (230,231).  However, 
contrary to rodent models, the transcription factor Ngn3 is not necessary for the 
formation of zebrafish pancreatic endocrine cells. Zebrafish ngn3 is not expressed the 
pancreas, and ngn3 null mutants do not display any apparent endocrine defects.  Rather, 
the role of ngn3 is replaced in zebrafish by another bHLH transcription factor, ascl1b, 
which works in concert with neurod1 to regulate zebrafish endocrine formation (230).  
Nonetheless, beyond the endocrine initiation steps, the transcriptional program regulating 
later endocrine subtype specification appears to be conserved between mammals and 
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zebrafish.  For example, the transcription factor Arx plays the same role in zebrafish and 
mammals: repression of β cell fate and promotion of α cell fate.  Knockdown of arx 
completely abolished α cell development (232). 
Altogether, the conservation of the genetic controls of pancreas differentiation, 
together with its experimental strengths, has defined zebrafish as a unique and powerful 
model in which to elucidate the molecular mechanisms of pancreas development.  For 
example, it was first shown in zebrafish studies that differentiation of endocrine cells 
from pancreatic progenitors requires suppression of Bone morphogenetic protein (BMP) 
signaling.  Subsequently, the usage of BMP inhibitor has been adopted into the protocol 
for the in vitro differentiation of β cells from embryonic stem cells (233-235).  Thus, this 
system has demonstrated its capacity to provide translatable targets for β cell restoration 
strategies. 
 
iii. Pancreatic hormones in zebrafish metabolic regulation 
Zebrafish and mammals exhibit a similar metabolic profile with regards to nutrient 
usage and storage (216,236).   Furthermore, zebrafish share cellular metabolic enzymes 
as well as signaling pathways that control both glucose and lipid metabolism (237).  For 
example, both Glucagon and GLP-1 can be derived from zebrafish proglucagon peptides, 
and both Glucagon and GLP-1 have been found to play important roles in zebrafish 
glucose regulation (238-240).  The sequence alignment of these peptides among 
zebrafish, mouse and human reveals that zebrafish proglucagon gene products are 
strongly conserved (241).  As in mammals, zebrafish initiate gluconeogenesis during 
fasting, and this process is highly regulated by Glucagon (242).  Conversely, increased 
blood glucose dampens Glucagon release (243,244).  Moreover, stimulation of the 
Glucagon receptor increases intracellular cAMP levels and represses the key liver 
gluconeogenesis gene phosphoenolpyruvate carboxykinase (pepck), showing that 
zebrafish share many downstream signaling pathways with mammals (237).  
Interestingly, GLP-1 in fish does not exhibit incretin effects, but rather potently acts to 
increase glucose via promoting liver glucogenolysis and gluconeogenesis (242,245).  
Several studies indicate that in teleost fishes, the Glucagon and GLP-1 signals may share 
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similar cellular and physiology functions during development and in metabolism control; 
this is further discussed in Chapter three.  
As in mammals, insulin signaling in zebrafish exhibits essential roles in energy 
storage and glucose metabolism.  Injection of insulin into adult zebrafish lowers blood 
glucose and increase glycogen synthesis (246).  Moreover, ablation of β cells in either 
larvae or adult zebrafish induces hyperglycemia (247,248).  These data indicate that 
insulin secreted from β cells in zebrafish has conserved roles in the regulation of 
metabolism, and that the loss of β cells or insulin signaling in zebrafish can be used to 
mimic diabetes.  There are two insulin genes (insa and insb) in the zebrafish genome 
(249).  In contrast to observations in mouse, the expression pattern of the two zebrafish 
genes are very different (249).  While insa is mainly expressed in pancreatic β cells, insb 
is strongly expressed in the zebrafish head during development.  The divergent 
expression patterns of two genes underlie different functions during development.  As 
gene duplication often results in functional subdivision among orthologues via changes to 
expression pattern, insb may execute the mammalian insulin role of regulating central 
neuron system development and function (129).  Because of this, studies of insa gene in 
zebrafish provide the opportunity to specifically analyze the role of pancreatic insulin 
pancreas development without confounding influences from the central neuron system.  
Gene duplication events also affected the insulin receptor (insr), resulting in two insr 
genes in zebrafish, insra and insrb.  Both genes exhibit ~68% identity to human INSR, 
and can respond to human insulin stimulation (250).  Activation of insulin signaling in 
zebrafish stimulates conserved downstream signal transduction pathways, such as Akt 
phosphorylation (250). The specific roles of insulin signaling in zebrafish are further 
discussed in chapters four and five. 
 
iv. β cell regeneration models in zebrafish 
In order to perform β cell ablation and regeneration studies, several approaches have 
been developed in both embryonic and adult zebrafish.  Relative to mammals, zebrafish 
exhibit a much higher potential for β cell regeneration following injury, which makes 
zebrafish a more powerful model for investigating which cellular and moleular pathways 
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are involved, or could be involved, in regeneration.  As with mouse models, zebrafish β 
cell ablation can be induced via chemical and surgical interventions, as well as using 
transgenic models.  It has been shown that a single high dose of STZ can be injected into 
adult zebrafish and that this results in β cell death and hyperglycemia.  Zebrafish 
recovered rapidly following the STZ treatment: increased proliferation of islet cells and 
ductal cells was observed shortly after STZ treatment (247) and normal blood glucose 
was achieved within 2 weeks (247,251).  This model was further exploited to analyze 
how the regeneration of other tissues is influenced by a hyperglycemic environment, in 
models of diabetic complications (252).  Besides STZ-induced β cell ablation, surgical 
partial pancreatecotomy has also been carried out in adult zebrafish (247).  Extensive 
duct cell regeneration and fibrotic tissue were observed following surgery, and extensive 
β cell proliferation was deduced as the primary mechanism of β cell regeneration in this 
model.    
To date, two zebrafish transgenic models have been reported that permit temporally-
controlled β cell ablation and regeneration.  In the first, Tg(ins:cre)Tg(ins:loxp-BFP-loxp-
DTA), the cell lethal toxin, Diphtheria Toxin-A (DTA), was specifically expressed in β 
cells after Cre-mediated recombination (224).  This method of ablation triggered β cell 
neogenesis from pancreatic duct progenitors.  In the second model, the Tg(ins:NTR) 
model, bacterial Nitroreductase (NTR) was induced in β cells under control of the insulin 
promoter.  NTR activates the innocuous prodrug metrodinazole (MTZ), thereby 
producing a cytotoxic product that induces cell death.  Addition of dissolved MTZ to the 
media rapidly and thoroughly induces cell death exclusively within NTR+ β cells.  β cells 
rapidly regenerate following the removal of MTZ (253,254).  This model has been used 
throughout this dissertation and discussed extensively in the following chapters. 
Interestingly, as in mouse models, compensatory β cell production in response to 
excessive nutrition is observed in both zebrafish larvae and juveniles (255).  Also, over-
fed zebrafish developed obesity and exhibited pathophysiology similar to obese humans 
and mice, which further justifies the investigation of insulin resistance-induced β cell 
compensation using this zebrafish (256).  It is also been shown that adult zebrafish 
recover from hyperglycemia and impaired glucose metabolism that is induced by 
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persistent glucose exposure, suggesting the presence of β cell regeneration mechanisms 
that respond to insulin signaling (257).  
Altogether, these studies reveal that the cellular and molecular pathways for 
pancreatogenesis and β cell regeneration are conserved between zebrafish and mammals.  
The condensed embryonic developmental period and rapid rate of β cell regeneration 
make zebrafish uniquely suited for studying these processes, and has contributed to the 
comprehensive understanding of in vivo β cell regeneration processes.  Understanding the 
cellular origins and molecular triggers for β cell regeneration under different 
environmental conditions will lead to the development of rational drug targets for 
diabetes treatment.  The following chapters will further discuss how these complex 
biological mechanisms are unified, and how tissue regeneration mirrors development.  
 
I.F. Rationale and Research Aims 
Insufficient functional β cell mass underlies the development of diabetes mellitus.  
Regeneration of new β cells will allow for reestablishment of balanced metabolism and 
provides a justified foundation hope for a diabetes cure.  Both in vitro and in vivo β cell 
regeneration approaches recapitulate certain aspects of embryonic pancreas development.  
As two of the key functional genes in the pancreas, glucagon and insulin gene products 
not only play an essential role in regulating metabolism, but also can mediate the balance 
between α and β cell quantities during embryonic development.  Under normal 
physiological conditions, glucagon secreted from α cells and insulin secreted from β cells 
act as counter-balanced Yin-Yang factors to maintain glucose metabolism; imbalance of 
these hormones leads to metabolic disease.  For example, the glucagon gene is strongly 
activated after β cell injury or impaired insulin signaling (165). The restoration of balance 
between these two hormones is achievable by increasing the number of β cells or 
decreasing α cells (165).  The surprising result that spontaneous α cell to β cell 
transdifferentiation occurs after extreme β cell ablation (160) indicates that the mature 
pancreas has innate potential to correct this misbalance.  Furthermore, it is likely that the 
machinery controlling α and β cell quantities responds directly to insulin and glucagon 
input and this then help the organism sense and correct the unbalanced hormonal state.  In 
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this study, I have used two approaches to introduce a state of insufficient insulin 
signaling, and then I analyzed the impact of glucagon/GLP-1 and insulin on β cell 
generation/regeneration. The overall hypothesis of my dissertation is that:  
Glucagon and Insulin signaling pathways exhibit counter-balanced effects 
in regulating pancreatic endocrine cell quantities, and that this feedback 
regulation is crucial for regenerating new β cells following β cell injury or 
in states of insulin deficiency. 
 
To test this hypothesis, I have pursued the following specific aims: 
Aim 1/ Chapter three: Characterize the role of Glucagon/GLP-1 in β cell 
regeneration following severe β cell ablation.  In this Aim, I have used the NTR-induced 
β cell ablation, transgenic zebrafish models, HOT-Cre lineage tracing, as well as genetic 
and pharmaceutical manipulation to investigate the role of glucagon gene products in β 
cell neogenesis. 
Aim 2/ Chapter four: Investigate the role of insulin in regulating pancreatic 
endocrine homeostasis using approaches that deplete insulin signaling but not β cells, per 
se.  In this Aim, I have used genetic methods to inhibit the production of the insulin 
peptide or to block insulin signaling in target cells, to uncover a novel role for insulin 
signaling in regulating the differentiation of pancreatic progenitor cells. 
Aim 3/ Chapter five: Examine the impact of insulin in regulating acinar cell fate 
stability and the development of the exocrine pancreas. In this aim, I have investigated 
the impact of insulin signaling on exocrine pancreas development, which may give 
insights into the role of insulin signaling in acinar cell fate maintenance and 
transformation.  
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CHAPTER TWO: Materials and methods 
 
II.A. Zebrafish maintenance and strains 
Zebrafish were raised under standard laboratory conditions at 28.5˚C.  All animal 
procedures were conducted in accordance with OLAW guidelines and were approved by 
the Indiana University Institutional Animal Care and Use Committee.   
The following transgenic lines in Table 2-1 were used in the experiments. 
Tg(gcga:Cre; cryaa:YFP)s962 ,Tg(sst2:Cre; cryaa:YFP)s963 and Tg(hs:loxp-mcherry-
STOP-loxp-dnIRS2-GFP) were constructed and generated by meganuclease transgenesis 
as described (222).  To construct the Cre transgenes, glucagon promoter (gift of F. 
Argenton) or sst2 promoter was subcloned into ins:Cre; cryaa:Venus.  A 2 kb sst2 
promoter region was amplified from the CH211-232H16 zebrafish genomic clone 
(CHORI) using the oligos: 5’-GCATG AATTC AGCCT CTATG TCCTT CGTCT and 
5’-GCATG GATCC TGCTG CTTCT TTAAC TCAG. To construct the hsp70l-loxP-
mCherry-STOP-loxP-dn-irs2a-GFP transgene, the N-terminus of irs2a was amplified 
from BAC DKEYP-24D6 using the oligos: 5’- GGCGC GCCAC CATGG CGAGT 
CCGCC GCCG and 5’-CTCGC CCTTG CTCAC CATGG CTGCC ATGCT GTCAG T 
and EGFP was amplified from using: 5’-ACTGA CAGCA TGGCA GCCAT GGTGA 
GCAAG GGCGA G and 5’- CGAGC TGTAC AAGTA AAGCG GCCGC. The two 
resulting products were fused by PCR and cloned into plasmid hsp70l-loxP-mCherry-
STOP-loxP-H2B-GFP_cryaa-cerulean (Addgene #24334) using AscI and NotI.  
For Hot-Cre lineage tracing, heat shock activations were performed at 38.5˚C for 20 
minutes at 3 dpf.  If β cell ablation was required, larvae were recovered at 28.5˚C for 3 
hours before ablating β cells.  In order to induce dnIRS2-GFP overexpression via HotCre 
system, heat shock activations were performed at 38.5˚C for 20 minutes at the time point 
indicated in the legends. 
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II.B. Detection of protein, mRNA, and cell proliferation  
Whole mount immunofluorescent staining and western blot were used in detecting the 
protein signal. In vitro hybridization and quantitative PCR were used to detect mRNA 
expression. In order to detect cell proliferation, EdU incorporation assays were performed 
as described (258).  
The following primary antibodies in Table 2-2 were used for immunoflurescent 
staining. Alexa Fluor-conjugated antibodies were used for visualization (Life 
Technologies).For western blot, mouse anti p-Akt473 (cell signaling) has been used. The 
expression of p-Akt473 is determined by normalizing to α-tublin that is visualized by 
mouse anti-α tubulin antibody (Santa cruze).  
For quantitative PCR, we enriched for endodermal organs by manual dissection of the 
digestive system with watchmakers forceps (Dumont #5, F.S.T.), which included 
pancreas, intestine, and liver from 4, 5, and 7 dpf larvae.  20-30 endoderm preparations 
were pooled for each condition to minimize variability between dissections.  mRNA was 
extracted with Trizol (Life Technologies) and reverse transcribed with iScript (BioRad). 
The Mastercycler Realplex PCR system (Eppendorf) was used with Sybr Green mix 
(Invitrogen) and Mytaq (BioLine) to generate Ct values. The relative expression of each 
sample was determined by normalizing to laminB1 (lmnb1) or β-actin using the relative 
standard curve method (259). The primer sets in Table 2-3 have been used for 
quantitative PCR analysis.  
For In vitro hybridization, the following primer sets in Table 2-4 have been used to 
synthesis the probe. The probe template was PCR amplified from cDNA with the 
described primer sets and then in vitro synthesized and labeled using Dig RNA labeling 
kit T7(Roche). The In vitro hybridization procedure was then performed as described 
before (260) and stained with BM purple AP Substrate (Roche).  For 
immunofluorescence In vitro hybridization, Vector Red (Vector Inc.) was used.  
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II.C. Microinjections  
H2B-RFP mRNA, dnIRS2-GFP mRNA, insulin mRNA and sox32 mRNA was 
transcribed with SP6 mMessage machine kit (Invitrogen) in vitro.  In order to label the 
differentiated dorsal pancreatic endocrine cells, 100 pg H2B-RFP mRNA were injected 
into zygotes.  Anti-dsRed (Clontech) and Alexa568 antibodies (Life Technologies) were 
used to amplify the signal.  In order to block insulin signaling or over expression insulin, 
200pg dnIRS2-GFP mRNA or 200pg Insulin mRNA were injected into zygotes. Anti-
GFP (Aves Labs) and Alexa488 antibodies were used to amplify the dnIRS2-GFP 
expression signal. In order to induce endoderm specific differentiation, 200pg sox32 
mRNA was injected into zygotes.  
In order to knock specific gene expression, the following antisense morpholinos list 
in Table2-5 (Gene Tools LLC) were injected into zygotes. Among them, gcgaMO and 
arxaMO are translation blocking morpholino. The morpholinos were designed to bind at 
the translation start site of the target mRNA which then block the protein translation. The 
insaMO and insbMO are splicing morpholino. The morpholino were designed to bind at 
the exon-intron junction of the target gene pre-mRNA. Injection of the morpholino will 
interrupt the pre-mRNA splicing and results in exon deletion or alternative splicing 
products. 
Specificity of morpholino knockdown was addressed in multiple ways: First, 
significant off-target effects were unlikely in insulina, glucagon or arxa morphants, as we 
observed no gross morphological defects, which are characteristic of such off-target and 
other non-specific toxic effects in morphants (261).  Secondly, gcga and arxa morpholino 
phenotypes recapitulated phenotypes seen in mouse with knockdown of components of 
the glucagon signaling pathway (262,263) or Arx(85) .  Thirdly, regeneration of β cells in 
the gcga knockdown was rescued by injection of recombinant human Glucagon peptide 
or the Glp1 receptor agonist Exendin-4, but not the Glp1 receptor antagonist Exendin9-39 
(Figure 5A-G; S16).  Finally, injection of a second arxa morpholino (arxaMO2 = 5’- 
ATGTT TGTAT CGTCC TCAGT CGTGC) produced identical phenotype in the islet 
(R.M.A., unpublished). To address morpholino efficacy, gcgaMO eliminated glucagon 
protein in the islet (Figure 4D’), and arxaMO specifically eliminated expression of an 
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arxa-GFP DNA reporter construct that was co-injected into zygotes (R.M.A. 
unpublished).   
For detecting insaMO and insbMO efficiency, mRNA was extracted from 2 dpf 
control and MO-injected embryos and cDNA was synthesized as described above. The 
PCR product was then run through 1% agarose gel and image was taken with Carestream 
Gel Logic system. 5’-CATTCCTCGCCTCTGCTTC and 5’-
GGAGAGCATTAAGGCCTGTG primer set were used for detection insaMO efficiency 
and 5’-CAGACTCTGCTCACTCAGGAAA and 5’-GCGTGTAATGGTCATTTATTGC 
primer set were used for detection insbMO efficiency. The alternative splicing products 
were cut from the gel and sent for sequencing.  
 
II.D. Drug/chemical treatments 
The chemical used in the experiments were listed in Table 2-6. Specifically, For β cell 
ablation, Tg(ins:CFP-NTR)s892 or Tg(ins:Flag-NTR)s950 animals were incubated in 0.1% 
DMSO (Sigma) ± 10 mM Metronidazole (MTZ, Sigma) in egg water.  After ablation 
(generally 24 hrs), embryos were washed extensively with egg water, and recovered for 
1-16 days.   
For peptide treatments, a mixture of KCl (0.2M), phenol red (0.1%), and either 
vehicle, recombinant human Glucagon (Sigma), Exendin-4 (Sigma), Exendin9-39 
(Sigma) was injected into the pericardial sac of each embryo following ablation.  The 
peptides were dissolved in H2O for stock solution (1mM) and then stored at -20˚C. The 
final working solution is 1μM and 4nl/larvae were injected. The total mass of each drug 
injected was 0.004 pM/larva. For Glucose/Mannose injection, stock Glucose (Sigma) or 
Mannose (Sigma) was dissolved in H2O and stored in -20˚C at the concentration of 10%. 
The Glucose/Mannose working concentration is 0.25% and 4nl was injected into the 
pericardial sac of each embryo. Thus, Glucose or Mannose was injected with a final mass 
of 10 ng/larva.  After injection, embryos recovered at 28˚C for 5 h before ablation. 
For inhibition of Akt pathway, Tg(ins:CFP-NTR)s892embryos were incubated in 0.1% 
DMSO± 1μM wortmannin (sigma) from 14hpf and fixed at 30 hpf or 42 hpf. For 
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inhibition of MAPK pathway, Tg(ins:CFP-NTR)s892 embryos were incubated in 0.1% 
DMSO± 100μM U0126(sigma) from 14 hpf and fixed at 32 hpf.  
 
II.E. Glucose measurements  
Glucose measurement in zebrafish embryos was performed as described (248) using a 
glucose assay kit (Biovision). Briefly, pools of 15-20 embryos were counted and 
homogenized in glucose measurement buffer (10 ul/ embryo).  Three groups were used 
for each treatment condition. To measure glucose level, glucose oxidase specifically 
oxidizes free-glucose generating a compound that reacts with the glucose probe to 
produce resorufin, which can be detected colorimetrically (O.D. 570 nm). Specific 
measurement steps were performed according to the manufacturer provided 
instructions.The fluorescence signal was read using Spectra Max-M5 (Molecular device). 
The data was displayed with the mean glucose amount per larvae.  
 
II.F. Transplantation 
In order to analyze the specific roles of Insulin signaling on endoderm, chimeric 
zebrafish embryos have been generated by cellular transplantation procedure as described 
by previous research. In order to induce endoderm specific replacement, sox32mRNA 
were synthesized in vitro and injected (200pg/embryo) into the donor embryos at one cell 
stage. 4ng sox32MO was injected into zygotic host embryos to promote the contribution 
of donor cells. In order to inhibit insulin signaling in the donor cells, 200pg dnIRS2-GFP 
mRNA was injected. Tg(sox17:GFP) were used in the donor embryos to mark and trace 
the differentiated endoderm . Wildtype were used in the host embryos. Both donor and 
host embryos were dechorionated at blastula stage and then placed in the transplantation 
agar molds. Transplantation was performed under the dissecting scope and directed by an 
oil-filled Hamilton syringe with a micrometer drive.   
In order to analyze the differentiation of blastula stem cells in developed zebrafish 
host larvae system, a novel transplantation approach has been used. Tg(sox17:GFP) 
donor embryos were injected with 200pg sox32mRNA alone or co-injected with 200pg 
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dnIRS2-GFPmRNA. Dechorinated blastula stage donor embryos were placed in the agar 
molds and host larvae were mounted in a 35 mm petri dish with 2% methylcellulose. 
Transplantation was performed with the same system and needles as above. About 20-40 
cells were extracted from the donor and injected into 4 dpf host larvae at endoderm cavity 
behind liver and above pancreas. To create the β cell ablated host environment, 
Tg(ins:Flag-NTR;cryaa:mCherry)s950 embryos were treated ± 10 mM MTZ from 3dpf to 
4dpf and MTZ was removed 2 h prior transplantation. To determine whether blood 
vessels can integrate with transplanted donor tissue, Tg(ubi:zebrabow) donor embryos 
with ubiquitous RFP expression were injected with 200pg sox32mRNA and transplanted 
into 4 dpf Tg(flk1:GFP) host larvaes.  
 
II.G. Data and statistical analysis 
For the pancreatic cell counting, the images stacks were taken using confocal 
microscope (Zeiss, LSM700) with the interval of 1.5 μM. The images were then analyzed 
using imageJ software and target cell populations were counted manually. The date was 
then displayed as mean cell number/ larvae. Dissecting fluoresce scope (Leica M205) 
was used for the whole amount imaging for zebrafish embryos.  
Data are expressed as mean ± SD, and statistical significance was tested by ANOVAs 
analysis or Student’s t-test (as noted in figure legend).  For two way ANOVAs analysis, 
Bonferroni posttest was used for statistical analysis. For one way ANOVAs analysis, 
Tukey Post Hoc test was used for statistical analysis and statistic was analyzed using 
Prism software. Significant differences from controls are indicated as follows: p ≤ 0.05 
(*), p ≤ 0.01 (**), p ≤ 0.001 (***). 
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Table 2-1. Transgenic lines used for experiments.  
Name Usage Reference 
Tg(neurod1:GFP)nl1 Pan-endo markerChapter 3, 4 Obholzer, N. et al., 2008 
(264) 
Tg(sox17:GFP)s870 Endoderm marker Chapter 3,4 Sakaguchi, T. et al., 2006 
(265) 
Tg(ins:Cre; cryaa:YFP)s924 β cell lineage tracing Chapter 3 Hesselson, D. et al., 2009 
(222) 
Tg(Ins:CFP-NTR)s892 β cell ablation Chapter 3,4 Curado, S. et al., 2007 (266) 
Tg(gcga:GFP)ia1 α cell marker Chapter 3,4 Pauls, S. et al., 2007 (267) 
Tg(ins:dsRed)m1018 β cell markerChapter4 Anderson, R. et al., 2009 
(258) 
Tg(ins:Flag-NTR; 
cryaa:mCherry)s950 
β cell ablationChapter3,4 Andersson, O. et al., 2012 
(248) 
Tg(hs:loxp-mCherry-STOP-
loxp-H2BGFP)s925 
Lineage tracing Chapter3,4 Hesselson, D. et al., 2009 
(222) 
Tg(flk1:GFP)s844 Blood vessel marker Chapter3,4 Jin, S. et al., 2005 (268) 
Tg(ubi:zebrabow)a131 transplantation Chapter4 Pan,Y. et al., 2013 (269) 
Tg(ela3l:cre;cryaa:YFP) Acinar cell lineage tracing 
Chapter3,4 
Hesselson, D. et al., 2011 
(183) 
Tg(hs:cre)VU297 Inducible cre Chapter4,5 Ni, T. et al., 2012 (270) 
Tg(gcga:Cre;cryaa:YFP)s962 α cell lineage tracing Chapter3,4 Ye, L. et al., 2015 (271) 
Tg(sst2:Cre; cryaa:YFP)s963 δ cell lineage tracing Chapter3 Ye, L. et al., 2015 (271) 
Tg(hs:loxp-mcherry-STOP-
loxp-dnIRS2-GFP) 
Inducible dnIRS2 expression 
Chapter4,5 
unpublished 
Tg(fabp10:dsRed; 
ela3l:GFP)gz12 
Liver and acinar marker Chapter5 Anderson, R. et al., 2009 
(258) 
 
 
 
47 
 
Table 2-2. Primary antibodies used for immunofluorescence staining. 
Name Raised species Dilution Company 
anti-GFP chick 1:500 Aves Labs 
anti-Insulin guinea pig 1:100 Biomeda 
anti-Glucagon mouse 1:100 Sigma 
anti-somatostatin rabbit 1:100 Serotec 
anti-dsRed rabbit 1:250 Clontech 
anti-PCNA mouse 1:100 Alcam 
anti-PHH3 rabbit 1:00 Cell signaling 
anti-Alcam mouse 1:00 Zn-8 
anti-cleaved Cap3 rabbit 1:100 Cell signalling 
anti-Pdx1 guinea pig 1:100 gift of Dr. C. Wright 
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Table 2-3. Primers used for qPCR analyses. 
Gene name 
 
Strand Sequence 
laminB1 lmnb1chapter3 sense 5’-ACCCGCGGCAAGAGAAAGCG 
  antisense 5’-TCCTGCCATCGGCTGGTCCT 
preproinsulin-a insa chapter3 sense 5’-TCTGCTTCGAGAACAGTGTG 
  antisense 5’-GGAGAGCATTAAGGCCTGTG 
Preproglucagon-
a 
gcga chapter3 sense 5’-AAGGCGACAGCACAAGCACA 
  antisense 5’-
GCCCTCTGCATGACGTTTGACA 
aristaless related 
homeobox-a 
arxa chapter3 sense 5’-AAAAGCAAGTCGCCCACCGT 
  antisense 5’-
AATTTGGGCGGCAGGTGCATGT 
mafa mafa chapter3 sense 5’-ATTGTTCGCCGGGCTGTGTT 
  antisense 5’-TGCTTTTGGCACAACCGGCA 
mafb-a mafba chapter3 sense 5’-
CGCCAAACTGTGTTTGCGCTGA 
  antisense 5’-
AGGCGGCTTTAACGGGAGAAGT 
neuronal 
differentiatoin1 
neurod1 
chapter3 
sense 5’-
ACGCAGCGCTGTGATATACCGA 
  antisense 5’-
TCGCGTTCAACTGGGCGTTCAT 
elastase 3 like ela3l chapter3 sense 5’-GCTGAGCCTGTGACACTGAG 
  antisense 5’-TCTCTGTGTGTTGGTTTTCTGG 
trypsin trp chapter3,4,5 sense 5'-AGACCGTCTCTCTGCCTTCA 
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  antisense 5’- CAACACGCCATGATAACGAC 
isl LIM 
homeobox 1 
isl1 chapter3 sense 5’-
AGCAGCAGCAACCCAACGACAA 
  antisense 5’-
TGCACCTCCACTTGGTTTGCCT 
opsin 1, short-
wave-sensitive 1 
opn1sw1 
chapter3 
sense 5’-CCCAAATGGGCGTTCTACCT 
  antisense 5’-CAAGGACCATCCCGTCACAA 
insulin receptor-a insra chapter4 sense 5’-CGGCTCGCTGTGTTGTATTG 
  antisense 5’-TACTGTCCCTCCTCTCACGG 
insulin receptor-b insrb chapter4 sense 5’-TCGCCTACATCTTGTGCCTC 
  antisense 5’-AGCTCAAGCCCCTGAAATCC 
pancreatic and 
duodenal 
homeobox 1 
pdx1 chapter4 sense 5’ -
ACACGCACGCATGGAAAGGACA 
  antisense 5’-GCGGGCGCG 
AGATGTATTTGTT 
β-actin β-actin 
chapter4 
sense 5’ -
GGCACGAGAGATCTTCACTCCCC 
  antisense 5’ -
GGGGAAAACAGCACGAGGGGC 
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Table 2-4. Primers used for In Situ Hybridization. 
Gene name 
 
Strand Sequence 
preproglucagon-a gcga chapter3 sense 5’-
ATAAGCGAGGAGACGATCCA 
  antisense 5’-
gctaatacgactcactataggGCAATGAA
GCCATCAGTTCTC 
glucagon receptor-a gcgra chapter3 sense 5’-
GAGTGTCACCGCAGTTCAGT 
  antisense 5’-
gctaatacgactcactataggCTGTCCGT
CTGCATCACACT 
Glucagon receptor-b gcgrb chapter3 sense 5’-CCGCTCATATTTGTGCTGCC 
  antisense 5’-
gctaatacgactcactataggAGCGGAGC
CTTCATTGTTGA 
insulin receptor-a insra chapter4,5 sense 5’-GCTCGTGCGCGTGTTCATAT 
  antisense 5’-
gctaatacgactcactataggTTTCCGTG
GCCTGAGTTC 
insulin receptor-b insrb chapter4,5 sense 5’-
GGCTGGACACATCTGTGGTTG 
  antisense 5’-
gctaatacgactcactataggCGGTGGAG
GACAATTATATCGTAG 
pancreatic and 
duodenal homeobox 1 
pdx1 chapter4 sense 5’-
GGGAGACTGCAGGTAGAGCA 
  antisense 5’-
gctaatacgactcactataggGCCTTTTG
CCAATCTGTTTGC 
*Note: all the antisense primers contain the T7 promoter sequences which indicate as 
lower case characters.  
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Table 2-5.  Morpholino sequences 
Name Target gene Morpholino sequence 
Dose 
standard 
control 
MO 
no target in 
Danio rerio 
chapter3 
5’- CCTCT TACCT CAGTT ACAAT 
TTATA 
4 or 8 ng 
arxaMO aristaless related 
homeobox-a 
chapter3 
5’-TATCG TCGTC GTACT GACTG 
CTCAT 
4 ng 
gcgaMO preproglucagon-
a chapter3 
5’- GGCAA AATAC TGGAC GCCTT 
TCATT 
8 ng 
insaMO preproinsulin-a 
chapter4,5 
5’-
CCTCTACTTGACTTTCTTACCCAGA 
4 ng 
insbMO preproinsulin-b 
chapter4 
5’-
AAGTTGGAGACGTTGCTCACCCAG
C 
2 ng 
sox32MO sex determining 
region Y-box 32 
chapter4 
5’-
GCATCCGGTCGAGATACATGCTGT
T 
4 ng 
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Table 2-6. Drug treatments 
Name 
Purpose Dose 
Metronidazole β cell ablationChapter 3, 4 10mM 
Human-Glucagon Gcgr activatorChapter 3 0.004pM/larva; 
14pg/larva 
Exendin-4 GLP-1r activator Chapter 3 0.004pM/larva; 
16.7pg/larva 
Exendin-9-39 GLP-1r antagonist Chapter 3 0.004pM/larva; 
13.5pg/larva 
Glucose Increase blood glucose Chapter 3,4 10ng/larva 
Mannose Osmotic controlChapter4 10ng/larva 
Wortmannin PI3K inhibitorChapter3,4 0.1μM 
U0126               ERK inhibitor Chapter3,4 100μM 
 
 
 
  
53 
 
CHAPTER THREE: Glucagon is essential for α cell transdifferentiation and β cell 
neogenesis 
(as published in: Ye, L.; Robertson, M. A.; Hesselson, D.; Stainier, D. Y. R.; Anderson, 
R. M. Development 2015, 142, 1407–1417.) 
 
III.A. Summary  
The inter-conversion of cell lineages via transdifferentiation is an adaptive mode of 
tissue regeneration, and an appealing therapeutic target.  However, its clinical 
exploitation is contingent upon discovery of contextual regulators of cell fate acquisition 
and maintenance.  In murine models of diabetes, glucagon-secreting α cells 
transdifferentiate into insulin-secreting β cells following targeted β cell depletion, 
regenerating the form and function of the pancreatic islet.  However, the molecular 
triggers of this mode of regeneration are unknown.  Here, using lineage-tracing assays in 
a transgenic zebrafish model of β cell ablation, we demonstrate conserved plasticity of α 
cells during islet regeneration.  In addition, we show that glucagon expression is 
upregulated after injury.  Through gene knockdown and rescue approaches, we also find 
that peptides derived from the glucagon gene are necessary for α to β cell fate switching.  
Importantly, while β cell neogenesis was stimulated by glucose, α to β cell conversion 
was not, suggesting that transdifferentiation is not mediated by glucagon/GLP-1 control 
of hepatic glucose production.  Overall, this study supports the hypothesis that α cells are 
an endogenous reservoir of potential new β cells.  It further reveals that glucagon plays 
an important role in maintaining endocrine cell homeostasis through feedback 
mechanisms that govern cell fate stability. 
 
III.B. Introduction 
Glucagon and insulin, secreted by pancreatic α (α) and β (β) cells, respectively, exert 
opposing regulatory actions on glucose metabolism.  Glucagon increases circulating 
glucose levels by stimulating hepatic glycogenolysis and gluconeogenesis.  Conversely, 
insulin decreases glucose levels by eliciting cellular influx and storage of glucose while 
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dampening hepatic glucose production.  In the pancreatic islet, α and β cells are 
physically juxtaposed; each cell type receives and responds to secreted signals from the 
other to modulate secretory activities (i.e. cell function).  For instance, insulin represses 
glucagon expression and release from the α cell, while glucagon stimulates β cell insulin 
secretion (272,273).  Deranged regulation of insulin and glucagon signaling consequent 
to β cell dysfunction or destruction causes diabetes mellitus, a devastating disease that 
afflicts more than 360 million people worldwide (274).  With the loss of insulin 
signaling, unchecked glucagon signaling drives hyperglycemia and thereby the morbid 
complications associated with diabetes (165).  However, the mechanisms by which acute 
changes in intra-islet hormone signaling affect islet cell composition or islet cell fates are 
largely unknown. 
Restoration of β cell mass is a conceptually proven approach to cure diabetes (18), 
but its widespread implementation will require a vast supply of functional β cells derived 
from either exogenous (e.g. stem cells) or endogenous (e.g. facultative progenitors) 
sources.  It is clear from models of β cell regeneration in the mouse that the mode and 
extent of pancreatic injury influences mechanisms of regeneration, and these models have 
revealed that new β cells can arise from several endogenous sources.  Firstly, β cell 
regeneration may be mediated by proliferation of surviving β cells (162).  Secondly, 
neogenesis from duct or duct-associated progenitor cells may occur spontaneously, or in 
response to injury via pancreatic duct ligation (176,177), though contradictory reports 
indicate that this process may be rare (179,180,275).  Thirdly, spontaneous 
transdifferentiation of β cells from α or δ cells occurs in conditions of extreme β cell loss 
(160,170).  Likewise, with some limitations, α and β cells can be interconverted through 
gain or loss of key pancreatic transcription factors, including Arx, Pax4, and Pdx1 
(65,86,153).  Together these studies have revealed plasticity in the endocrine pancreas, 
and indicate that other pancreatic endocrine cells may be an exploitable source of new, 
functional β cells.  However, the endogenous extracellular cues triggering α to β cell 
transdifferentiation are unknown. 
Here, using transgenic zebrafish models of β cell ablation, we have investigated 
cellular and molecular mechanisms of new β cell formation during regeneration.  The 
zebrafish is an attractive and useful model for studying mechanisms of pancreas 
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formation and disease repair because of its conserved architecture, composition, 
development, and attributes that permit rapid loss-of-function analyses 
(221,244,276,277).  In addition, the heightened regenerative capacity of the zebrafish 
facilitates the discovery of novel organ repair mechanisms that may be present, but 
dormant, in mammals (278).  In this manuscript, we use lineage-tracing tools to 
demonstrate conserved plasticity of α cells during regeneration in the zebrafish islet.  
Importantly, and for the first time, we show that glucagon gene activation is responsible 
for this α cell fate switch; blockade of this signaling pathway via glucagon knockdown 
nearly extinguishes β cell regeneration.  Importantly, our data further suggest that 
transdifferentiation is not solely dependent on the gluconeogenic properties of glucagon.  
Overall, this study supports the hypothesis that α cells constitute an endogenous reservoir 
of new β cells that is pharmacologically exploitable. 
 
III.C. Results  
β cell regeneration occurs by neogenesis in zebrafish.  
To investigate the origin of regenerating β cells, we used transgenic models of 
conditional β cell ablation.  In Tg(ins:CFP-NTR)s892 and Tg(ins:Flag-NTR)s950, 
nitroreductase converts metronidazole (MTZ) into a toxic compound that rapidly induces 
β cell apoptosis (266).  Treatment of embryos with MTZ from 3 to 4 days post 
fertilization (dpf) ablated all β cells, and after its removal, β cell mass rapidly recovered 
at a rate greater than normal larval neogenesis (Figure 3-1A-F).  We observed that free 
glucose levels were elevated in β cell ablated larvae (Figure 3-1G), confirming the 
functionality of larval β cells.  Free glucose levels peaked one day into the recovery 
period (1 day post ablation, dpa), but importantly, by 8 dpf there was no difference in 
glucose levels between ablated and control groups.  This restoration of sufficient overall 
β cell function, despite only partial recovery of β cell mass indicates that individual β 
cells may be hyperfunctional.  To determine whether surviving β cells contributed to islet 
regeneration in our model, we used a genetic lineage tracing approach (222).  
Specifically, Tg(insa:Cre;cryaa:YFP)s924 (hereafter ins:Cre) was crossed with the 
inducible reporter line Tg(hsp70l:loxp-mcherry-stop-loxp-H2B-GFP;cryaa:CFP)s923 
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(hereafter hs:CSH) (222).  First, as a control, we heat-pulsed ins:Cre; hs:CSH larvae at 3 
dpf to mark insulin+ β cells with H2B-GFP and found that 41% of β cells were labeled at 
4 dpf (Figure 3-7A,B,G).  In accord with previous studies (222), we saw no change in the 
quantity of H2B-GFP+ β cell between 1 and 2 days after labeling (Figure 3-7A-D,H).  
Next, we heat-pulsed ins:Flag-NTR; ins:Cre; hs:CSH embryos at 3 dpf, shortly before 
MTZ treatment and found that in 1 dpa regenerating islets, only 2% of all post-ablation 
insulin+ β cells were labeled (Figure 3-1H-I; Figure 3-7I; n=13).  This result indicates that 
pre-existing β cells do not significantly contribute to regeneration in our model. 
To further exclude a significant contribution of pre-existing β cells to islet 
regeneration in our model, we used Tg(ins:Kaede)s949 fish in which β cells were labeled 
by the green-to-red photo-convertible fluorescent protein Kaede (248).  When Kaede was 
converted to red at 72 hpf, control (unablated) islets were comprised of two populations 
of β cells at 96 hpf.  Most exhibited yellow (green plus red) fluorescence, indicating ins+ 
cells that existed during labeling, while some β cells exhibited only green fluorescence, 
indicating that they were generated in the 24 hr period after labeling (Figure 3-7J,K).  In 
regenerating Tg(ins:CFP-NTR)s892 islets, when Kaede was converted at 72 hpf 
immediately after MTZ treatment the 1 dpa islets contained only unconverted green ins+ 
cells (Figure 3-7L-M).  Together, our ins:Cre and ins:Kaede data demonstrate that the 
essentially all β cells are ablated by MTZ treatment in the NTR model, and that islet 
regeneration occurs through β cell neogenesis. 
 
β cells transdifferentiate from α cells during regeneration. 
In mice, severe β cell ablation triggers α to β cell conversion (160,161).  We reasoned 
that if this switch occurred in our model, that intermediate cell phenotypes would be 
detected as α cell character gives way to β cell character.  To test this hypothesis, we used 
triple transgenic Tg(ins:FlagNTR); Tg(gcga:GFP); Tg(ins:dsRed) zebrafish in which α 
and β cells were marked in green and red, respectively.  Although no β cells remained 
after MTZ treatment at 0 dpa, several GFP+ dsRed+ double positive cells were detected at 
1 and 2 dpa (Figure 3-1J-K, Figure 3-8).  Next, to distinguish between α to β cell 
transdifferentiation and de novo co-expression of glucagon and insulin during 
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differentiation of β cell progenitors, we used temporally restricted α cell lineage tracing.  
Tg(gcga:Cre; cryaa:YFP)s962 (hereafter gcga:Cre) fish were crossed with hs:CSH and 
gcga:cre; hs:CSH embryos were heat pulsed at 3 dpf and analyzed at 4 dpf.  This 
approach marked 17% of Gcg+ α cells and 8.5% of β cells with H2B-GFP, but no δ cells 
(Figure 3-1L; Figure 3-9A-E).  This may reflect activity of the glucagon promoter in 
some β cells or their progenitors during neogenesis in embryos/larvae and adults (Figure 
3-10).  Even so, when we heat-pulsed gcga:cre; hs:CSH; ins:Flag-NTR embryos at 3 dpf 
to mark gcga+ cells, then ablated β cells with MTZ treatment from 3-4 dpf, Gcg+ α cells 
were the only cells that remained marked by H2B-GFP (Figure 3-1M).  At 2 dpa, we 
observed that approximately 13.1% of newly generated β cells (1.9 cells out of 14.5 
cells/islet) were H2B-GFP marked (Figure 3-1N,O).  When this is normalized to the 
efficiency of gcga:Cre it suggests that approximately 11 β cells (77%) per recovering 
islet are derived from gcga:cre expressing cells.  Since all β cells, including those labeled 
by gcga:Cre, are destroyed by MTZ treatment, this observation indicates that new β cells 
originated from pre-labeled α cells. 
Additionally, it was recently shown that somatostatin+ delta (δ) cells spontaneously 
convert into insulin producing cells in young, β cell ablated mice (170).  In order to 
determine if δ cells could also switch identity in zebrafish, we used Tg(sst2:Cre; 
cryaa:Venus)s963 (hereafter sst2:Cre) to similarly trace δ cells.  sst2:Cre labeled 45% of δ 
cells and 1.5% of insulin+ cells in intact islets, and in regenerating islets only 1% of the 
new insulin+ β cells were labeled (Figure 3-2A-E).  Concordantly, regenerating islets 
rarely showed co-localization of insulin and somatostatin (Figure 3-11).  These data 
indicate that δ cells do not typically share the capacity of α cells to transdifferentiate to β 
cells in response to β cell ablation in zebrafish. 
 
α to β cell transdifferentiation can be marked by label retaining assay in the 
zebrafish principal islet.  
In the pancreata of both gcga:GFP and gcga:cre; hs:CSH fish, we consistently 
observed a small fraction of GFP marked cells outside the islet that did not stain for either 
insulin or glucagon (Figure 3-12).  These may represent immature cells that express the 
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glucagon promoter construct, but are not yet committed to the α or β cell fate (pro-α 
cells) (279).  Our genetic tools would not distinguish between β cells formed from such 
pro-α cells or from the conversion of mature α cells inside the islet.  Thus, to further test 
whether mature hormone expressing α cells can transdifferentiate to β cells during 
regeneration, we used a Label Retaining Cell (LRC) assay to mark a discrete population 
of endocrine cells in the principal islet (222,280).  For these experiments, embryos were 
injected with mRNA encoding Histone H2B-RFP, which is a stable fluorescent protein 
that is exponentially diluted by cell division (Figure 3-3A).  Zebrafish endocrine cells 
derived from the dorsal pancreatic bud differentiate, cluster into an islet, and become 
largely quiescent by 24 hpf, and therefore retain H2B-RFP fluorescence (222).  
Conversely, ventral pancreatic bud-derived progenitor cells undergo intensive 
proliferation before differentiating and thus do not retain the fluorescent signal (H2B-
RFP-) (2).  Therefore using this approach makes it possible to discern the population of 
dorsal pancreatic bud derived endocrine cells as H2B-RFP+ cells (Figure 3-3B). 
We used multiple criteria to demonstrate that the label retaining cells in the principal 
islet were committed endocrine cells.  First, we determined that nearly all H2B-RFP+ 
cells in the islet were positive for neurod:GFP (a pan-endocrine marker) and sox17:GFP 
(an endoderm marker) and expressed insulin, glucagon, or somatostatin (Figure 3-3C,D, 
3-13A-C).  A small number of H2B-RFP+ cells in the principal islet were kdrl:GFP 
positive and this fraction was similar to the size of the sox17 negative and neurod-
negative fractions (Figure 3-13D,E), suggesting that the non-endocrine H2B-RFP+ cells 
are endothelial cells.  The quantity of H2B-RFP+ α, β, and δ cells remained constant 
during development (Figure 3-3E), which indicates that dorsal bud derived α and δ cells 
are also largely quiescent, as previously reported for β cells (222).  Taken together, our 
data show that the LRC assay marks differentiated, quiescent pancreatic endocrine cells 
in the principal islet.  Moreover, H2B-RFP- ventral bud-derived pancreatic progenitor 
cells continuously differentiate into endocrine cells and contribute to principal islet 
formation in zebrafish larvae (Figure 3-3E), in accord with previous findings (222,280).  
Next, we used the LRC assay to investigate the origin of new β cells in β cell-ablated 
Tg(ins:CFP-NTR)s892 larvae.  We found that 35.7% of new β cells in 1 dpa regenerating 
islets were H2B-RFP+, indicating that they arose from pre-labeled dorsal bud-derived 
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endocrine cells (Figure 3F,G, red arrowhead).  Given our data above that δ cells and 
surviving β cells do not contribute to β cell regeneration, these H2B-RFP+ β cells most 
likely arise from H2B-RFP+ α cells.  In further support of this assertion, a subset of H2B-
RFP+ β cells was also glucagon positive (Figure 3-13F, white arrow).  Finally, we 
examined the expression of Pdx1 in putative transdifferentiating α cells.  Initially Pdx1 is 
expressed in all pancreatic progenitors, and later in differentiated β and δ cells (281).  
Importantly, the role of Pdx1 as a critical transcription factor for β cell development and 
maturation is conserved in zebrafish (227,282).  In the 4 dpf pancreas, Pdx1 was 
expressed in β and duct cells, but not in glucagon+ α cells (Figure 3-3H).  However, after 
β cells were ablated, many Pdx1+ Gcg+ α cells were detected in the islet (Figure 3-3I,J), 
consistent with previous observation in mouse models that Pdx1 is expressed in α cells 
during α to β cell transdifferentiation (160,161). 
Since pre-existing α cells switched to β cells in our ablation model, we hypothesized 
that α cell mass would decrease unless compensated by proliferation or neogenesis.  We 
found no difference in α cell mass at any of the stages examined through 20 dpf (Figure 
3-14A).  To measure proliferation rate, we injected 1 dpa larvae with EdU and found that 
α cell labeling was significantly increased in the regenerating group (Figure 3-3K, Figure 
3-14B, C).  We observed similar results using the M-phase marker phospho-histone H3 
(Figure 3-14D-I).  No significant β cell proliferation was detected at 1 dpa (Figure 3-S8J-
L).  This further supports our results above that neogenesis, rather than proliferation of 
pre-existing β cells, is the primary source of during the initial stage of β cell regeneration 
in our model.  Subsequently, however, β cell proliferation may also contribute to the 
restoration of β cell mass in the later stages of regeneration. 
Next, we excluded the possibility that any replication of dorsal bud derivatives 
confounded the LRC assay by titrating the injected H2B-RFP mRNA.  We found that 
RFP fluorescence was completely lost only with a 16-fold dilution, suggesting that 
labeled cells can divide three times (1÷(2)3) and remain detectable (Figure 3-15A-E).  
Since we found no significant change of the H2B-RFP+ islet cell number between 0 dpa 
and 1 dpa (Figure 3-15F-H), and since we only detected ≤2 EdU+ H2B-RFP+ cells per 
regenerating islet (Figure 3-15I), these data indicate that dilution of H2B-RFP signal by 
proliferation is negligible.  Moreover among the proliferating α cells, most were found to 
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be H2B-RFP- (Figure 3-15J).  Altogether, our data suggest that dorsal bud derived 
endocrine cells do not proliferate, but that H2B-RFP+ α cells directly convert to β cells.  
The increased rate of H2B-RFP- α cell proliferation may compensate for the loss of α cell 
mass due to α to β cell conversion during regeneration phase.  In sum, our data show that 
β cells formed during islet regeneration arise both from α cell transdifferentiation (H2B-
RFP+) and from differentiation of ventral bud-derived pancreatic cells (H2B-RFP-), 
which could be naïve progenitors or ventral bud derived endocrine cells.  These findings 
prompt the question of how these two cellular regeneration sources are coordinately 
regulated.  
 
α cells and glucagon are required for β cell regeneration.  
To test the necessity of α cells in islet regeneration, we eliminated them by zygotic 
injection of arxa morpholino (arxaMO).  The homeobox transcriptional repressor Arx is 
conserved between humans and zebrafish, and orthologues have 68% identity in their 
peptide sequences.  Importantly, loss of Arx results in depletion of α cells from the 
endocrine pancreas in human, mouse and fish (85,88,232,283).  In arxaMO-injected, but 
not control MO-injected islets, glucagon protein and mRNA were undetectable, though 
neither morpholino generated general morphological defects (Figure 3-3L, M, Figure 3-
S10A-C and data not shown).  β cell number was statistically unaffected, and δ cell 
number increased (Figure 3-16D,E).  Next, we tested how the loss of Arx influenced β 
cell regeneration from dorsal and ventral bud-derived sources by co-injecting arxaMO 
and H2B-RFP mRNA into Tg(ins:CFP-NTR) embryos.  In arxaMO-injected larvae, the 
number of H2B-RFP + regenerated β cells was significantly reduced compared with 
control morpholino injected larvae (Figure 3-3N, O), showing that Arx is required for β 
cell transdifferentiation from α cells.  Interestingly, regenerating islets in arxaMO-
injected larvae had an increased number of insulin+ somatostatin+ cells, suggesting that α 
cell loss may facilitate δ to β cell transdifferentiation (Figure 3-16F-H).  Surprisingly, 
loss of Arxa also resulted in a dramatic decrease of H2B-RFP- β cell regeneration (Figure 
3-3N, O).  Thus, in addition to our earlier findings, which show that α cells can be direct 
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precursors of β cells, α cells may also provide local or systemic cues that regulate 
neogenesis from ventral bud-derived precursors. 
To test whether glucagon could be such a cue, we isolated endodermal organs from 
ablated and control embryos (Figure 3-4A, Figure 3-17), then used quantitative PCR to 
examine insulin (insa) and glucagon (gcga) expression (other genes we examined are 
listed in Supplemental Table 3-1).  As expected, insulin was depleted at 0 dpa, but 
showed recovery at 1 and 3 dpa (Figure 3-4B).  In contrast, gcga expression mirrored free 
glucose measurements: elevated at 0 and 1 dpa, but returned to baseline by 3 dpa (Figure 
3-1G, Figure 3-4B).  In situ hybridization at 4 and 5 dpf showed that gcga expression was 
restricted to the pancreas and that expression in control and regenerating islets followed 
the same trend, which qualitatively supports the qPCR data (Figure 3-18A-H).  Zygotic 
injection of translation-blocking glucagon morpholino (gcgaMO) into Tg(gcga:GFP) 
zygotes caused no gross developmental defects (Figure 3-18I); however, it eliminated 
glucagon protein expression, increased gcga:GFP+ cell number, and decreased β cell 
formation (Figure 3-4C-E).  Moreover, using the LRC assay we found that gcgaMO 
impaired ventral, but not dorsal bud-derived β cell formation (Figure 3-4F; Figure 3-19).  
Conversely, the expansion of α cell mass was associated with increased α cell 
proliferation and neogenesis from duct associated progenitors (Figure 3-20), consistent 
with the endocrine phenotypes reported in mutant mice deficient in the glucagon pathway 
(139,141,284,285). 
We next asked if β cell regeneration was impacted following glucagon knockdown by 
co-injecting gcgaMO and H2B-RFP mRNA into Tg(ins:CFP-NTR) zygotes, and found 
that β cell regeneration from both H2B-RFP+ and H2B-RFP- sources was significantly 
reduced (Figure 3-5A,D,G).  The effect of gcgaMO on β cell regeneration and α cell 
transdifferentiation was further confirmed by gcga:cre; hs:CSH α cell lineage tracing.  
We found a significant reduction of total β cells and H2B-GFP+ β cells in gcgaMO-
injected regenerating islets (Figure 3-5H-J).  These results mirror our arxaMO results in 
which α cell loss influences β cell regeneration from both cellular sources, and is 
consistent with both local and systemic functions of glucagon. 
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Glucagon or Exendin-4 infusion restores β cell regeneration.  
Selective proteolysis results in production of several peptide products from the 
glucagon gene, including glucagon and Glucagon-Like Peptide-1 (GLP-1), which signal 
through distinct receptors. Using glucagon gene knockdown, we could not distinguish 
between actions of these peptides on β cell regeneration.  Because human glucagon binds 
and activates zebrafish Glucagon receptor (Gcgra), and the GLP-1 receptor agonist 
Exendin 4 (Ex-4) activates zebrafish GLP-1 receptor (Gcgrb) (245,286), we therefore 
parsed their roles by infusing recombinant human glucagon and Ex-4 into the circulation 
of β cell-ablated zebrafish larvae.  When we infused glucagon or Ex-4 into control β cell-
ablated embryos, we observed that glucagon increased H2B-RFP- β cell production, but 
had no significant effect on transdifferentiating H2B-RFP+ cells (Figure 3-5A-C,K).  
Neither Ex-4 nor the GLP-1 receptor antagonist Ex-9-39 significantly affected β cell 
regeneration (Figure 3-21).  In contrast, in gcgaMO-injected β cell-ablated embryos we 
found that either glucagon or Ex-4 infusion rescued β cell regeneration from both H2B-
RFP+ α cells and H2B-RFP- ventral bud-derived sources (Figure 3-5A,D-G; Figure 3-22).  
Together, these data suggest that glucagon and GLP-1 may have permissive effects on α 
to β cell transdifferentiation. In addition, both pathways can modulate β cell neogenesis 
from the ventral bud-derived sources, which are likely duct-derived progenitors. In 
accord with these interpretations, we found that the glucagon receptor (gcgra) and the 
GLP1 receptor (gcgrb) were expressed widely in zebrafish endodermal organs at 4 and 5 
dpf, including the pancreas and liver (Figure 3-23). 
A primary action of glucagon signaling is stimulation of hepatic glucose production. 
Previous studies showed that glucose is critical for β cell differentiation (287) and is a 
potent β cell mitogen (288-290).  Thus, we performed glucose infusions to determine 
whether glucagon might influence β cell production indirectly through liver-derived 
glucose.  Injected glucose was cleared from larvae by 6 hours, and free glucose was 
decreased in gcgaMO-injected larvae (Figure 3-24).  In concordance with a previous 
report (255), glucose treatment modestly increased β cell mass (Figure 3-6A-C).  
Similarly, when we infused regenerating larvae with glucose, we observed an increased 
number β cells (Figure 3-6D-F).  Quantification of label retaining populations showed 
that the increased regeneration was confined to the ventral bud derived H2B-RFP- 
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progenitors, which indicated that glucose did not directly affect α cell transdifferentiation 
(Figure 3-6F).  In support of this interpretation, we found no increase in expression of 
Pdx1 in α cells after treatment with glucose (Figure 3-25).  Finally, to further dissect the 
roles of hyperglycemia and glucagon signaling on regeneration from each β cell source, 
we tested whether glucose could rescue β cell regeneration in gcga morphants.  While we 
observed an increase in regenerating β cells in both glucose and glucagon treated larvae, 
only glucagon could restore H2B-RFP+ β cell formation (Figure 3-6G-K).  Together, our 
data support a model in which glucagon per se is necessary for α to β cell conversion, 
while glucose levels regulated by glucagon or GLP-1 signaling drive β cell neogenesis 
from ventral bud progenitors (Figure 3-6L). 
 
III.D. Discussion 
Diabetes results from the depletion or dysfunction of β cells, and their replacement 
will be central to a cure.  Even though β cell replacement strategies can be effective in 
principle, they are limited by β cell availability (54), necessitating the identification of 
novel exogenous or endogenous sources of therapeutic β cells.  Here, we have exploited a 
zebrafish model of conditional β cell ablation, in which functional β cell mass rapidly 
recovers, to study mechanisms of vertebrate β cell regeneration.  We have investigated 
the origins of regenerating pancreatic β cells in this zebrafish β cell ablation model using 
two approaches: a cre-lox based genetic lineage tracing approach that indelibly marks 
endocrine cells with temporal precision and a non-genetic cell tracing approach that 
marks quiescent, differentiated endocrine cells (222).  Using these approaches, we 
distinguished two sources of new β cells: a ventral pancreatic bud-derived source, which 
may include “naïve” duct-associated progenitor cells that have been previously described 
(2,291), and non-β endocrine cells (α cells in particular) that transdifferentiate into β 
cells.  Thus, we have shown for the first time the spontaneous, facultative conversion of α 
cells into β cells in an organism other than mouse.  Most importantly, we identified that 
activation of glucagon is required for β cell regeneration from both precursor pools.  
Furthermore, our results demonstrate that key physiological actions of glucagon in 
regulating blood glucose are conserved with mammals, just as with insulin 
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(221,244,248); in particular, we found that in zebrafish glucagon activity is correlated 
with blood glucose levels, and that glucagon expression is up-regulated in the absence of 
β cells.  These findings further validate the zebrafish as a model for studying human 
metabolic disease.  
In our study, we have found that α to β cell transdifferentiation was strongly 
diminished in glucagon knockdown embryos and that this process could be restored by 
infusion of either glucagon or Exendin-4.  Thus, we have uncovered a novel mechanism 
that regulates the spontaneous α to β cell transdifferentiation through the action of 
physiologically relevant peptide hormone signaling pathways; in particular, peptides 
derived from the glucagon gene.  However, since exogenous treatment with 
glucagon/Exendin-4 did not further increase α to β transdifferentiation, these results 
suggest that glucagon gene products are important permissive signals facilitating the 
destabilization of α cell identity.  Moreover, our data suggest that activation of the 
glucagon gene may coordinately regulate β cell regeneration from α cells and pancreatic 
duct-associated progenitor cells.  The effect of glucagon on the latter source may act 
indirectly through increased gluconeogenesis, as glucose potently increased H2B-RFP- β 
cells, even in gcga knockdown islets.  Interestingly, we found that newly formed H2B-
RFP+ β cells in the principal islet often form contacts with extra-islet H2B-RFP- β cells 
via long cellular extensions.  This observation suggests that α cell transdifferentiation 
within the islet may help recruit new β cells to the core of the islet, and thus regenerate 
normal islet structure (L.Y. and R.M.A. unpublished result).  
The glucagon gene gives rise to multiple active endocrine peptides through selective 
proteolysis of Preproglucagon by prohormone convertases (PC).  The α cells yield 
glucagon via PC2 activity, while GLP-1 is generated mainly in intestinal L cells by 
PC1/3 activity (292).  In mammals, glucagon and GLP-1 have counter-regulatory actions 
on blood glucose: glucagon stimulates hepatic glucose production, while GLP-1 inhibits 
it through stimulation of β cell and inhibition of α cell functions (293).  However, in our 
zebrafish ablation model, the regeneration defect observed in glucagon morphants could 
be rescued by injection of either recombinant human glucagon, or the GLP-1 receptor 
agonist Exendin-4.  Indeed, glucagon and GLP-1 have similar effects upon cAMP 
generation and hepatic glucose production in teleost fish (294).  This may be due to loss 
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of the ancestral GLP-1 receptor, together with the evolved capacity of a duplicated 
glucagon receptor to bind GLP-1 (242).  Thus, we speculate that in fish, the glucagon 
signaling pathway executes some of the functions of GLP-1 in mammals. In mammalian 
animal models of diabetes and in human diabetic patients, up-regulation of Pc1/3 
expression and GLP-1 production in α cells was observed together with increased 
Glucagon secretion (295-297).  Furthermore, GLP-1 production in α cells is associated 
with β cell compensation and regeneration in response to β cell injury (298-300).  Thus, it 
is possible that the increased glucagon/GLP-1 signaling observed in our zebrafish β cell 
ablation model reflects a conserved function of GLP-1 signaling in mammalian β cell 
regeneration.  GLP-1 receptor is abundantly expressed in pancreatic ducts, β cells, and 
embryonic α cells (123).  While it is unclear whether adult α cells express GLP-1 
receptors, these receptors are expressed in insulin/glucagon dual hormone positive cells 
in the rat pancreas (122,123).  Thus, we anticipate that GLP-1 receptor expression 
increases in α cells during transdifferentiation; this will be an area of future study.  In 
addition to the demonstrated functions of GLP-1 signaling during β cell regeneration, we 
cannot exclude the role of glucagon signaling in this process given the fact that glucagon 
plays a role in the maturation and function of β cells. For instance, injection of glucagon 
into chick embryos increases β cell mass and decreases α cell mass (240).  Furthermore, 
insulin expression is delayed and ultimately reduced in the islets of Gcgr-/- mice 
(139,140), and fetal mice treated with glucagon morpholinos showed impaired 
differentiation of early β cells (141).  Indeed, we found that both glucagon receptor 
(gcgra) and GLP-1 receptor (gcgrb) were expressed throughout the pancreas in zebrafish 
larvae.  Thus, further research is needed to delineate how different peptides derived from 
the glucagon gene work together to restore islet cell composition and function following 
loss of β cell number.  
Due to the limitations of our current tools, we cannot discern whether ventral bud-
derived H2B-RFP- α cells also transdifferentiated into β cells, and if these precursors are 
mature or immature α cells.  β cell neogenesis may involve a glucagon-positive 
intermediate that may initially exhibit some characteristics of α cells, but subsequently 
mature into β cells.  Intriguingly, the presence of insulin:mCherry and glucagon:GFP 
dual positive cells in the non-ablated larval and adult zebrafish pancreas suggest that this 
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process may be active in the homeostasis of the islet cell mass.  Indeed, it has been 
proposed that a pro-α cell population exists as a facultative progenitor that exhibits 
features of β and α cells in mammals (279), although this proposition contradicts earlier 
lineage tracing studies  (54)that showed that mature β and α cells arise from distinct 
lineages.  As ~20-65% of α cells are not marked by the Glucagon:Cre transgenic mice 
(54,79,301,302), it is possible that relevant subpopulations of α cells have gone 
undetected in these studies.  The development of novel mouse and zebrafish transgenic 
strains where cre is more faithfully regulated by the endogenous Glucagon locus may 
shed light on this possibility. 
Consistent with the hypothesis that α cells are a relevant source of new β cells in 
regenerating islets, the loss of α cells due to the knockdown of arxa strongly diminished 
the regeneration of β cell mass.  In arxMO-injected islets, we expect that α cell 
progenitors are diverted to δ and β cell identities, as in the mouse Arx knockout, where 
increases of 200% and 31%, respectively, were observed (85).  In arxaMO-injected islets, 
we found that δ cell numbers were indeed increased, as was the number of β cells, though 
the latter was not statistically significant (Figure S10D,E).  In regenerating islets, the 
knockdown of gcga phenocopies the loss of α cells observed in the arxa knockdown, 
providing strong evidence that peptides derived from the glucagon gene are critical 
regulators of α cell conversion.  As in murine disruptions of the glucagon signaling 
pathway (139,140,164,284), we found that α cell mass was not only maintained, but 
expanded through proliferation and neogenesis.  That the number of potential α cell 
progenitors of β cells was expanded, yet β cell regeneration was depressed further 
underscores the importance of glucagon for cell fate switching.  Finally, as hypoglycemia 
is expected to result from α cell/glucagon depletion, we hypothesize that the observed 
reduction of β cell neogenesis from ventral pancreatic bud-derived tissues in arxa 
morphants results from a combination of at least two factors: (1) loss of glucose, which 
acts as a stimulator of β cell differentiation (270), and (2) fewer α cells acting as 
progenitors of β cells.   
Regeneration studies in mice have shown that the mode and extent of β cell 
regeneration is dependent on the injury model.  Proliferation of surviving β cells 
predominates after targeted ablation of 70-80% of β cells (22,162), while conversion of α 
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or δ cells to β cells occurs only with extreme β cell loss (>99%) (160,170).  Likewise, we 
would hypothesize that lower levels of β cell ablation in zebrafish may mitigate 
transdifferentiation in this model.  Additionally, plasticity of α and δ cells is not constant 
with age.  In prepubescent mice, δ cells, but not α cells, are competent to transform into β 
cells after injury (170).  In contrast, fetal α cells can be reprogrammed to β cells by 
misexpression of Pdx1, while α cells of newborn mice cannot (65).  Intriguingly, 
regenerating islets in STZ-treated adult zebrafish show increased PCNA staining in the 
mantle region (247), which is consistent with an induced proliferation of α cells, just as 
we observe in regenerating larvae (Fig 3K).  Whether the endocrine plasticity of the 
zebrafish larval pancreas is maintained in juveniles, and adults, and whether this is 
dependent on extreme β cell loss, are important questions that are being addressed in our 
ongoing studies. 
Our data do not distinguish between the possibilities that peptides derived from the 
glucagon gene act directly on α cells, or that they act indirectly through other tissues 
(such as the liver) to produce non-glucose intermediate messengers that feed back to α 
cells.  Indeed, it has been recently shown that hyperplasia of α cells in Gcgr knockouts 
can be phenocopied by tissue-specific knockdown of the glucagon receptor in 
hepatocytes (164), revealing that a circulating factor derived from the liver may partially 
mediate this hyperplastic effect.  Thus, it will be important to investigate how α and β cell 
mass are affected in this system when challenged by β cell depletion and hyperglycemia.  
In addition, given the multiple paracrine actions of glucagon in the islet, it will be 
important to examine the role of the glucagon receptor as well as the GLP-1 receptor 
specifically within the α cells, using tissue-specific knockdown or hyperactivation 
approaches. 
In summary, our data are consistent with a model whereby the glucagon/GLP-1 
signaling pathway works through two routes to elicit new β cell formation: (1) non-
autonomously through stimulation of hepatic glucose production, which can stimulate β 
cell formation from naïve duct associated progenitor cells (224,287); (2) autonomously 
within the α cell compartment to regulate α cell mass and cell identity (Figure 6L).  Arx 
is a potent reprogramming factor that is essential for α cell development and maintenance 
(85,86,154).  As such, suppression of Arx in α cells will be essential for their conversion 
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to β cells.  Therefore we hypothesize that arxa expression is negatively regulated by 
excessive glucagon/GLP-1 signaling in α cells.  Loss of glucagon/GLP-1 signaling by 
multiple approaches results in hyperplasia of α cells and increased glucagon content 
concomitant with increased expression of Arx (165,284).  Our data provide a connection 
between glucagon/GLP-1 signaling and the maintenance of α cell fate.  As α cells appear 
to be epigenetically programmed to enable their conversion to β cells in humans (303), 
investigating how glucagon/GLP-1 signaling pathways link to epigenetic regulators will 
be an exciting area for further study.  Understanding how such extrinsic signals can 
regulate α cell stability will facilitate novel diabetes therapies that promote β cell 
replenishment.  Furthermore, together with the observation that α cells appear to have a 
heightened capacity for regeneration by neogenesis from duct-associated progenitors 
(153), our results support the hypothesis that the α cell pool constitutes an extensive 
reserve of new β cells.  Our data indicate that peptides derived from the glucagon gene 
are factors critical for regulation of this endogenous repair mechanism, and suggest that 
stimulation of endocrine transdifferentiation may unlock unlimited sources of new β 
cells. 
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Figure 3-1.  β cell neogenesis from α cell transdifferentiation in zebrafish. (A-E) 
Confocal projections showing α (red) and β (green) cells in the principal islet of intact 
(A,B) and ablated (C,D,E) Tg(ins:CFP-NTR) larvae at 0, 1, and 16 days post ablation 
(dpa). (F) Quantification of insulin+ cells in intact (gray line) and regenerating islets (red 
line) from 0 to 20 dpf (n≥3 for all groups except control 20 dpf, n=1).  The ratio of β cells 
in regenerating vs. control islets is indicated. (G) Blood glucose measurements of non-
ablated larvae (gray), and larvae in which β cells were ablated from 3-4 dpf (red) (n=3). 
(H,I) Confocal projections of β cell lineage marked islets in 5 dpf control and 1 dpa 
Tg(ins:Cre); Tg(hs:CSH); Tg(ins:Flag-NTR) larvae.  β cells were labeled by inducible 
H2B-GFP at 3 dpf before ablation and stained for GFP (green) and insulin (red).  (J,K) 
Confocal planes of ablated (J) and regenerating (K) islets in Tg(ins:Flag-NTR); 
Tg(gcga:GFP); Tg(ins:Red) larvae. Red arrows in K indicates gcga:GFP+ins:Red+ β cells 
in regenerating islet.  (L-N) confocal planes of Tg(gcga:cre); Tg(hs:CSH); Tg(ins:Flag-
NTR) islets labeled by H2B-GFP before ablation, and stained for GFP (green), insulin 
(red), and glucagon (blue).  α cells are indicated by white arrows and β cells by red 
arrows.  (L) 6 dpf non-ablated islet, (M) 4 dpf ablated islet at 0 dpa, and (N) 6 dpf islet at 
2 dpa.  H2B-GFP+ labeled regenerating β cells are indicated in yellow.  (O) 
Quantification of H2B-GFP+ and H2B-GFP- β cells in 2 dpa islets (n=10). Statistical 
analysis: Student’s t-test was used in O. 
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 Figure 3-2.  δ cells but not regenerating β cells are lineage marked by sst2:Cre.  (A-A’’’) 
Merged and single channel images of 5 dpf Tg(sst2:Cre); Tg(hs:CSH); Tg(ins:Flag-NTR) 
islets that were heat shocked at 3 dpf and stained for GFP(green), insulin (red) and 
somatostatin (white). Somatostatin+δ Cells are labeled by H2B-GFP.  (B, C) Merged and 
single channel images of 5 dpf non-ablated (B) or 1 dpa (C) Tg(sst2:Cre); Tg(hs:CSH); 
Tg(ins:Flag-NTR) islets that were heat shocked at 3 dpf and stained for GFP(green), 
insulin (red) and DNA (blue).  (D) Quantification of total somatostatin+, 
somatostatin+/H2B-GFP+, insulin+, and insulin+/H2B-GFP+ cells in non-ablated 5 dpf 
Tg(sst2:Cre); Tg(hs:CSH); Tg(ins:Flag-NTR) islets.  45% of somatostatin+ cells and 
1.5% of insulin+ cells are marked by sst2: Cre (n=15).  (E) Quantification of insulin+ and 
insulin+/H2B-GFP+ cells in 5 dpf regenerating islets.  1% of insulin+ cells are marked by 
sst2: Cre (n=9). 
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Figure 3-3.  α to β cell transdifferentiation can be marked by label retaining assay in the 
zebrafish principal islet.  (A-B) Schematic of the label retaining assay.  (A) Zygotes were 
injected with H2B-RFP mRNA.  Fluorescent signal from H2B-RFP protein was diluted 
by mitosis.  (B) The label retaining assay marks quiescent, early differentiated pancreatic 
endocrine cells derived from the dorsal bud.  (C,D) Confocal planes of H2B-RFP-labeled 
5 dpf islets.  (C) Tg(neurod:GFP) (n=4), (D) wild type islet stained for insulin (green), 
glucagon (blue) and somatostatin (white) (n=5).  (E) Quantification of H2B-RFP+ and 
H2B-RFP- cells expressing insulin, glucagon, and somatostatin (n≧3 for all).  (F) H2B-
RFP labeled regenerating islet of 5 dpf/1 dpa Tg(ins:CFP-NTR) larva stained for CFP 
(green) and Glucagon (white).  Red arrowheads indicate H2B-RFP+ regenerating β cells, 
white arrowhead indicates H2B-RFP- regenerating β cells in the islet and yellow 
arrowhead indicates H2B-RFP- β cells in the extra-pancreatic-duct region (epd).  (G) 
Quantification of 1 dpa H2B-RFP+ and H2B-RFP- β cells(n=7).  (H,I) Confocal planes 
showing Pdx1 (red), glucagon (white) and insulin (green) expression in 4 dpf non-ablated 
(H) and ablated (I) islets.  Pdx1+ α cells are marked by white arrows.  (J) Quantification 
of α cells expressing Pdx1 in 4 dpf non-ablated (n=5) and ablated islets (n=6).  (K) 
Quantification of proliferating (EdU+) α cells in 5 dpf non-ablated and 1 dpa islets (n≧7 
islets examined).  (L,M) Confocal planes showing glucagon (red) and insulin (green) 
staining in control MO (L) and arxaMO-injected (M) 5 dpf larvae.  Glucagon+ cells are 
absent from arxaMO islets.  (N) Confocal projection of arxaMO-injected 5 dpf/1 dpa 
Tg(ins:CFP-NTR) islet labeled with H2B-RFP lacking most β cell regeneration.  (O) 
Quantification of 1 dpa β cells in control MO (gray, n=16) and arxaMO-injected (red, 
n=19) islets.  Statistical analysis: Student’s t-test was used in J,K and two way ANOVA 
followed by Bonferroni posttest was used in E,O.   
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Figure 3-4.  glucagon is required for islet development. (A) Image of endodermal organs 
isolated from 4 dpf larvae. p:pancreas, li:liver, ib:intestinal bulb. (B) Quantitative PCR of 
insulin and glucagon in control and ablated larvae.  insulin expression was diminished 
and gcga expression transiently increased during regeneration; n=3 independent 
experiments.  (C-E) gcgaMO blocks glucagon protein expression and increases α versus β 
cell ratio.  (C,D) Confocal projections of 5 dpf control MO (C) and gcgaMO-injected (D) 
Tg(gcga:GFP);Tg(ins:dsRed)  larvae stained for Glucagon (red).  (E) Quantification of 
gcga:GFP+ α cells and insulin+ β cells in control MO (n=15) and gcgaMO-injected 
(n=10) islets.  (F) Quantification of H2B-RFP+ and H2B-RFP- β cells at 3 and 5 dpf in 
control (n≥3) and gcgaMO-injected (n=5) islets.  Ventral bud derived H2B-RFP- β cells 
are specifically diminished in gcga morphants.  Two way ANOVA followed by 
Bonferroni posttest was used in B, E and F for statistical analysis.  
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Figure 3-5.  Differential regulation of β cell progenitor pools by glucagon gene products.  
(A-F) Confocal projections of 1 dpa H2B-RFP-labeled Tg(ins:CFP-NTR) control islets 
(A-C) and gcgaMO-injected islets (D-F), and that were treated with vehicle (A,D), 
recombinant glucagon (B,E), or Exendin-4 (C,F).  Islets were immunostained for CFP 
(green) and glucagon (white).  β cell regeneration was restored with glucagon or Ex-4 
injection, but not with Ex-9-39 injections. (G) Quantification of H2B-RFP+ and H2B-
RFP- β cell number in control regenerating (n=7) and gcgaMO-injected regenerating 
islets treated with vehicle (n=9), glucagon (n=13), Ex-4 (n=12), or Ex-9-39 (n=17).  (H-I) 
Confocal planes of 1 dpa Tg(gcga:cre);Tg(hs:CSH);Tg(ins:FlagNTR) control and 
gcgaMO injected regenerating islets stained with glucagon (white) and insulin (red).  α 
cells were labeled (white arrow) at 3 dpf by H2B-GFP before MTZ treatment.  Yellow 
arrow indicates H2B-GFP+ β cells and blue arrow indicates H2B-GFP- β cells.  (J) 
Quantification of H2B-GFP+ and H2B-GFP- β cells in regenerating control (n=10) and 
gcgaMO-injected islets (n=13).  (K) Quantification of H2B-RFP+ and H2B-RFP- β cells 
in regenerating islets treated with vehicle or glucagon (n=14). Two way ANOVA 
followed by Bonferroni posttest (G) and Student’s t-test (J, K) and were used for 
statistical analysis.  
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Figure 3-6.  Differential regulation of β cell progenitor pools by glucagon and glucose.  
(A,B) Confocal projections of Tg(ins:CFP-NTR) islets with 1 day treatment of mannose 
(osmolality control, A) and glucose (B) and stained for CFP (green) and glucagon (red).  
(C) Quantification of insulin+ cells showed that glucose treatment increases β cell mass 
(n=18).  (D,E) Confocal projections of 5 dpf/1 dpa H2B-RFP mRNA-injected islets that 
were mannose (D) or glucose-treated (E) during regeneration and stained for CFP (green) 
and glucagon (white).  (F) Quantification of H2B-RFP+ and H2B-RFP- β cells in control 
(n=7) and glucose treated (n=7) islets shows a specific increase in H2B-RFP- population.  
(G-J) Confocal projections of 5 dpf/1 dpa Tg(ins:CFP-NTR) islets injected with H2B-
RFP mRNA alone (G), or co-injected with gcgaMO (H-J).  Samples treated with vehicle 
(G, H), glucose (I) or with glucagon (J).  (K) Quantification of H2B-RFP+ and H2B-RFP- 
cells from islets in control (n=27), gcgaMO (n=15), gcgaMO +glucose (n=17), gcgaMO 
+glucagon (n=22). Only glucagon rescued H2B-RFP+ β cell regeneration.  (L) A model 
integrating distinct roles of glucagon on β cell formation.  Loss of β cells triggers α cell 
proliferation and activation of glucagon.  Increased output of glucagon and GLP-1 drives 
regeneration from two sources.  In the first (a), glucagon/GLP-1 acts autonomously in α 
cells to permit their transdifferentiation to β cells.  In the second (b), glucagon/GLP-1 
acts non-autonomously through intermediates (e.g. liver derived glucose) to drive β cell 
formation from duct-associated progenitors.  Student’s t-test (C, F) and One way 
ANOVA followed by Tukey’s Post Hoc test (K) were used for statistical analysis.  
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Figure 3-7.  Pre-existing β cells do not contribute to β cell regeneration.  (A-D) Confocal 
projections (A,C) and confocal planes (B,D) of Tg(hs:CSH); Tg(ins:cre) islets at 4 dpf 
(A,B) and 5 dpf (C,D) that were heat shocked at 3 dpf and stained for insulin (red), GFP 
(green), and DNA (blue).  Insulin+ cells were specifically labeled by H2B-GFP.  (E, F) 
Confocal projections of 4 dpf Tg(ins:cre) (E) and Tg(hs:CSH) (F) islets showed no 
aberrant or leaky H2B-GFP fluorescence after heatshock.  (G) Quantification of insulin+ 
and insulin+/H2B-GFP+ cells at 4 dpf showed 41% of β cells were marked (n=11).  (H) 
The number of labeled β cells remained constant from 4 to 5 dpf (n=7).  (I) 
Quantification of total and H2B-GFP+ β cells in the regenerating islets represented in Fig 
1I.  Only ~2% of new β cells were labeled (n=13). (J-M) Epifluorescent images of 
ins:Kaede; ins:CFP larvae.  (J) Green Kaede and (J’) converted red Kaede in the β cells 
of a 72 hpf larva.  (K) A 96 hpf larva 24 hours after photo-conversion exhibited β cells 
present during UV exposure (yellow) as well as new β cells formed after the exposure 
(green only, arrow).  (L) Neither green Kaede (L) nor converted red Kaede (L’) are 
evident at 72 hpf after MTZ-ablation of β cells. (M) A 96 hpf photo-converted larvae 24 
hours after photoconversion and cessation of MTZ treatment shows only new β cells 
(green, arrows).Student’s t-test was used in H for statistical analysis.  
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 Figure 3-8.  Emergence of gcga:GFP+ ins:dsRed+ dual hormone cells during 
regeneration.  (A-D) Confocal planes of Tg(gcga:GFP); Tg(ins:dsRed); Tg(ins:Flag-
NTR) islets in non-ablated 3 dpf (A), ablated 4 dpf (B), 1 dpa (C), and 2 dpa (D) larvae 
stained for DNA (blue).  gcga:GFP+ ins:dsRed+ dual hormone expressing cells are 
marked by red arrows.  (E) Quantification of ins:dsRed+ single positive and ins:dsRed+ 
gcga:GFP+ dual positive cells in regenerating islets from 1 to 3 dpa (n≥3). 
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 Figure 3-9.  Characterization of glucagon promoter activity in Tg(gcga:Cre). (A) Merged 
and single channel confocal planes of 6 dpf Tg(gcga:cre);Tg(hs:CSH) islets heat shocked 
at 3 dpf and stained for GFP (green), Insulin (blue) and glucagon (red).  (B) Confocal 
plane of 4 dpf Tg(gcga:cre);Tg(hs:CSH) islet heat shocked at 3 dpf and stained for 
Somatostatin (white) and GFP (green).  (C) Quantification of total glucagon+ and H2B-
GFP+ glucagon+ cells in A shows that ~17% of α cells were marked (n=10).  (D) 
Quantification of total Ins+ and H2B-GFP+ Ins+ cells in A shows that ~8.5% of β cells 
were marked (n=6). (E) Quantification of Sst+ and Sst+ H2B-GFP+ cells in B (n=11).  (F-
G) Confocal planes of 4 dpf Tg(gcga:cre) (F) and Tg(hs:CSH) (G) islets showed no 
aberrant or leaky H2B-GFP expression after heat shock.   
 
84 
 
 Figure 3-10.  ins+ gcga+ cells during early islet development.  (A) Confocal planes of 1 
dpf Tg(gcga:GFP); Tg(ins:dsRed) islet showed that the majority of ins+ cells at 1 dpf are 
also gcga+.  Single positive insulin expressing cells are indicated by arrows.  (B) 
Confocal planes of 3 dpf Tg(gcga:GFP); Tg(ins:dsRed) islet showed ins+ gcga+ cells in 
the principal islet (arrow) and ins+ gcga+ newly formed β cells (arrowhead) in the 
extrapancreatic duct.  (C-D) Merged and single channel confocal planes of fluorescent in 
situ hybridization (C) proglucagon (red) expressed in ins+ cells (green) at 1 dpf in 
Tg(ins:CFP-NTR) islets immunostained for GFP (green).  (D) insulin (red) expressed in 
gcga+ cell(green) in 1 dpf Tg(gcga:GFP) islet immunostained for GFP (green).  (E) 
Quantification of ins+ gcga+ and ins+ cells at 1 dpf through 7 dpf.  Tg(gcga:GFP); 
Tg(ins:dsRed) islets showed a decrease of dual hormone-expressing cells with islet 
maturation.  
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 Figure 3-11.  Insulin and somatostatin are rarely co-expressed in non-ablated or 
regenerating islets. (A-B’’’) Merged and single channel confocal images of 4 dpf 
Tg(ins:CFP-NTR) islets stained for CFP (green), somatostatin (red), and glucagon 
(white), that were not ablated (A), or ablated from 2-3 dpf (B).  Regenerating insulin+ β 
cells (arrow) were rarely labeled.  (C,D)  Quantification of β cells and regenerated β cells 
that were insulin+ or insulin+ somatostatin+.  
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Figure 3-12. Characterization of glucagon promoter activity in extra-insular endocrine 
cells. (A) Confocal Plane of 4 dpf Tg(gcga:cre); Tg(hs:CSH) islet heat shock at 3 dpf 
stained for Glucagon (red) and GFP (green).  Green arrow head indicates Glucagon-H2B-
GFP+ Cells outside the islet.  (B,C) Quantification of total and extra-insular H2B-GFP+ 
cells in Tg(gcga:cre);Tg(hs:CSH) larvae heat shocked at 3 dpf.  At 4 dpf (B), 3 out of 18 
samples were found to have extra-insular H2B-GFP+ cells.  At 6 dpf (C), 1 out of 22 
samples was found to have extra-insular H2B-GFP+ cells. (D) Merged and single channel 
confocal planes of 3 dpf Tg(gcga:GFP) islets stained for GFP (green) and glucagon (red).  
Arrowhead indicates gcga:GFP+ glucagon- cells in pancreatic duct region outside of 
principal islet.  (E) Merged and single channel confocal planes of 3 dpf 
Tg(gcga:GFP);Tg(ins:dsRed) islets stained for GFP (green) ,dsRed (red) and Glucagon 
(white).  Arrowhead indicates gcga:GFP+ ins:dsRed-Glucagon- cells in pancreatic duct 
region outside of principal islet.  (F) Quantification of gcga:GFP+ glucagon- and 
gcga:GFP+ glucagon+ cell number in principal islet from 3 dpf through 6 dpf.  The 
percent of gcga:GFP+ glucagon- cells is consistent but small. (G) Quantification of 
insular and extra-insular gcga:GFP+ cell numbers.   
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 Figure 3-13.  H2B-RFP label retaining assay marks early differentiated endocrine cells.  
(A-D) Confocal planes of islets labeled with H2B-RFP. (A) Wild type islet stained for 
Insulin (green), Somatostatin (white) and Glucagon (blue) at 5 dpf.  There are 2 
endocrine populations in the islet: H2B-RFP+ (arrows) and H2B-RFP- (arrowheads).  
Yellow arrow indicates H2B-RFP+ cells in the islet lacking hormone staining.  (B) 
Tg(neurod:GFP) islet stained for GFP (green) at 3 dpf.  Yellow arrow indicates neurod- 
H2B-RFP+ non-endocrine cells in the principal islet.  (C) Tg(sox17:GFP) islet stained for 
GFP (green) at 3 dpf.  Yellow arrows indicate sox17- H2B-RFP+ non-endodermal cells in 
the principal islet.  (D) Tg(kdrl:GFP) islet region stained for GFP (green) and Glucagon 
(white) at 4 dpf.  Yellow arrows indicate kdrl:GFP+ H2B-RFP+ blood vessel cells in the 
principal islet.  (E) Quantification of sox17- H2B-RFP+, neurod- H2B-RFP+, and islet 
hormone (Ins/Gcg/Sst)- H2B-RFP+ cell quantities in the islet.  (F) 1 dpa regenerating 
Tg(ins:CFP-NTR) islet stained for CFP (green) and glucagon (blue). The white arrow 
indicates a triply positive ins:CFP-NTR+ glucagon+ H2B-RFP+ β cell. 
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Figure 3-14.  Proliferation of α cells but not β cells during β cell regeneration.  (A) 
Quantification of α cell number between 5 dpf and 20 dpf in control (gray) and 
regenerating (red) islets (n≧3).  (B-C) Confocal planes of non-ablated (B) or 1 dpa (C) 5 
dpf Tg(ins:FlagNTR) islets labeled with EdU (red) and stained for Glucagon (green). 
White arrows indicate Glucagon+ EdU+ cells in 1 dpa islet.  (D-I) Confocal projections of 
Tg(ins:CFP-NTR) islets stained for phospho-histone H3 (green), glucagon (red), insulin 
(blue) and DNA (white) that were not ablated (D-F) or ablated from 3-4 dpf and 
regenerating (G-I).  Islets were analyzed at 5 dpf (D,G), 6 dpf (E,H), and 7 dpf (F,I).  No 
phospho-histone staining was observed in any non-ablated islet (n=21) and 17.6% of 
regenerating islets showed staining (n=17).  (J-K) Confocal planes of non-ablated (J) or 1 
dpa (K) 5 dpf Tg(ins:CFP-NTR) islets labeled with EdU (red) and stained for GFP 
(green).  (L) Quantification of ins+ EdU+ cells in intact and ablated 5 dpf islets. Two-way 
ANOVA was used in A and Student’s t-test was used in L for statistical analysis.  
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Figure 3-15.  Proliferation of H2B-RFP+ cells during regeneration does not dilute H2B-
RFP mRNA.  (A-E) Confocal projections of 5 dpf islets injected with decreasing amounts 
of H2B-RFP (red) mRNA that were immunostained for insulin (green) and glucagon 
(blue) to show endocrine differentiation.  (A’-E’) heat map representation of H2B-RFP 
fluorescence from confocal projections in A-E.  Note that there is detectable H2B-RFP 
signal when mRNA was injected at the dose of 12.5 pg/embryo, which is an eightfold 
dilution.  (F-G) Confocal projections of H2B-RFP mRNA injected 5 dpf control (F) and 1 
dpa regenerating (G) islets that were labeled with EdU (white) for 1 hour, and stained for 
glucagon (green), RFP (red), and DNA (blue).  (H) Quantification of total H2B-RFP+ 
cells in islets from 3 dpf to 5 dpf in both intact islet (grey) and ablated islets (red).  There 
is a significant decrease of total H2B-RFP+ cell quantity in the islet during β cell ablation, 
but no difference of total H2B-RFP+ cell number in the islet during regeneration between 
0 dpa and 1 dpa.  (I) Quantification of H2B-RFP+ Edu+ cell number during regeneration 
showed there are at most 2 Edu+ H2B-RFP+ cells per islet during regeneration.  (J) 
Quantification of H2B-RFP+ and H2B-RFP- Glucagon+ Edu+ cell number in 1 dpa 
regenerating islets showed that 75% of proliferating α cells were H2B-RFP-. Two-way 
ANOVA was used in H for statistical analysis.  
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 Figure 3-16.  arxa knockdown induces the appearance of insulin/somatostatin co-
expressing cells.  (A-B) Confocal projections of 4 dpf control MO (A) and arxaMO- (B) 
injected Tg(ins:CFP-NTR) islets stained for somatostatin (red), glucagon (white) and 
GFP (green).  (C) Control MO and arxaMO-injected 4 dpf larvae show no general 
developmental defects.  (D-E) Quantification of total insulin+ and somatostatin+ cell 
number in 4 dpf control and arxaMO-injected larvae.  (F-G) Confocal planes of 1 dpa 
control (F) and arxaMO-injected (G) Tg(ins:CFP-NTR) regenerating islets stained for 
somatostatin (red), glucagon (white) and GFP (green).  White arrow in G indicates 
somatostatin+ insulin+ regenerating β cells in arxaMO-injected regenerating islet.  (H) 
Quantification of total insulin+ β cells and insulin+ somatostatin+ β cells in 1 dpa control 
and arxaMO-injected regenerating islets.  Student’s t-test was used in D,E, and H for 
statistical analysis.  
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 Figure 3-17.  Endodermal organ cDNA preparations are enriched for endoderm.  
Quantitative PCR analysis on cDNA isolated from pools of dissected endodermal organs 
(pancreas, liver, intestine) and non-endodermal organs (the remainder of the larva).  
Preparations were tested for markers of the endocrine pancreas (insa), the exocrine 
pancreas (trypsin), and a non-endodermal opsin (opn1sw1).  Virtually all of the insa and 
trypsin signal was limited to the endodermal fraction, while opn1sw was restricted to the 
non-endodermal fraction.  insa and trypsin were normalized to the expression level in 
endoderm, while opn1sw1 was normalized to non-endoderm. n=6 for all samples.  
 
 
 
 
 
 
 
 
 
 
 
95 
 
 Figure 3-18. glucagon expression is increased in regenerating pancreata, but not is 
required for general embryonic development.  Expression of glucagon revealed by in situ 
hybridization in non-ablated control (A-D), 0 dpa β cell-ablated (E,F), and 1 dpa 
regenerating (G,H) Tg(ins:CFP-NTR) islets at 4 dpf (A,B,E,F) and 5 dpf (C,D,G,H).  
(A,C,E,G) Arrows indicate glucagon expression in photomicrographs of whole larvae.  
(B,D,F,H) Confocal projections of islets.  (I) 2 dpf embryos and 5 dpf larvae injected 
with control MO or gcga MO. 
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 Figure 3-19.  gcga knockdown decreases ventral pancreatic bud-derived β cell 
differentiation.  (A-D’’’) Merged and single channel confocal projections of Tg(ins:CFP-
NTR) islets injected with H2B-RFP mRNA alone (A-B’’’) or H2B-RFP mRNA + gcga 
MO that were stained for glucagon (white) ,CFP (green) and DNA (blue) at 3 dpf (A,C) 
and 5 dpf (B,D).  
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 Figure 3-20. gcga knockdown increases α cell proliferation and neogenesis. (A-B) 
Merged and single channel confocal planes of 4 dpf control (A) and gcgaMO-injected 
(B) Tg(gcga:GFP) islets labeled by insulin antibody (white) and EdU incorporation (red). 
(C) Quantification of EdU+ gcga:GFP+ proliferating α cells in control (n=10) and 
gcgaMO injected (n=12) islets. (D,E) Merged and single channel confocal planes of 3 dpf 
control (D) and gcgaMO-injected (E) Tg(gcga:GFP) islets that were injected with H2B-
RFP mRNA and labeled by Glucagon antibody (white).  (F,G) Quantification of H2B-
RFP+ gcga:GFP+ dorsal bud-derived α cells (F) and H2B-RFP- gcga:GFP+ ventral bud-
derived α cells (G) in control (n=7) and gcgaMO (n=7) islets. (H-I) Confocal projections 
of 3 dpf control (H; n=7) and gcgaMO-injected (I; n=7) Tg(gcga:GFP) islets. Arrows 
indicate newly forming gcga:GFP+ cells derived from pancreatic ducts. 
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 Figure 3-21.  Glp-1 receptor agonist or antagonist treatment does not affect β cell 
regeneration.  (A-B’) Merged and single channel confocal projections of 5 dpf 
regenerating 1 dpa H2B-RFP mRNA injected islets that were treated with Exendin-4 (A) 
or Exendin-9-39 (B) during regeneration (comparable untreated control islets are shown 
in Figure 4).  (C) Quantification of H2B-RFP+ and H2B-RFP- regenerated β cells in 
vehicle, Exendin-4, and Exendin-9-39 treated islets. Two-way ANOVA was used in C for 
statistical analysis.  
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 Figure 3-22.  Glucagon or Exendin-4 injections rescue β cell regeneration in gcga MO-
injected islets.  (A-D’’) Merged and single channel confocal projections of 5 dpf/1 dpa 
regenerating H2B-RFP mRNA-injected (red) islets that were not morpholino-injected (A), 
or injected with gcgaMO (B-D) and stained for CFP (ins:CFP-NTR; green), glucagon 
(white), and DNA (blue). 
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 Figure 3-23.  glucagon receptor and glp-1 receptor mRNAs are expressed in the larval 
pancreas.  (A-D) Whole mount in situ hybridization showing regionally restricted 
expression of glucagon receptor (gcgra; A,B) and glp-1 receptor (gcgrb/glp1r; C,D) in 
the endodermal organs of 4 dpf (A,C) and 5 dpf (B,D) larvae. Note that both receptors are 
expressed throughout the pancreas, including exocrine and islet regions.  Abbreviations: 
pa: pancreas; li: liver; ib: intestinal bulb. 
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 Figure 3-24.  glucagon gene products regulate free glucose levels in zebrafish.  (A) Free 
glucose levels measured periodically after mannose control (gray line) or glucose (red 
line) injection (arrow).  (B) Free glucose measurement of control (gray line) and gcga 
MO-injected (red line) larvae at 3, 4 and 5 dpf.  (C) Free glucose measurement in control 
uninjected and gcgaMO-injected Tg(ins:CFP-NTR) larvae in which β cells were ablated 
from 3 to 4 dpf.  In both B and C, morpholino-injected zebrafish have diminished glucose 
levels. Two-way ANOVA was used in B and C for statistical analysis.  
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 Figure 3-25.  Quantity of Pdx1+ α cells is not affected by glucose injection.  (A-D’’’) 
Merged and single channel confocal projections of 5 dpf non-ablated control (A-B’’’) and 
1 dpa regenerating (C-D’’’) Tg(ins:CFP-NTR) islets that were not injected (A,C) or were 
injected with glucose (B,D) at 4 dpf.  Islets were stained for Pdx1 (red), CFP (ins:CFP-
NTR; green), and glucagon (white).  Pdx1+ glucagon+ double positive cells are marked 
with white arrows in C,D.  (E) Quantification of Pdx1 expression in α cells of intact and 
regenerating larvae was not altered by glucose injection; control group (n=8) and glucose 
treated group (n=12). Two-way ANOVA was used in E for statistical analysis.  
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Table 3-1. Pancreatic gene expression in regenerating endoderm. 
age gene 
 insa gcga arx mafa mafb neurod ela3l 
0 
dpa 
4 
dpf 
-22.08** +1.577** -1.262 -1.335* -1.801** -1.189 -1.010 
1 
dpa 
5 
dpf 
-39.43*** +2.00*** -1.317 +1.682*** -1.275 -1.324 +1.054 
3 
dpa 
7 
dpf 
-10.45*** -1.15 -1.243 +1.686*** +1.022 +1.262* -1.241* 
Positive and negative value indicates fold increase or decrease of gene expression in 
regenerating endoderm compared with age matched un-ablated control. MTZ was 
added from 3 dpf to 4 dpf for ablation of β cells.  n=3 for each group.  Two way 
ANOVA analysis * p≤0.05, ** p≤0.01, *** p≤0.001 
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CHAPTER FOUR: An insulin signaling feedback loop regulates pancreas 
progenitor cell differentiation during islet development and regeneration. 
(As submitted for publication with Robertson, M. A.; and Mastracci, T.M., 2015) 
 
IV.A. Summary 
As one of the key nutrient sensors, insulin signaling plays an important role in 
integrating environmental energy cues with organism growth. In adult organisms, relative 
insufficiency of insulin signaling induces compensatory expansion of insulin-secreting 
pancreatic β (β) cells. However, little is known about how insulin signaling feedback 
might influence neogenesis during the establishment of β cell mass during embryonic 
development. Here, using genetic approaches and a unique cell transplantation system in 
developing zebrafish, we have uncovered a novel role for insulin signaling in negatively 
regulating the differentiation of pancreatic progenitors. Blocking insulin signaling in 
pancreatic progenitors hastened the expression the essential β cell genes insulin and pdx1, 
and promotes β cell fate at the expense of α cell fate. This indicates that insulin signaling 
constitutes a tunable mechanism for β cell compensatory plasticity during early 
development. Moreover, using a novel blastomere-to-larva transplantation strategy, we 
found that loss of insulin signaling in the endoderm-committed blastomeres drove their 
differentiation into β cells. Furthermore, the extent of this differentiation was dependent 
on the function of the β cell mass of the host. Altogether, our results indicate that 
modulation of insulin signaling will be crucial for the development of β cell restoration 
therapies for diabetics; further clarification of the mechanisms of insulin signaling in β 
cell progenitors will reveal therapeutic targets for both in vivo and in vitro β cell 
generation. 
 
IV.B. Introduction 
Insulin is a crucial gluco-regulatory peptide hormone produced by pancreatic β cells 
that is released in proportion to levels of circulating glucose. Under conditions of 
fluctuating metabolic demands and energy availability, the effective functional β (β) cell 
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mass (insulin releasing capacity of the pancreas) is regulated to match physiological 
demands through β cell compensation. While compensation can be transiently mediated 
in part via increased insulin production and release from existing β cells, long term β cell 
compensation involves the expansion of β cell mass by multiple mechanisms 
(36,209,304). For instance, physiological stresses like over-nutrition and pregnancy can 
accelerate β cell replication (305-307). Additionally, β cells may arise via neogenesis 
from non- β cell sources, including differentiation from facultative progenitor cells and 
conversion from other pancreatic endocrine cells (160,161,170,171,176,308), though 
much remains to be discovered about the mechanisms regulating this process. The failure 
of β cell compensation to meet insulin demand will result in diabetes mellitus, a 
metabolic disease of insufficient insulin signaling that is characterized by uncontrolled 
hyperglycemia and its associated morbid complications. A comprehensive understanding 
of molecular mechanisms that sense insulin insufficiency and translate it into β cell 
compensation responses will impact the design of better diabetes therapies. 
Several growth factors and cytokines have been shown to regulate β cell replication in 
response to metabolic demand. In the adult islet, insulin secreted by β cells appears to 
feedback upon β cells to regulate islet size and β cell mass (309). Activation of insulin 
receptor triggers its autophosphorylation, which is followed by downstream signal 
propagation via the key effector Insulin Receptor Substrates 1/2 (IRS1/2) to the Akt and 
Mitogen Activated Protein Kinase (MAPK) pathways; these mediate many growth and 
metabolism responses (310). Knockout of insulin receptors in β cells (βIRKO) abolished 
compensatory β cell mass expansion in adult mice and resulted in hyperglycemia (311). 
Further, this suggests that reported influences of glucose on β cell replication may be due 
in part to the indirect effects of augmenting insulin secretion (312). Although much is 
known about replication-induced β cell mass compensation, little is known regarding the 
cellular and molecular mechanisms of neogenesis induced β cell mass compensation. 
It is likely that some mechanisms regulating β cell compensation via neogenesis are 
common to both the mature and developing pancreas, and the embryo is an especially 
amenable system in which to study β cell formation. However, while the intrinsic 
developmental programs regulating endocrine differentiation have been very well 
characterized (313), the extrinsic signals that control induction and differentiation of β 
106 
 
cells, and match β cell mass to the needs of the embryo are less well understood. Among 
the pathways studied are FGF and Notch signaling, which suppress differentiation of 
pancreas progenitors (99,106,107)and EGF signaling, which influences β cell neogenesis 
(314-316). Interestingly, little is known about the roles of the pancreatic hormones during 
development. While glucagon signaling regulates α (α) cell mass by proliferation, 
neogenesis, and fate switching mechanisms (139,141,284), it is not clear whether other 
islet hormones like insulin have a significant role in the acquisition and stability of cell 
fates in the developing islet. Even though the insulin signaling pathway has been deeply 
studied using mouse knockout models, the results from previous developmental studies 
appear contradictory. Mice lacking insulin receptor exhibit severe hyperglycemia at birth 
despite grossly normal islets (317-319). However, knockout of either or both of the 
mouse insulin orthologues (320)or downstream effectors like Akt lead to marked islet 
hyperplasia (321). Therefore, further investigations of the roles of insulin in other model 
systems may help resolve how insulin signaling regulates β cell neogenesis during 
development as well as in pathologies like diabetes. 
Zebrafish are a relevant and powerful system in which to study β cell formation and 
homeostasis: they share key features of their carbohydrate metabolism and their β cell 
differentiation program with mammalian systems (221), while they also afford many 
experimental advantages (322). As in mice and humans, the zebrafish pancreas arises 
from two Pdx1-expressing progenitor domains that fuse to establish the architecture of 
the pancreas (226,267,323). In zebrafish, the dorsal bud appears at approximately 14 
hours post fertilization (hpf) and gives rise to endocrine cell types, which then cluster into 
the principal islet by 24 hpf. In contrast, the ventral bud emerges from the endoderm 
around 34 hpf, then migrates towards, and engulfs the principal islet while differentiating 
into both exocrine and endocrine lineages. In this study, we have used zebrafish as a 
model system to explore the role of insulin signaling on β cell generation during 
development.  Using genetic approaches in zebrafish that either inhibit insulin production 
or impair activity of its downstream effector, IRS2, we show here that insulin signaling 
has an inhibitory role during early pancreas development: loss of insulin signaling drove 
the early differentiation of pancreatic progenitors into β cells. Moreover, using a novel 
blastomere-to-larva transplantation strategy, we found that loss of insulin signaling in 
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endoderm-committed blastomeres fostered their differentiation into β cells, and that the 
extent of this differentiation was dependent on the function of the host β cell mass. Our 
data suggest that manipulation of the insulin signaling pathway will be crucial for 
regenerative medicine approaches to diabetes therapies, including β cell differentiation 
from in situ progenitors during regeneration and from stem cells in vitro.  
 
IV.C. RESULTS 
Knockdown of insulin drives β cell early differentiation 
To determine whether pancreatic progenitor cells are competent to receive insulin 
signals, we first performed whole mount in situ hybridization to illuminate the expression 
of insulin receptors. There are two isoforms of zebrafish insulin receptor, insulin receptor 
a (insra) and -b (insrb) (250). We found that both were strongly expressed in zygotes, 
indicating that maternal contributions may affect early embryonic development (Figure 4-
1A, Figure 4-8A-B). Only insrb was expressed in the embryonic pancreatic endoderm 
during early pancreas development, as visualized by co-localization with endoderm 
marker sox17 at 48 hours post fertilization (hpf) (Figure4-1A-C). However, both insra 
and insrb were expressed in the pancreas, liver and intestine in larvae at 108 hpf, which 
may reflect metabolic roles for insulin signaling during later developmental stages 
(Figure 4-1A, Figure 4-8). 
In order to analyze the roles of insulin signaling during pancreatic progenitor 
differentiation we designed specific splice-blocking morpholinos (MOs) to knockdown 
insulin during embryogenesis (Figure 4-1D). A morpholino targeting the exon 2-intron 2 
boundary was used to disrupt zygotic insulin a (hereafter insa) pre-mRNA splicing 
(Figure 4-9A). Injection of insa morpholino (insaMO) resulted in two aberrant splicing 
products of insa pre-mRNA, indicating efficacy of the morpholino (Figs. 4-9B-C, 4-10). 
Furthermore, using immunofluorescent staining, we observed a loss of Insulin protein in 
insaMO β cells (Figure 4-1E-F), but no general developmental defects were observed in 
insaMO-injected embryos (Figure 4-9D). Due to genomic duplication, zebrafish have a 
second orthologue of insulin, insb (249,320). In contrast to the mouse Insulin paralogues 
Ins1 and Ins2 that are expressed identically (320,324,325), the expression patterns of 
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zebrafish insulin paralogues differ significantly. While insa is expressed only in 
pancreatic β cells, insb is widely expressed, especially in the head and somatic 
musculature, suggesting that these two genes execute different developmental functions 
in zebrafish (249). To test this hypothesis, we knocked down insb using a morpholino 
that targeted the exon 4-intron 4 boundary (Figure 4-11). In insbMO-injected embryos we 
observed efficient disruption of insb splicing and severe developmental defects, including 
microcephaly and shortening of the antero-posterior axis (Figure 4-11B). However, the 
expression of insulin protein in the islet and the number of pancreatic β cells was not 
affected (Figure 4-11E-G). 
Next, we analyzed β cell formation during development in insa-deficient embryos. 
For this, we considered differentiation from both sources of β cells: the dorsal (early) and 
ventral (late) pancreatic buds. We have previously shown that β cells derived from each 
of these origins can be distinguished by a label retaining cell assay (LRC) (222), in which 
embryos are initially uniformly labeled by zygotic injection of H2B-RFP mRNA, and the 
fluorescent intensity of the encoded fluorescent protein is diluted only by mitosis. The 
dorsal derived β cells (DBCs), which differentiate early and become quiescent, remain 
H2B-RFP positive. In contrast, ventral bud-derived progenitor cells lose H2B-RFP signal 
via extensive proliferation before ventral β cell (VBC) differentiation (222). Using this 
approach we quantified DBCs and VBCs in insaMO-injected pancreata throughout 
development. Consistent with our previous findings (222,271), we found that only DBCs 
were present in the principal islet of control embryos at 24 hpf, whereas H2B-RFP- VBCs 
cells were detected after 48 hpf and continued to increase throughout development 
(Figure 4-2A-C,G,H). We found that insaMO did not influence DBC number, but β cell 
mass derived from the ventral bud was sharply increased (Figure 4-2D-F, G, H). 
Surprisingly, a significant number of H2B-RFP- VBCs were detected in insaMO embryos 
at 24 hpf (Figure 4-2A, D). Despite this early increase, we found no difference in total β 
cell number at 96 hpf between insaMO-injected and control groups (Figure 4-2C, F, H). 
These data indicate that loss of insulin expression in the early pancreatic islet drives 
ventral bud-derived pancreas progenitor cells to precociously differentiate into β cells. 
We examined the proliferation of β cells at 24 hpf using both phosphohistone H3 (PHH3) 
immunofluorescence and EdU DNA incorporation assays and thereby excluded the 
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possibility that the precocious H2B-RFP- β cells detected in the 24 hpf insaMO-injected 
embryos were derived from hyper-proliferative dorsal bud-derived cells. In both analyses, 
proliferating β cells were not observed in control or insaMO-injected pancreata at 24 hpf 
(Figure 4-12A-D). These data support the interpretation that the supernumerary H2B-
RFP- β cells in insaMO-injected embryos arose by neogenesis from ventral bud sources 
rather than by proliferation of existing β cells or other dorsal bud-derived sources. 
Concordantly, in 24 hpf insaMO-injected pancreata, but not in control pancreata, ectopic 
insulin+ cells were detected in the ventral endoderm (Figure 4-12E-I). 
Previous studies have shown that homeodomain transcription factor Pdx1 is critical 
for both pancreas progenitor and β cell development. The pancreas is derived from a pool 
of multipotent progenitor cells that express Pdx1 (64,68). During differentiation, Pdx1 
expression subsides in most pancreatic cellular lineages, but is enhanced in β cells where 
it is essential for β cell differentiation and fate maintenance (63,281,326). These roles of 
Pdx1 are conserved in zebrafish to regulate β cell formation as well as ventral pancreatic 
progenitor differentiation (227,282). To analyze the mechanisms underlying insulin 
directed β cell formation, we analyzed the expression of Pdx1 in both control and 
insaMO-injected embryos. Our data showed that Pdx1 expression was restricted to the 
principal islet in 24 hpf embryos, and after the induction of the ventral pancreatic bud at 
48 hpf, Pdx1 was expressed in both the principal islet and adjacent endoderm (Figure 4-
2I, J). After insaMO knockdown, we observed expansion of the Pdx1 domain in the 
principal islet region (Figure 4-2K, L, arrow), which is consistent with our interpretation 
that insulin loss drives excess β cell differentiation from ventral pancreas. Quantitative 
PCR further confirmed an increase in Pdx1 expression at early stages of pancreas 
development (24 and 48 hpf), but not during later stages (72 and 96 hpf; Figure 4-2O). 
The loss of insulin signaling due to insaMO not only expanded pdx1 expression in the 
principal islet, but also increased pdx1 expression in the adjacent endoderm (Figure 4-
2K-L, arrowheads), from which the ventral pancreatic progenitor cells are derived. We 
next investigated how loss of insulin affected induction of the ventral pancreatic bud by 
analyzing the co-expression of Pdx1 and Ptf1a, two transcription factors that together 
define the ventral pancreatic progenitor domain (68). This domain was marked by 
immunofluorescent staining of Pdx1 in Tg(ptf1a:EGFP)jh1 embryos. At 41 hpf, we found 
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that all Ptf1a+ cells in the ventral endoderm were also Pdx1+, suggesting that they are the 
equivalent of mammalian pancreatic progenitor cells (Figure 4-2M), and is in accord with 
ptf1a lineage tracing studies in zebrafish (304). Surprisingly, in contrast to the expansion 
of Pdx1 domain observed with insaMO knockdown, we observed that pancreatic ptf1a 
expression was decreased after insaMO knockdown, as was the number of Pdx1+ ptf1a+ 
ventral pancreatic progenitors (Figure 4-2N, P). These findings indicate that knockdown 
of insulin induces early differentiation of β cells from ventral pancreatic progenitors, and 
consequently diminishes the ventral pancreatic progenitor pool. In accord with this 
finding, we also observed decreased of total pancreatic size in insaMO injected larvae 
(date not shown). Overall, our findings suggest that insulin signaling is part of a feedback 
loop by which newly functional β cells modulate the continued differentiation of 
pancreatic progenitors. As such, the loss of insulin can induce a compensatory increase of 
β cell differentiation during early islet development (Figure 4-12J). 
 
Intracellular blockade of insulin signaling induces precocious β cell differentiation. 
 In order to further investigate the influence of insulin signaling on β cell 
differentiation, we generated a truncated mutant form of zebrafish IRS2 that retains the 
N-terminal pleckstrin homology and phosphotyrosine binding domains, but substitutes 
GFP for the C-terminal SH2-binding domains (Figure 4-S6A). As such, this construct 
(dnIRS2-GFP), is expected to act as a dominant negative regulator of insulin signaling as 
seen with similar constructs [4,69,70]. Indeed, when dnIRS2-GFP mRNA was 
transcribed in vitro and injected into zygotes, we observed that dnIRS2-GFP protein was 
enriched at the plasma membrane in 5 hpf embryos (Figure 4-3A-B) and remained 
expressed in the embryos through 24 hpf (Figure 4-13B). To determine whether this 
mode of insulin signaling blockade affected the formation of β cells, we examined the 
expression of pdx1 and insulin in dnIRS2-GFP mRNA-injected embryos at 24 hpf. 
Relative to controls, we observed a marked increase in pdx1 expression in the pancreatic 
region and a 32% increase in the number of ins+ β cells marked by Tg(insa:dsRed) 
(Figure 4-3E-G). Concordantly, treatment with the PI3 kinase inhibitor wortmannin, 
which should block some aspects of downstream insulin signaling (308), also resulted in 
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increased β cell formation in Tg(insa:CFP-NTR) embryos (Figure 4-3H, Figure 4-14A-
F). In contrast, blockade of the MAPK pathway via the Erk inhibitor U0126 did not 
significantly influence β cell number (Figure 4-14G). Taken together, these results 
suggest that early β cell formation from progenitors may be primarily regulated via the 
PI3K branch of the insulin signaling pathway.  
Next, we generated a conditional transgenic model to knockdown of insulin signaling 
through temporally defined misexpression of dnIRS2-GFP. This Cre recombinase-
switchable, heat shock-inducible transgenic line, Tg(hs:loxp-mcherry-loxp-stop-dnIRS2-
GFP;cryaa:CFP), was crossed with Tg(hs:Cre) (327)to generate double transgenic 
embryos in which dnIRS2-GFP is globally inducible by heat shock, hereafter dnIRS2 
(Figure 4-13C). We verified the efficiency of insulin signaling blockade in dnIRS2 
embryos using immno-blot for phospho-Akt protein that was extracted from 54 hpf 
control and dnIRS2 embryos after heat induction. These dnIRS2 transgenic embryos 
showed a 65% decrease in phospho-Akt as compared with controls (Figure 4-13D). 
Using this model, we then analyzed how Pdx1 expression responded to dnIRS2 over-
expression. In control 24 hpf embryos, Pdx1 was expressed predominantly in dorsal 
endocrine cells and weakly in adjacent endoderm (Figure 4-3I). However, in dnIRS2 
embryos, Pdx1 expression was strongly increased in both the principal islet (arrows) and 
the adjacent pre-pancreatic endoderm (Figure 4-3J, arrowheads). Furthermore, at 48 hpf, 
dnIRS2 embryos showed an increased pdx1 expression pattern that was similar to that of 
insaMO-injected embryos (Figure 4-13E). Next, we analyzed β cell development in 
dnIRS2 embryos. As with insulin knockdown, we found increased β cell formation in 
dnIRS2 transgenic embryos (Figure 4-3K-M). Interestingly, we also noted a significant 
decrease in the number of glucagon+ α cells (Figure 4-3K-M). Together, our results 
indicate that insulin signaling blockade induces compensatory β cell differentiation from 
progenitors within the ventral pancreatic bud. In addition, our data suggest that insulin 
signaling also influences the specification of non-β endocrine subtypes in the islet. 
 
Knockdown of insulin induces ectopic Pdx1 expression in α cells and destabilizes α 
cell fate 
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To examine how insulin signaling affects α cell fate specification during 
development, glucagon expression was examined in control and insaMO-injected 
Tg(insa:CFP-NTR) embryos at 54, 80, and 100 hpf (Figure4-4A-B, Figure 4-15A-F). We 
noted a striking disorganization of islet cells in the insaMO-injected larvae. 
Characteristically, α cells are located in the islet mantle and β cells are clustered in the 
islet core in both zebrafish and mouse islets (Figure 4-4A, Figure 4-15A-C). However, in 
insaMO-injected islets, this islet architecture was inverted: a core of glucagon+ α cells 
was surrounded by insulin+ β cells (Figure 4-4B, Figure 4-15D-F). Furthermore, as in 
dnIRS2 embryos, insaMO-injected islets contained a decreased number of α cells (Figure 
4-4I). Moreover, we found that this impaired level of α cell development in the insulin 
knockdown in embryos was sustained into adulthood (Figure 4-15G-J). However, there 
was no significant influence on somatostatin+ delta (δ) cell number. Also, the total 
endocrine cell number, as marked by Tg(neurod:GFP), only slightly increased in 1 dpf 
insaMO-injected embryos. Together these data indicate that increased β cell content may 
come at the expense of α cell fate in insulin-deficient islets (Figure 4-16).  
 To test this interpretation, we first examined the expression of Pdx1 in the α cells of 
control and insaMO-injected islets. We found that in insaMO-injected islets Pdx1 
expression was often aberrantly co-expressed in glucagon+ α cells (Figure 4-4C,D,J, and 
4-17A-E), suggesting a failure of α cell maturation or destabilization of α cell fate. α cells 
exhibit a degree of plasticity during development and regeneration. For instance, mis-
expression of Pdx1 induces α cell fate instability and results in α to β transformation in 
some contexts (65). Furthermore, in zebrafish (271) and mouse (160,161) models of 
extreme β cell ablation, α cells can spontaneously transdifferentiate into β cells through 
an intermediate Pdx1+ glucagon+ stage. Based on this, we hypothesized that the increase 
of Pdx1 expression in α cells of insaMO-injected embryos would result in the instability 
of α cell fate, particularly during β cell regeneration. To test this, we ablated β cells in 
Tg(insa:CFP-NTR)s892 embryos with metronidazole (254,266), and then quantified 
insa:CFP-NTR+, glucagon+, and bihormonal insa:CFP-NTR+ glucagon+ cells in 
regenerating control and insaMO-injected islets. In insaMO knockdown islets we 
observed increased β cell regeneration, and that many of these regenerated β cells were 
co-labeled with glucagon (Figure4-4E, F, K). To distinguish between the possibilities that 
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these double positive cells had formed by the differentiation of progenitor cells, or by the 
transdifferentiation of glucagon+ α cells, we performed genetic α cell lineage tracing 
using the Hot-Cre system. Specifically, the Tg(gcga:Cre)s962 line was used together with 
Tg(hsp70l:loxp- mcherry-stop-loxp-H2B-GFP;cryaa:CFP)s923 to label α cells with H2B-
GFP via heat-shock before β cell ablation (271). Thus, if α cell identity was lost during β 
cell regeneration, these pre-labeled α cells would transform into glucagon- H2B-GFP+ 
cells. Indeed, in insaMO-injected embryos we found that a significant population of α 
cells pre-labeled in this fashion lost glucagon expression during β cell regeneration 
(Figure 4-17F-H), suggesting that some α cells do not maintain their fate after insulin 
knockdown. The loss of glucagon expression could indicate that α cells have de-
differentiated, or have been converted into another endocrine cell type. However, we 
hypothesize that α to β cell conversion predominates after loss of insulin signaling as 
observed in previously published studies of transdifferentiation after β cell ablation in 
zebrafish (271).  
To further test this hypothesis we again used the LRC lineage tracing approach, in 
which all early differentiated endocrine cells (<40 hpf) of the principal islet are labeled 
because of their quiescence. In this experiment, cells of any endocrine subtype that 
transdifferentiate into β cells during regeneration were labeled with H2B-RFP, while 
those arising by neogenesis were unlabeled (271). Consistent with our interpretation of α 
to β cell transdifferentiation, we found that the β cell ablated insaMO-injected islets 
showed a 2.5 fold increase of regenerated H2B-RFP+ β cells, but no change in the 
quantity of regenerated H2B-RFP- β cells (Figure 4-4G, H, L). Together, these data 
suggest that loss of insulin signaling increases β cell regeneration mainly through the 
increase of α cell conversion. In summary, we have demonstrated that blocking of insulin 
signaling via insaMO decreases α cell formation and induces Pdx1 expression in α cells. 
Furthermore, the increased α to β cell conversation following cell ablation in insaMO 
embryos may result from instability of the α cell fate consequent to diminished of insulin 
signaling.  
 
Loss of insulin signaling in transplanted blastomeres promotes β cell generation.  
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To distinguish whether the precocious β cell differentiation observed in our insulin 
signaling-knockdown models was due to autonomous loss of insulin signaling in 
endodermal progenitors, we used mosaic analysis. For these, sox32 mRNA was injected 
into donor zygotes to drive endoderm formation while sox32 morpholino was used to 
block host embryo endoderm formation (328); in these chimeras, transplanted donor cells 
replaced most endodermal tissues in host embryos (Figure 4-5A-B). Thus, we generated 
chimeric embryos in which endodermal gene expression was independently manipulated. 
When we injected dnIRS2-GFP mRNA into donor zygotes to specifically block insulin 
signaling in the transplanted cells, we found that the differentiating donor endoderm 
showed an expanded Pdx1+ domain, identical to that seen with global dnIRS2 over 
expression (Figure 4-5C-D). This result indicates that the endodermal pancreas 
progenitor cells directly respond to insulin signaling by suppressing Pdx1 expression. 
Thus far our findings have demonstrated that in a developmental context insulin 
signaling acts as a negative regulator, inhibiting the early differentiation of ventral 
pancreatic progenitors. This prompted the question of whether blocking insulin signaling 
in transplanted multipotent progenitor cells, such as stem cells, could favor their 
differentiation into β cells in a more mature context. To address this in a manner that 
would be relevant to stem cell therapy, we performed a novel blastula to larval cell 
transplantation assay (Figure 4-6A-C). For this, sox32 mRNA-injected donor blastula 
endoderm cells were transplanted into larval stage hosts, adjacent to the pancreas. First, 
to validate this approach, we verified the survival and integration of donor endoderm into 
host tissues; we transplanted donor blastula cells from Tg(ubi:zebrabow) embryos that 
expressed a ubiquitous RFP label, into host Tg(flk1:GFP) larvae that expressed GFP 
throughout the vasculature. We found that blood vessels pervaded the transplanted donor 
tissue (Figure 4-6D-E), demonstrating an interaction between the donor and host tissues. 
At one day post transplantation we found that about 80% of host embryos (75/90) had 
successfully integrated transplanted donor cells. 
We next analyzed the differentiation of these endoderm-committed blastomeres in the 
context of wild type or β cell-ablated hosts. First, we found that control donor cells 
differentiated into sox17: GFP+ endodermal cells by 1 day post transplantation in wild 
type hosts, but did not further differentiate into Pdx1+ cells (Figure 4-6I, Figure 4-18A). 
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However, when control donor cells were transplanted into β-cell ablated host larvae, 
some Pdx1+ cells were detected in control donor tissue after 1 day post transplantation 
(Figure 4-6F, I, Figure 4-18B). This finding revealed that β cell ablation in hosts non-
autonomously influences the differentiation of transplanted donor endoderm cells. Next, 
when insulin signaling in the transplanted donor cells was impaired by dnIRS2 mRNA 
injection, we observed a significant increase of Pdx1 induction in donor cells after 
transplantation; this increase was even more striking in donor cells that were integrated 
into β cell ablated hosts (Figure 4-6H,I, Figure 4-19C). Together, these results indicate 
that insulin signaling in the endoderm-committed progenitor-like cells autonomously 
regulated Pdx1 expression, and that this was further influenced by β cells in a non-
autonomous manner. 
Next, to determine whether donor cells can differentiate into pancreatic endocrine 
cells, we examined insulin and glucagon protein expression two days after 
transplantation. No insulin or glucagon positive cells were detected in donor cells that 
were transplanted into non-ablated host larva (data not shown) and this is consistent with 
the absence of Pdx1 induction in a non-ablated host environment. In contrast, when donor 
cells were transplanted into β cell-ablated host larvae, they differentiated into both 
insulin+ β cells and glucagon+ α cells (Figure 4-7A,B, Figure 4-19A,B). Furthermore, 
when donor cells that were injected with dnIRS2 mRNA were transplanted into β cell 
ablated host larvae, there was a significant increase of insulin expression in the 
transplanted cells, while, no glucagon+ cells were detected (Figure 4-7C-E, Figure 4-
19C). This is in accord with our earlier results that showed that inhibition of insulin 
signaling impairs α cell differentiation. Lastly, in a reciprocal manner, we found that the 
presence of transplanted dnIRS2 endoderm, but not control endoderm, increased the 
competence of host tissue-derived pancreata for β cell regeneration (Figure 4-7F, Figure 
4-20). In summary, here we have demonstrated that insulin signaling regulates Pdx1 
expression and β cell formation in transplanted blastula stage endodermal progenitor 
cells. However, further differentiation toward pancreatic and β cell fates requires 
additional permissive signals secreted by the host larva environment in response to β cell 
ablation.  
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IV.D. Discussion 
The coordinated growth and development of the pancreatic β cell mass involves many 
phases, including specification of the pancreatic progenitor population, its expansion, β 
cell differentiation, and their proliferation. Here, we provide evidence that insulin 
signaling acts as a negative feedback signal to regulate pancreatic progenitor cell 
differentiation. Using multiple approaches, we have shown that when progenitors lacking 
insulin signaling they are primed for early differentiation into β cells. As such, 
insufficient insulin signaling influences the compensatory production of β cells via 
neogenesis. This precocious β cell differentiation during embryonic development may 
have long-term negative effects by prematurely depleting the pancreatic progenitor pool 
and destabilizing α cell fate. In addition, using a novel blastomere-to-larva transplantation 
strategy, we found that loss of insulin signaling in the endoderm committed blastomeres 
drove their differentiation into β cells. Taken together, our data suggest that modulation 
of insulin signaling will be crucial for β cell replacement strategies that hinge upon in 
vitro and in vivo approaches to β regeneration for the treatment of diabetes.  
 
A conserved role for insulin signaling in islet development 
In many vertebrate species, there are two waves of pancreatic endocrine cell 
differentiation during primary and secondary transition stages (226,277,323,329). The 
first wave appears shortly after the specification of pancreatic progenitor domain, persists 
during its expansion, preceding the main pancreas progenitor differentiation program 
(54,74,291,313,330). Our results suggest are consistent with a role for insulin as a local, 
physiologically relevant signal that feeds back to block pancreas progenitor cell 
differentiation, precisely regulating their expansion. Loss of insulin signaling initially 
induces compensatory differentiation of progenitor cells into β cells. Consistent with this, 
a comparable response was also observed in mice lacking insulin expression. Although 
loss of both mouse Insulin orthologues is required to induce hyperglycemia, islet 
hyperplasia was observed in the single Ins1 and Ins2 knockouts, and double null mice 
(320). Indeed, islet size is significantly increased in Ins1-/-Ins2-/- mice at birth and the β 
cell mass in Ins2-/- mice was increased almost threefold at 7 weeks of age, indicating that 
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increased β cell mass expands to compensate for low insulin production (320,324). This 
is further supported by the finding that expression of human INSULIN in the Ins1-/-; Ins2-
/- mouse reverses the compensatory β cell hyperplasia (331). These findings together with 
our results support the hypothesis that insulin acts as a negative regulator for β cell 
formation during development (320,324). However, this hypothesis appears to be 
contradicted by findings in Insr-/- mice. These mice initially appear unaffected as 
neonates, showing a normal β cell mass; however, immediately after feeding, 
hyperglycemia and hyperinsulinemia develop due to severe insulin resistance, and this 
results in neonatal death (317,318). This contradictory result may due to 
compensatory/redundant activation of IGF-1 receptors in the absence of Insulin receptors 
(319). It has been proposed that the local production of  IGF-1 in the pancreas acts as 
negative regulator factor of β cell mass, as knockout of Igf1 in pancreas increases β cell 
differentiation and a 2.3 fold enlarged islet cell mass (332). Thus, the de-repression of β 
cell differentiation resulting from loss of InsR signaling is likely countered by redundant 
activation of IGF1R signaling, explaining the contradictory results. On the other hand, 
our data does not exclude the possibility that insulin regulates pancreatic progenitor 
differentiation in part via IGF1R, given the complex interaction between the insulin and 
IGF1 signaling pathways (310,319). However, given that Insulin binds the IGF1R and 
InsR/IGF1R heterodimers with much lower affinity than InsR (333), it is likely that our 
manipulations affect insulin receptor signaling rather than IGF1R signaling. In further 
support of this interpretation, knockdown either of Igf1 or Igf1R in zebrafish results in 
severe neural and gross developmental defects (334,335), which differ significantly from 
the insulin knockdown phenotypes reported here. This supports our conclusion that 
insulin receptor signaling is the major insulin family member that suppressing 
differentiation of pancreas progenitor cells. 
 
Insulin signaling maintains pluripotency in multiple contexts 
Insulin secreted by pancreatic β cells is one of the most important nutrient sensors. It 
has been classically viewed as a mitogen, stimulating proliferation and promoting cell 
survival (310). However, recent studies have shown that insulin plays key roles both in 
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maintaining stem cell fate and regulating stem cell differentiation (146-148,336). For 
example, self-renewal of human embryonic stem (ES) cells requires the activation of 
insulin and IGF signal pathways; blocking these signals promotes ES cell differentiation 
(146,336). Also, in Drosophila larvae, starvation reduces the number of hematopoietic 
progenitor cells by increasing their differentiation, and these starvation effects are 
mediated by the insulin signaling pathway (148,337). Furthermore, reduced systemic 
insulin signaling and down-regulation of the downstream insulin signaling component 
Akt/PI3K promotes hematopoietic and skin  stem cell differentiation (148,338). 
Consistent with previous findings, our study clearly supports a role for insulin in 
regulating progenitor cell differentiation in the developing pancreas, which is reminiscent 
to the well-described roles of Notch in controlling pancreatic progenitor cell 
differentiation. Notch signaling in pancreatic progenitors stimulates self-renewal in this 
progenitor pool and blocks endocrine cell differentiation via repression of the bHLH 
transcription factor Ngn3 (110,339). Moreover, Notch signaling is required to sustain 
Ptf1a expression in early pancreatic progenitors (340). Disruptions of Notch signaling in 
early pancreatic progenitor cells induces premature differentiation of pancreatic 
endocrine cells and diminishes the pancreatic progenitor pool (110,341). The strong 
phenotypic similarities of insulin signaling and Notch signaling loss suggest that the 
pathways interact: insulin signal may act as a positive regulator of Notch signaling in 
pancreatic progenitor cells. Indeed, there is accumulating evidence supporting intensive 
cross talk between PI3K/Akt and Notch pathways. For instance, during megakaryocyte 
development the PI3K/AKT pathway is activated by Notch stimulation, which in turn 
enhances Notch-dependent differentiation (342). Cooperation between Notch and insulin 
signaling may therefore integrate environmental and metabolic cues to regulate 
progenitor cell maintenance and differentiation. Therefore, we hypothesize that, 
inhibition of insulin signaling in pancreatic progenitor cells would impair positive circuits 
between PI3K/Akt and Notch, activating the endocrine differentiation program, and 
resulting in the premature differentiation of pancreatic progenitor into β cells. Additional 
studies in our lab are aimed at further clarifying the interaction of notch and insulin 
signaling during progenitor differentiation. 
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Potential mechanisms of insulin signaling in endocrine cell fate regulation  
In addition to regulating pancreatic progenitor cell differentiation, our data also 
suggest that insulin plays a crucial role in endocrine subtype specification during 
differentiation. After blockade of insulin signaling we found an increase of β cell 
formation from the pancreatic progenitors and a decrease of α cell fate. This function of 
insulin signaling may be partially mediated via regulation of Pdx1 expression as our 
results show that loss of insulin signaling promotes Pdx1 expression in pancreas 
progenitors as well as transplanted blastula stem cells. As one of the key transcription 
factors in regulating β cell specification and function, Pdx1 enhances transcription of β 
cell programed genes such as Insulin, Glut2, Glucokinase, and Mafa but inhibits α cell 
programmed genes like Arx and Glucagon (343-345). Enforcing expression of Pdx1 in 
pancreatic endocrine progenitor cells result in increased β cell number and decreased α 
cell number during embryonic stages (65). Besides regulating pancreatic progenitor 
differentiation, Pdx1 has also been shown by previous studies to be able to directly drive 
α to β cell fate switch. In mouse models, mis-expressing Pdx1 in α cells drove postnatal 
conversion of glucagon+ Pdx1+ cells into β cells (65). Moreover, we have recently shown 
that in zebrafish models, these Pdx1 mis-expressing immature “α-like” cells are unstable, 
and can transdifferentiate into β cells (271). Our studies have indicated in addition to loss 
of α cell number, loss of insulin during development induced the formation of Pdx1+ 
glucagon+ “α like” cells. These “α-like” cells appeared to be unstable and therefore they 
are likely to be the source of increased α to β cell conversion after insulin loss.   
The induction of Pdx1 in response to diminished insulin signaling may be due to 
activation of the forkhead transcription factor Foxa2, which is negatively regulated by 
insulin signaling (346-348). Foxa2 binds to the Pdx1 promoter region and is crucial for 
Pdx1 expression in pancreatic progenitors and mature β cells (343,349,350). Furthermore, 
it has been proposed that activation of both insulin and Notch represses Foxa2 activity 
(346,348,351-353). Thus, we propose a model in which reduced insulin and Notch 
signaling activities enhances the transcription and nuclear translocation of Foxa2 in 
endodermal progenitor cells; together this drives the activation of Pdx1.  
The forkhead transcription factor Foxo1 also has important roles in metabolic 
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regulation downstream from insulin signaling (354,355). The loss of Foxo1 results in β 
cell dedifferentiation, revealing a role in β cell fate maintenance (39). Similarly, it is 
likely that Foxo1 also has a hand in insulin-regulated pancreatic progenitor 
differentiation. In mature β cells, Foxo1 and Pdx1 exhibit mutually exclusive localization 
in the nucleus and Foxo1 blocks Pdx1 transcription by disrupting Foxa2-dependent 
transcription at the Pdx1 promoter (356). Thus insulin signaling may be regulating the 
expression of Pdx1 via multiple mechanisms, including forkhead proteins and Notch, and 
ultimately it is the inappropriate expression of Pdx1 that drives β cell hyperplasia and α 
cell hypoplasia in our insulin knockdown models. This hypothesis, that Foxa2 and Foxo1 
are the link between insulin signaling and Pdx1 expression, is under investigation in our 
lab; future studies are aimed and clarifying this and other downstream mechanisms of 
insulin during regulation of pancreas development.  
 
A potential role for insulin signaling in programming β cells in vitro 
Understanding and manipulating the regulatory mechanisms of insulin signaling in 
pancreatic progenitors during developmental stages can potentially facilitate the 
programing of embryonic stem cells into β cells in vitro. When we transplanted 
endoderm-fated blastomeres, which are similar to embryonic stem cells, into zebrafish 
larvae, the dnIRS2-expressing “insulin resistant” blastomeres differentiated into Pdx1+ 
progenitor cells and β cells with a much greater efficiency than wild type controls. This 
result indicates that blocking this feedback action of insulin signaling in endoderm 
progenitors may facilitate β cell production in vitro. However, we also observed that the 
transplanted blastomeres only expressed the β cell markers Pdx1 and insulin when they 
were transplanted into β cell-ablated host larvae. This result demonstrates that blocking 
insulin signaling alone is not sufficient to drive β cell production and that additional 
signaling factors released from host larvae in response to β cell ablation are needed to 
facilitate β cell differentiation. Furthermore, our results reveal bidirectional signaling, as 
these “insulin resistant” blastomeres can also indirectly promote β cell regeneration in 
host tissues. This is consistent with previous studies that show that transplanted stem cells 
can secrete angiogenic and growth factors (357,358). In fact, some functional benefits 
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observed after stem cell transfer might be due in part to the secretion of soluble factors 
that act as paracrine or endocrine fashion to promote tissue regeneration (357,359,360). 
Thus, we propose that in our model, the pancreatic progenitors interact through the 
release of secreted signaling factors that act as paracrine or systemic signals. Additional 
studies are needed to identify these signaling factors and to test this hypothesis; unveiling 
these mechanisms will be essential for understanding the deficiencies of β cell 
compensation that are seen in insulin resistant and diabetic states. 
Lastly, recent studies have indicated that endogenous pancreatic multipotent 
progenitor (PMP) cells are present in adult pancreas both in human (361-363)and mouse 
(176,364), and that metabolic stress can influence their proliferation and differentiation 
into β cells (364). Maintaining the balance of self-renewal and differentiation in these 
progenitor cells is likely to be crucial for long-term β cell compensation in response to 
metabolic stresses. Given our findings that insulin signaling plays an important role in 
regulating the progenitor cell differentiation during development, understanding the roles 
and mechanisms of insulin signaling in adult pancreatic progenitors, and how to 
appropriately manipulate insulin signaling in these populations, may prove to be critical 
for developing new regenerative therapies for diabetes.  
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 Figure 4-1. Inhibition of insulin signaling in pancreatic progenitor cells via insaMO. (A) 
In situ hybridization for insra and insrb in the developing zebrafish embryos. (B-C) 
Fluorescent in situ hybridization of insrb (red) in Tg(sox17:GFP) endoderm (green) at 48 
hpf. (D) Schematic of blocking endoderm receiving insulin signaling from dorsal β cells 
via insulin morpholino (insaMO) knockdown.  (E-F) Confocal plane of 3 dpf 
Tg(insa:CFP-NTR) control and insaMO injected islets stained for CFP (green), insulin 
(red) and glucagon (white). Abbreviations: z, zygote; ed, endoderm; p, pancreas; li, liver. 
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Figure 4-2. insulin knockdown increases Pdx1 expression and drives early pancreatic 
progenitor differentiation into β cells. (A-F) Confocal planes of 24 hpf, 48 hpf, and 80 
hpf Tg(insa:CFP-NTR) control (A-C) and insaMO (D-F) islets stained for CFP (green) 
and insulin (blue). H2B-RFP mRNA was zygotically-injected to distinguish dorsal (H2B-
RFP+) and ventral (H2B-RFP-) pancreas derived β cells. (G) Quantification of H2B-RFP+ 
β cell number in control and insaMO-injected islets from 24 hpf to 96 hpf.  (H) 
Quantification of H2B-RFP- β cell number in control and insaMO injected islets from 24 
hpf to 96 hpf. (I-L) In situ hybridization of pdx1 expression in 24 hpf and 48 hpf control 
(I, J) and insaMO injected embryos (K, L). Black arrows show the pancreatic principal 
islet. Black arrow heads indicate the expression of Pdx1 in ventral endoderm. (M-N) 
Confocal plane of 48 hpf Tg(ptf1a:GFP) control and insaMO injected endoderm stained 
for CFP (green) and Pdx1(red). pi: principal islet. (O) Real time PCR to detect Pdx1 
expression in both control and insaMO injected embryos from 24 hpf to 96 hpf. (P) 
Quantification of the number of Pdx1+Ptf1a+ pancreatic progenitor cells in both control 
and insaMO injected embryos. One way ANOVA was used in O and Student’s t-test was 
used in P for the statistical analyses. 
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Figure 4-3. Insulin signaling blockade drives early differentiation of ventral pancreatic 
progenitors. (A) 5 hpf embryo injected with dnIRS2-GFP mRNA shows global green 
fluorescence. (B) Confocal plane shows the localization of dnIRS2-GFP to the plasma 
membrane. Co-injected H2B-RFP mRNA labels cell nuclei. (C-D) In situ hybridizations 
show pdx1 expression in control (C) and dnIRS2-GFP mRNA-injected (D) embryos. (E-
F) Confocal projections of 1 dpf Tg(insa:dsRed) islets in control (E) and dnIRS2-GFP 
mRNA-injected (F) embryos. (G) Quantification of insa:dsRed+ β cells in 24 hpf control 
and dnIRS2-GFPmRNA injected embryos. (H) Quantification of β cells derived from 
dorsal pancreas (H2B-RFP+) and ventral pancreas (H2B-RFP-) in 30 hpf control DMSO-
treated and 1μM wortmannin treated embryos. (I-J) Confocal projection of 24 hpf 
Tg(hs:CSdnIRS2-GFP) (control) and Tg(hs:csdnIRS2-GFP);Tg(hs:cre) (dnIRS2 mis-
expressing) pancreatic endoderm stained for GFP (green) and Pdx1(red). White arrows 
indicate the principal islet and arrowheads indicate the ventral endodermal region. (K-L) 
confocal planes of 54 hpf Tg(hs:CSdnIRS2-GFP) and Tg(hs:csdnIRS2-GFP);Tg(hs:cre) 
islets stained for GFP (green), Insulin (red), and Glucagon (white). (M) Quantification of 
Insulin+ β cells and Glucagon+ α cells in control (gray) and dnIRS2 mis-expressing (red) 
groups. Student t-test was used in G and Two way ANOVA was used in H and M. 
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Figure 4-4. Insulin knockdown impairs α cell development and destabilizes α cell fate. 
(A-D) Confocal projections of 100 hpf Tg(insa:CFP-NTR) control (A,C) and insaMO-
injected (B,D) islets stained for Glucagon (red) and CFP (green) (A,B), or Glucagon 
(white) and Pdx1 (red) (C,D). White arrows indicate Glucagon+ Pdx1+ double positive 
cells. (E-F) Confocal projections of 4 dpf Tg(insa:CFP-NTR) control and insaMO-
injected regenerating islets that were stained for Glucagon (red) and CFP (green). Yellow 
arrows indicate ins+ Glucagon+ double positive regenerating β cells. (G-H) Confocal 
projections of 4 dpf Tg(insa:CFP-NTR) control and insaMO-injected regenerating islets 
labeled with H2B-RFP. Yellow arrows indicate H2B-RFP+ ins+ double positive 
regenerating β cells. (I) Quantification of Glucagon+ cell number in 54 hpf, 80 hpf and 
100 hpf control and insaMO-injected islets. (J) Quantification of Glucagon+ Pdx1+ double 
positive cells in 100 hpf control and insaMO-injected islets. (K) Quantification of insa+, 
Gcg+, and insa+ Gcg+ cells in 1 day post ablation (dpa) control and insaMO-injected 
islets. (L) Quantification of H2B-RFP+ insa+ and H2B-RFP- insa+ regenerating β cells in 
1dpa control and insaMO-injected islets. Two way ANOVA was used in I, K and 
Student’s t-test was used in J. 
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 Figure 4-5. Insulin signaling blockade in transplanted endodermal progenitor cells 
promotes Pdx1 expression. (A) Endodermal transplantation scheme: blastula stage 
Tg(sox17:GFP) donor cells were transplanted into wild type host blastulae. (B) 1 dpf host 
embryo shows endoderm replacement with transplanted with Tg(sox17:GFP) donor cells. 
(C,D) Confocal projections of 1 dpf embryos with endoderm transplants from sox32 
mRNA (C; n=8) or sox32 and dnIRS2 mRNA (D; n=7) injected donors. Embryos were 
stained for GFP (green), Pdx1 (red), and DNA (blue).  
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Figure 4-6. Insulin signaling blockade in transplanted endodermal progenitor cells 
increases Pdx1 expression after transplantation into β-cell ablated host larvae.  (A) 
Blastula to 4 dpf larva cell transplantation scheme. (B) 5 dpf host larva shows 
transplanted Tg(sox17:GFP) donor cells at 1 day post transplantation. (C) Confocal 
projection of Tg(flk1:GFP) (green) host larva transplanted with Tg(ubi:zebrabow) donor 
cells (red) at 1 day post transplantation shows successful engraftment. (D) Quantification 
of percentage of Pdx1+ cells in transplanted sox17:GFP+ donor tissues. (E-G’’’) Merged 
and single channel confocal planes of chimeric host larvae show transplanted 
Tg(sox17:GFP) donor cells (outlined) at 1 day post transplantation, stained for GFP 
(green), Pdx1 (red), Alcam (white), and DNA (blue). (E-E’’’) sox32 mRNA-injected 
blastomeres transplanted into β cell-ablated host larvae. (F-F’’’) sox32 and dnIRS2 
mRNA-injected blastomeres transplanted into β cell-intact host larvae. (G-G’’’) sox32 
and dnIRS2 mRNA-injected blastomeres transplanted into β cell-ablated host larvae. 
Student t-test was used for statistical analysis in D. Abbreviations: sb, swim bladder; p, 
pancreas; ib, intestine bulb; li, liver. 
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Figure 4-7. Insulin signaling blockade in donor cells promotes Insulin expression and 
host β cell regeneration. (A-D) Merged and single channel confocal projections of 
transplanted Tg(sox17:GFP) donor cells in β cell-ablated host larvae stained for GFP 
(green), Insulin (red) and Glucagon (white) at 2 days post transplantation. (A,B) donor 
cells injected with sox32 mRNA only (C-D) donor cells were injected with sox32 and 
dnIRS2 mRNAs (E) Quantification of Insulin+ β cells in donor tissues that were 
transplanted into β cell ablated hosts.  (F) Quantification of host-derived regenerated β 
cells after transplantation with no cells (sham), or donor cells injected with sox32 mRNA 
alone, or sox32 plus dnIRS2 mRNAs.  Student’s t-test was used in F and one way 
ANOVA was used in G. (G) Model for the role of insulin signaling in regulating β cell 
differentiation and interaction between transplanted endoderm progenitor cells and the 
host environment. Abbreviation: pi, host larvae principal islet at 2 day post β cell 
ablation. 
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 Figure 4-8.  Expression of insulin receptor in pancreas during development. (A-B) real-
time PCR analysis of insulin, insulin receptor a (insra) and insulin receptor b (insrb) in 
whole embryos at specific time points indicated in the paragraph. n=3 for each time point. 
(C-D) fluorescent in situ hybridization indicating the expression of insulin receptors (red) 
in pancreatic islet β (ins:CFP in C, green) and α cells (gcg:GFP in D, green).  The in situ 
probe (insra+b) was designed to target a homologous region for both insra and insrb as 
indicated (Toyoshima, Y. et al., Endocrinology, 2008).  
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 Figure 4-9. Knockdown of insulin via insulin morpholino (insaMO). (A) Diagram 
illustrating how insaMO interrupts the normal splicing of pre-insulin mRNA. insaMO is 
designed to target the exon2-intron2 boundary of preproinsulin-a mRNA. insaMO results 
in two alternative splicing mRNA products. The primer set was designed at exon 1 and 
exon 3 to amplify the mRNA products. (B) Agarose gel showing amplified insulin PCR 
products using mRNA extracted from 2 dpf control and insaMO-injected embryos.  Note 
that a single PCR product with size of 420 bp was detected in control embryos but two 
abberant PCR products with the sizes of 520 and 360 bp were detected in insaMO-
injected embryos. β actin was used as internal control. (C) Expression of insulin-b mRNA 
in control and insaMO-injected embryos showed no alternation after insaMO injection. 
(D) No overt phenotype was observed in control embryos or those injected with 
increasing doses of insaMO from 2 ng to 8 ng.  
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 Figure 4-10. Disruption of insulin mRNA splicing with insaMO. The PCR products in 
control and insaMO-injected embryos were extracted and clone into pJet plasmid before 
sequencing. insaMO product 1 indicates the wild type 520 bp PCR product as indicated 
in Figure S2. insaMO product 2 indicates the 360 bp PCR product as indicated in Figure 
S2. Note that there is an insertion of an intron 3 fragment in PCR product 1 and a deletion 
of exon 2 in product 2.  
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 Figure 4-11. Knockdown of insb results in severe development defects. (A) Diagram 
illustrating how insbMO interferes with the splicing of pre-insulin b mRNA. insbMO 
binds the junction between exon 4 and intron 4 and induces the deletion of exon4.  The 
primer set was designed to amplify between exon 3 and exon 5. (B) Dose dependent 
developmental defects at 48 hpf after insbMO injection. Arrow indicates the strong 
influence on head development using 2 ng insbMO injection. (C) Agarose gel showing 
amplified insb PCR product from 2 dpf control and insbMO-injected embryos. Note that 
PCR product with size of 427 bp was detected in control embryos (arrow head) but not 
insbMO injected embryos. A weak product of 210 bp can be detected in insbMO-injected 
embryos (arrow). β actin was used as internal control. (D) Expression of insulin-a mRNA 
in both control and insbMO injected embryos showed that knockdown of insb did not 
interrupt insulin-a mRNA transcription. (E-F) Confocal images of 24 hpf control and 
insbMO islets of Tg(ins:CFP-NTR) embryos stained for CFP (green) and insulin (red).  
(G) Quantification of ins:CFP-NTR+ β cells in 24 hpf control(n=5) and insbMO-injected 
embryos(n=6).  
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 Figure 4-12. insaMO does not increase β cell proliferation. (A-B) Confocal projection of 
1 dpf control and insaMO-injected islets in Tg(ins:CFP-NTR) stained with CFP (green), 
PHH3 (red) and insulin (white). (C-D) Confocal planes of 1 dpf control and insaMO-
injected islets in Tg(ins:CFP-NTR) stained with CFP (green), Edu (red) and Insulin 
(white). (E-I) Confocal projections and planes of control and insaMO-injected endoderm 
in Tg(ins:CFP-NTR) stained for CFP (green) and Pdx1 (red). Note the formation of β 
cells from Pdx1+ ventral endoderm in insaMO-injected endoderm (yellow arrow). pi: 
principal islet. (J) Model showing how knockdown of insulin might drive β cell 
formation from the ventral endoderm associated with increased Pdx1 expression.  
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 Figure 4-13. Insulin signaling blockade via dnIRS2 mis-expression. (A) Schematic of 
dominant negative IRS2 (dnIRS2). (B) Control and dnIRS2-GFP mRNA-injected 
embryos at 24 hpf. (C) Scheme of dnIRS2-GFP mis-expression via the HOT-Cre system. 
Tg(hs:loxp-mcherry-loxp-dnIRS2GFP) was crossed with Tg(hs:Cre) and dnIRS2-GFP 
mRNA expression was induced upon heat shock induction. (D) Western blot indicating 
the expression of phospho-Akt 54 hpf in control and dnIRS2 mis-expressing embryos. 
Control: Tg(hs:loxp-mcherry-loxp-dnIRS2GFP)+Tg(hs:cre)-; dnIRS2: Tg(hs:loxp-
mcherry-loxp-dnIRS2GFP)+ Tg(hs:cre)+. dnIRS2 were heat-induced at 10 hpf, 24 hpf, 28 
hpf ,32 hpf, 36 hpf, and 48 hpf. (E) Quantification of phospho-Akt levels in control (n=6) 
and dnIRS2 embryos (n=5). Student’s t-test was used for statistical analysis. (F) 
Expression of pdx1 in 54 hpf control and dnIRS2 embryos using in situ hybridization.  
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 Figure 4-14. Treatment of PI3K inhibitor wortmannin increases β cell differentiation 
from ventral endoderm. (A-B)  Confocal projection of 30 hpf control (A) and 1 μM 
wortmannin-treated (B) islets from Tg(ins:CFP-NTR) stained with CFP (green). (C-D) 
Confocal planes of 30 hpf control (C) and 1 μM wortmannin-treated (D) islets with 
zygotic injection of H2B-RFP mRNA stained with CFP (green). It is noted that majority 
of control β cells were H2B-RFP+ but significant portion of H2B-RFP- β cells (yellow 
arrows) can be detected in wortmannin-treated embryos. (E) Quantification of β cell 
number in DMSO control (n=18), 0.25μM (n=13) and 1 μM wortmannin-treated embryos 
(n=17) at 30 hpf. (F) Quantification of β cells in DMSO control (n=17) and 1 μM 
wortmannin-treated (n=9) embryos at 42 hpf. (G) Quantification of β cell number in 
DMSO control (n=10) and U0126 treated (n=9) embryos at 32 hpf. U0126 was treated 
with the dose of 100 μM. One-way ANOVA was used in E and Student’s t-test was used 
in F, G for statistical analysis.  
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 Figure 4-15. Knockdown of insulin influences islet structure and α cell development. (A-
F) Confocal projections of control and insaMO-injected islets from Tg(ins:CFP-NTR) 
embryos at 54 hpf, 80 hpf and 100 hpf stained with CFP (green) and glucagon (red). (G,I) 
Confocal projections of two month old control and insaMO-injected islets stained with 
insulin (green) and glucagon (red). (H,J) Confocal planes of two month old control and 
insaMO injected islets stained with insulin (green) and glucagon (red). It is notable that 
the islet is consistently dysmorphic in insaMO-injected embryos and glucagon+ cells in 
insaMO primary located near extra-pancreatic duct region.  
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 Figure 4-16. The effects of insaMO on total endocrine cell number and δ cell number. (A-
H) Confocal projections of control islets and insaMO islets in 
Tg(neurod:GFP)Tg(ins:dsRed) at 1 dpf to 4 dpf. (I-J) Confocal projections of control and 
insaMO injected islets at 3 dpf stained with insulin (green) and somatostatin (red).  (K) 
Quantification of total endocrine cell number in both control and insaMO injected 
embryos from 1 dpf to 4 dpf. n≥7 for all the time points. (L) Quantification of total 
somatostatin+ cells in both control (n=5) and insaMO injected (n=6) embryos at 3 dpf. 
Two way ANOVA was used in K and Student’s t-test was used in L for statistical 
analysis.  
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 Figure 4-17. Knockdown of insulin increases α cell plasticity. (A-D) Confocal plane 
image showing both control and insaMO injected islets in Tg(gcga:GFP) at 30 hpf and 
100 hpf stained with Pdx1(red). (E) Quantification of gcga:GFP+(green bar) , gcga:GFP+ 
Pdx1+(yellow bar), gcga:GFP-Pdx1+(red bar) cell number in both control and insaMO 
injected embryos at 30 hpf and 100 hpf. n≥7 for all the time points. (F-G) Confocal plane 
image showing β cell regeneration islets in control and insaMO injected Tg(ins:Flag-
NTR) Tg(hs:loxp-mcherry-loxp-H2BGFP)Tg(gcga:cre)s962 embryos  stained with Insulin 
(white) , GFP (green)and Glucagon (red). Red arrow showing the H2B-GFP+Glucagon+ 
cells which represent the α cell population which retains α cell fate during β cell 
regeneration. White arrow showing the H2B-GFP+ glucagon- cells which represent the α 
cell population which lost α cell fate during β cell regeneration. (H) Percentage of H2B-
GFP+Gcg- cell population in both control (n=7) and insaMO regenerating (n=13) islet. 
Student’s t-test was used for the statistical analysis in H.  
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 Figure 4-18. Inhibition of insulin signaling increases Pdx1 induction in transplanted 
donor blastula stem cells (BSCs). (A) Confocal plane of control donor Tg(sox17:GFP) 
BSCs transplanted into host larvae without β cell ablation at 1 day post transplantation 
stained with Pdx1(red) and Alcam (white). (B) Confocal plane of control donor 
Tg(sox17:GFP) BSCs transplanted into host larvae with β cell ablation at 1 day post 
transplantation stained with Pdx1(red). (C) Confocal plane of donor Tg(sox17:GFP) 
BSCs injected with dnIRS2-GFP mRNA and then transplanted into host larvae with β 
cell ablation at 1 day post transplantation stained with Pdx1(red). 
 
 
 
145 
 
 Figure 4-19. Transplanted donor BSCs can be induced to differentiate into pancreatic 
endocrine cells in β cell ablated host larvae. (A-B) Confocal plane images of Confocal 
donor Tg(sox17:GFP) BSCs transplanted into host larvae with β cell ablation at 2 day 
post transplantation stained with Insulin(red) and Glucagon(white). (C) Confocal plane of 
donor Tg(sox17:GFP) BSCs injected with dnIRS2-GFP mRNA and then transplanted 
into host larvae with β cell ablation at 2 day post transplantation stained with Insulin(red) 
and Glucagon(white).  
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 Figure 4-20. Transplantation of BSCs increases host β cell regeneration. (A-C) Confocal 
projection of 2 day post ablation regenerating host islets without transplantation (sham 
control, A), transplanted with control Tg(sox17:GFP) donor BSCs (B) and transplanted 
with Tg(sox17:GFP) dnIRS2-GFP mRNA injected donor BSCs(C) stained with 
Insulin(red) and Glucagon(white).  
  
147 
 
CHAPTER FIVE: Insulin signaling is required for exocrine pancreas formation and 
acinar cell fate maintenance 
 
V.A. Summary 
As an integrated organ, the function of the pancreatic exocrine cells is highly 
regulated by pancreatic endocrine hormones including insulin, which is secreted from 
islet β cells. However, the impact of the pancreatic hormones on the exocrine pancreas 
during embryonic development is unclear. It is known that both pancreatic endocrine and 
exocrine components are derived from the same progenitor cells during development. 
Results in Chapter Four have revealed that insufficient insulin signaling during early 
development induce the precocious differentiation of pancreatic progenitors into β cells. 
However, the effect of insulin signaling on exocrine pancreas development is still 
unknown. In this study, using multiple genetic approaches, we have revealed that insulin 
signaling is critical for exocrine pancreas development. Insufficient insulin signaling 
during early embryonic development will impair pancreatic progenitor cell differentiation 
toward the exocrine cell lineage. Moreover, the impairment in exocrine pancreas persists 
until adulthood, indicating that the early loss of insulin signaling permanently altered the 
pancreatic differentiation program. Using a unique Hot-cre inducible transgenic system, 
we have shown that specific blockage of insulin signaling in differentiated acinar cells 
will induce the expression of the pancreatic progenitor and duct cell marker Pdx1. These 
data suggest that insulin signaling may be critical for maintaining the mature acinar cell 
fate. Altogether, our studies show that insulin signaling is not only important in 
regulating exocrine pancreas functions but is also indispensable to ensure the appropriate 
development of the exocrine pancreas. 
 
V.B. Introduction 
The pancreas is a compound organ that facilitates macronutrient breakdown and 
absorption and regulates whole body metabolism. In order to fulfill these complex roles, 
the pancreas is composed of both exocrine and endocrine components (44). The majority 
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of pancreatic tissue belongs to the exocrine component, which is made of the duct 
epithelium cells and acinar cells. Digestive enzymes and pancreatic juices are synthesized 
in acinar cells and then secreted into the pancreatic duct system, which is connected to 
the duodenum. Upon entering the intestine, these enzymes become activated to aid 
digestion. On the other hand, the pancreatic endocrine hormones are secreted from the 
islets of Langerhans, which are dispersed throughout the pancreatic exocrine tissue. 
Insulin is one of the key islet hormones; it is secreted from islet β cells and plays a 
fundamental role in regulating glucose homeostasis. 
Previous studies have shown that the cellular functions of the exocrine pancreas are 
directly regulated by insulin released from the islet, indicating the existence of an islet-
exocrine axis (137).  As acinar cells receive blood flow directly from the islet via the 
portal vein system, these cells are exposed to some of the highest insulin levels among all 
somatic cells (365), and consistent with this observation, insulin regulates the expression 
of insulin receptor on the surface of acinar cells (366). Moreover, amylase mRNA levels 
progressively decrease in an insulin-deficient, STZ-induced, rat model of β cell ablation; 
this effect can be reversed by insulin treatment (367).  Results from both in vitro and in 
vivo studies have revealed that insulin potentiates cholecystokinin-induced pancreatic 
exocrine secretion (368,369).  Important roles of insulin signaling in exocrine pancreas 
growth and function have also been revealed by clinical studies. Insufficient insulin 
signaling causes an increase in blood glucose, and can subsequently result in the 
development of diabetes mellitus. Type 1 Diabetes Mellitus (T1DM) is caused by 
autoimmune destruction of β cells, which results in absolute insulin deficiency. Clinical 
studies have demonstrated that acini surrounding insulin-containing islets are larger and 
contain more zymogen granules than acini surrounding insulin deficient islets, indicating 
that insulin can act as a local factor to directly regulate acinar enzyme synthesis and 
secretion in humans (370). Moreover, a decrease in exocrine pancreas size is correlated 
with T1DM (371-373). Furthermore, it is reported that the size of pancreas in children 
(<15 years old) with T1DM is correlated with duration of disease progress and severity of 
insulin deficiency (374-376). Together these clinical studies demonstrate that insulin may 
not only play important roles in the regulation of exocrine pancreas function but also in 
exocrine pancreas development and growth. However, our understanding of the influence 
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of insulin signaling on exocrine pancreas development in the embryonic period remains 
meager. 
 Endocrine cells, including the insulin-secreting β cells, and exocrine cells are derived 
from common progenitors that co-express two key transcription factors: Pdx1 and Ptf1a 
(48). The differentiation potential of these progenitors is highly regulated both by their 
environment and their innate genetic programming (181). In this study, we have used the 
zebrafish as a model (216,221) to study the influence of insulin signaling on exocrine 
pancreas development. Previous studies have shown that zebrafish and mammals have 
highly conserved metabolic profiles and pancreatic developmental programing (216,221). 
In addition, pancreas development is largely similar. As in mammals, the zebrafish 
pancreas is derived from two progenitor cell domains, the dorsal and ventral pancreatic 
buds (220). The zebrafish dorsal bud differentiates early, and gives rise solely to 
endocrine cells. These cluster to form the principal islet by 24 hours post fertilization 
(hpf). The zebrafish ventral bud, on the other hand, gives rise to both exocrine and 
endocrine cells. As in mice and humans, the zebrafish ventral pancreas progenitors 
initiate as multipotent progenitors that are marked by Pdx1 and Ptf1a expression 
(183,227,228). After their induction from the ventral endoderm, these progenitor cells 
migrate, and engulf the dorsal bud-derived cells at 34 hpf. As exocrine pancreas 
development progresses, ptf1a is excluded from duct cells, but remains expressed in 
acinar cells where it is crucial for acinar cell functions (72).  In mature acinar cells, Ptf1a 
complexes with other transcription factors to drive the expression of acinar cell functional 
genes, such as elastase and trypsin (377).  On the other hand, the expression of pdx1 is 
selectively activated in duct cells, but not acinar cells (223).   
In zebrafish larvae, the primary energy source transitions from yolk to extragenous 
nutrients; this is associated with the functional maturation of exocrine pancreas and is 
marked by digestive enzyme secretion from acinar cells (1,183).  The coincident timing 
of these transitions suggests that metabolic signals are involved in the regulation of 
exocrine pancreas development and maturation. As we have shown in Chapter Four, 
insulin signaling plays an important role in regulating pancreatic progenitor cell 
differentiation.  Loss of insulin signaling resulted in the precocious differentiation of 
pancreatic progenitor cells into β cells.  Since both pancreatic exocrine and endocrine 
150 
 
components are derived from the same progenitor pool, we therefore hypothesized that 
disruptions to the early progenitor cell differentiation program resulting from insulin 
deficiency would impair the development and maturation of exocrine pancreas.  
In this chapter, we have analyzed the insulin-exocrine pancreas axis during pancreas 
development.  Using multiple genetic approaches and the zebrafish as a model, we show 
that insulin signaling during early pancreas development drives pancreatic progenitor 
differentiation toward the exocrine cells fate. Moreover, our data reveal a critical period 
for insulin function during pancreatogenesis, as defects arising from insulin signaling 
impairment persist in adult animals.  Finally, insulin signaling suppresses Pdx1 
expression in differentiated acinar cells, and thereby contributes to the maintenance of 
acinar cell fate.  Further elucidation of the mechanisms by which insulin regulates 
exocrine pancreas development will contribute to the understanding of T1DM-associated 
exocrine pancreas insufficiency.  
 
V.C. Results 
Insufficient insulin signaling impairs exocrine pancreas development.  
In order to investigate how insulin signaling impacts pancreatic exocrine cell 
development, we used an inulin morpholino (insaMO) to knockdown insulin a mRNA.  
As shown in Chapter Four, insaMO is specific and efficacious, and knockdown of insulin 
via insaMO blocks insulin synthesis from pancreatic β cells. To visualize exocrine cell 
development, we used Tg(ptf1a:GFP), which is shown to be expressed in the retina, brain 
and pancreatic domain (183). Using this approach, we found that injection of insaMO 
strongly impaired exocrine pancreas development at 4 dpf (Figure 5-1A).  However, there 
was no significant difference of ptf1a:GFP expression in the hindbrain and retina, 
indicating this may be a pancreas-specific role for insa (Figure 5-1A).  In both mammals 
and zebrafish, ventral pancreas progenitors are derived from bi-potent endoderm 
progenitors that also gives rise to liver (220). Thus, we also investigated if knockdown of 
insulin influenced liver development using the transgenic fish line 
Tg(fabp10:dsRed);Tg(ptf1a:GFP), in which hepatocytes were marked by red 
fluorescence and acinar cells were marked with green fluorescence (Figure 5-6). We 
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observed that although insa knockdown strongly impaired pancreas development, the 
liver of insaMO embryos appeared grossly similar to controls (Figure 5-6A, B). This 
indicated that insulin signaling likely does not regulate the development of all endoderm, 
but rather acts as a local factor to regulate pancreas development.  To further probe this 
pancreatic role, the acinar cell-specific marker trypsin was analyzed by in situ 
hybridization (ISH) and real time PCR. We found a significant decrease in trypsin 
expression in the insaMO-injected embryos at 3 and 4 dpf as compared to controls 
(Figure 5-1B).  Moreover, real time PCR data revealed a 40% decrease in trypsin 
expression in the insaMO-injected embryos (Figure 5-1C). 
Next, we used the HOT-Cre system of inducible transgenes to block insulin signaling 
by overexpression of dominant-negative insulin receptor substrate 2 (dnIRS2).  In this 
synthetic construct, the C-terminal effector binding domain of IRS2 was substituted with 
GFP, which resulted in the preservation of binding affinity to the insulin receptor, but 
blocked transmission of insulin signaling further downstream (Figure 5-1D).  Using this 
system, we crossed Tg(hs:cre) (hereafter hs:cre) with Tg(hs:loxp-mcherry-loxp-
dnIRS2GFP) (hereafter dnIRS2), to generate embryos that could overexpress dnIRS2 and 
block insulin signaling upon heat shock induction (Figure 5-1E).  The efficiency of 
insulin signaling blockade by dnIRS2 was verified as described in Chapter Four.  We 
used Alcam immunostaining to visualize the exocrine pancreas, and observed that it was 
significantly smaller in dnIRS2 embryos than in controls (Figure 5-1F-G).  In order to 
confirm the defect of exocrine pancreas development, we analyzed trypsin expression via 
ISH at 72 hpf, and found that it was strongly reduced in dnIRS2-expressing embryos 
(Figure 5-6C-D).   
Next, we tested weather ablation of β cells influenced exocrine pancreas 
development. For this, we used the Tg(gata5:loxp-mcherry-loxp-DTA) transgenic line 
together with Tg(insa:cre) to generate embryos in which 48% of β cells were specifically 
destroyed by Diphtheria Toxin A (DTA; Figure 5-6C-E).  By 72 hpf, β cell-ablated 
embryos showed a 20% decrease in exocrine pancreatic length as compared to control 
marked by Alcam (Figure 5-6F).  
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Insulin knockdown impairs exocrine pancreas differentiation rather than 
proliferation. 
Since Insulin has been proposed as an important mitogen that stimulates proliferation 
(378), we then reasoned that the decrease in exocrine pancreas size in response to insulin 
deficiency might be due to a decreased exocrine pancreas proliferation. To test this, we 
first analyzed the proliferation rate of the exocrine pancreas via immuno-staining for the 
M-phase cell cycle marker phosphohistone H3 (PHH3). We observed that although there 
was a significant decrease in exocrine pancreas mass in insaMO-injected endoderm, we 
found that after normalizing to total ptf1a:GFP+ cell number, the PHH3+ ptf1a: GFP+ 
cell percentage in insaMO injected embryos was not changed at 48 hpf or 74 hpf, 
suggesting that the proliferation rate of exocrine cells was not decreased in response to 
the insulin knockdown (Figure 5-2A-C). To further confirm this result, we analyzed cell 
proliferation by EdU incorporation, which labels replicating DNA. Similarly, we did not 
observe a difference in the EdU+ ptf1a: GFP+ cell ratio between control and insaMO 
groups (Figure 5-2D-F). By the concordant data resulting from both approaches, we can 
exclude the possibility that the impairment of exocrine pancreas growth is due to altered 
pancreas proliferation. Since insulin is also an anti-apoptotic factor in pancreas (379), we 
also tested whether insulin knockdown increased the rate of apoptosis in the exocrine 
pancreas. For this, we used cleaved-Caspase 3 immunostaining. Metronidazole-induced β 
cell apoptosis in Tg(ins:CFP-NTR) embryos was used as a positive control (254)(Figure 
5-7A). We observed no cleaved-Caspase3+ acinar cells in either control or insaMO-
injected pancreata, indicating that inhibition of insulin signaling did not increase acinar 
cell death (Figure 5-7B-C).  
Since the knockdown of insulin affected neither proliferation nor apoptosis rates in 
the exocrine pancreas, we suspected that exocrine pancreas deficiency in insaMO-
injected embryos might be due to impaired differentiation. To analyze this, ptf1a: GFP+ 
cells in the ventral pancreas were traced over time. In accord with previous work (183), 
we found that, ptf1a: GFP+ cells were first detected around 33 hpf in the ventral 
endoderm of control embryos, and that these newly derived ptf1a: GFP+ cells were close 
to the dorsal pancreatic islet (Figure 5-3A). We found that after their induction from the 
ventral endoderm, these ptf1a: GFP+ cells expanded until they merged with the dorsal 
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endocrine cells (Figure 5-3A-F). Inhibition of insulin signaling via insaMO delayed the 
induction of ptf1a: GFP+ cells. The first ptf1a: GFP+ cells in insaMO-injected embryos 
were detected at 38 hpf near the anterior region of the dorsal bud, and these ptf1a: GFP+ 
cells failed to merge with the principal islet at 61 hpf (Figure 5-3G-M, P). The delayed 
appearance of ptf1a: GFP+ cells was not likely due to a general delay of development, as 
insaMO-injected embryos exhibited no general developmental defects (see also chapter 
four). Furthermore, our results indicate that insa knockdown not only delayed the 
initiation of ptf1a: GFP+ cells but also decreased the overall ptf1a: GFP+ cell quantity 
(Figure 5-3G-M, P).  
Both Ptf1a and Pdx1 are expressed in early pancreatic progenitor cells (227,228). 
During murine exocrine pancreas development, Pdx1 is repressed in the acinar cell 
lineage, but is continuously expressed in duct cells (380,381). In accord with previous 
findings, we found that Pdx1 expression in adult zebrafish exocrine pancreas was also 
limited to the duct cells (Figure 5-8). On the other hand Ptf1a is expressed only in acinar 
cells, and not duct cells (382). In order to investigate the dynamic expression of Pdx1 and 
Ptf1a during pancreatic progenitor differentiation, we performed immunostaining for 
Pdx1 in Tg(ptf1a:GFP) embryos. We found that in 33 hpf control pancreata, all ptf1a: 
GFP+ cells were also Pdx1+ (Figure 5-3A-B, Q).  However, in 44 hpf control embryos, 
there were three cell classifications in ventral bud derived pancreas: (1) Pdx1+ 
ptf1a:GFP+, (2) Pdx1+ ptf1a:GFP- and (3) Pdx1- ptf1a:GFP+ (Figure 5-3C-D, Q). In 
constrast to control embryos, all pf1a:GFP+ cells were also found to be Pdx1+ in 44 hpf 
insaMO-injected embryos (Figure 5-3I-J, Q). Moreover, in 61 hpf control embryos, only 
ptf1a:GFP+ Pdx1- and Pdx1+ ptf1a:GFP- cells, but not ptf1a:GFP+ Pdx1+ cells, were 
detectable (Figure 5-3E-F, Q). Yet, in 61 hpf insaMO-injected embryos, 67% of 
ptf1a:GFP+ cells were found to co-express Pdx1. 
Normally, during exocrine pancreas development, Pdx1 is selectively activated in the 
duct cell lineage (380). We therefore hypothesized that in the exocrine pancreas of 61 hpf 
insaMO-injected embryos that the Pdx1+ ptf1a:GFP+ cells represented  mis-differentiated 
acinar cells that also exhibited duct cell characteristics. To test this, we performed 
immuno-staining with 2F11 in Tg(ptf1a:GFP) embryos. 2F11 antibody marks zebrafish 
pancreatic duct cells, and the 2F11+ domain overlaps the pancreas duct marker sox9b 
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(383). Furthermore, 2F11 is expressed in a complementary pattern to ptf1a: GFP+ cells 
(Figure 5-3N). This is consistent with our observations that ptf1a: GFP+ cells do not 
express Pdx1 at 61 hpf (Figure 5-3E, F, Q). However, in 72 hpf insaMO-injected 
pancreas, we found that majority of ptf1a: GFP+ cells co-expressed 2F11. Furthermore, 
Notch signaling is repressed during acinar cell differentiation, but is maintained in 
differentiated pancreatic duct cells (111). We thus used the Notch reporter transgenic line 
Tg(tp1:nls-Red) to analyze whether insa knockdown could induce formation of acinar 
cells that inappropriately activate Notch signaling. Consistent with the findings above, we 
detected tp1:nls-Red+ ptf1a:GFP+ cells in 72 hpf insaMO-injected pancreas, but not in 
control pancreata (Figure 5-9).  
Altogether, we have shown that in the absence of insulin, zebrafish ventral pancreatic 
progenitor cells cannot differentiate appropriately into acinar cells and duct cells. 
Furthermore, insulin knockdown results in confused exocrine cell types, which co-
express both acinar and duct cell genes (Figure 5-3R). 
 
Inhibition of Insulin signaling activates Pdx1 expression in differentiated acinar 
cells 
Thus far, we have shown that inhibition of insulin signaling impairs the exocrine 
pancreas developmental program. We next asked whether insulin signaling directly 
influenced acinar cells during development. To test this, we analyzed the expression of 
the insulin receptor in exocrine pancreas using ISH. There are two isoforms of the insulin 
receptor in zebrafish, insra and insrb. Our results indicated that both genes are expressed 
in the exocrine compartment, and are especially highly expressed in acinar, but not duct 
cells at 72 hpf (Figure 5-10). The presence of insulin receptors in acinar cells indicates 
that insulin signals secreted from pancreatic β cells may directly act on acinar cells during 
development.  
In order to understand how insulin signaling influences differentiated acinar cells, we 
blocked insulin signaling in all differentiated elastase-expressing acinar cells. For this, 
we crossed dnIRS2 fish with Tg(ela3l:cre; cryaa:YFP) (hereafter ela:cre) fish to induce 
dnIRS2 in acinar cells upon heat shock induction. Tg(hs:loxp-mcherry-loxp-stop-H2B-
155 
 
GFP) (hereafter hs:CSH);ela:cre embryos were used as controls.. Our results showed that 
there was no significant change in pancreatic size between control and dnIRS2; ela:cre 
embryos (Figure 5-5C,E). This is consistent with our finding above that knockdown of 
insulin does not influence acinar cell proliferation or death. However, we observed that 
blockade of insulin signaling resulted in altered acinar cell morphology. Using Alcam to 
mark the border of exocrine pancreas cells in 84 hpf control embryos, we found that 
acinar cells were much larger than pancreatic duct cells and acinar cellular nuclei were 
located basally (Figure 5-4A). However, after insulin signaling blockade with dnIRS2; 
ela:cre, we could no longer distinguish acinar cells by morphology (Figure 5-4E,F). 
Next we analyzed Pdx1 expression and found that in the exocrine pancreas at 84 hpf, 
Pdx1 expression was detected in 2F11+ duct cells, but not acinar cells (Figure 5-5A-B). 
However, after insulin signaling blockade using dnIRS2GFP; ela:cre, we found that 
many dnIRS2-GFP+ acinar cells expressed Pdx1 after heat shock induction (Figure 5-5E-
F). In contrast, in the control ela:cre; hs:CSH embryos, Pdx1 was completely excluded 
from H2B-GFP labeled acinar cells (Figure 5-4C). Pdx1 has a key role in promoting 
pancreatic β cell formation and the misexpression of Pdx1 in pancreatic α cells can 
induce α to β cell transdifferentiation (65,271). With this data in mind, we hypothesized 
that activation of Pdx1 in acinar cells would promote acinar to β cell transdifferentiation. 
To test this hypothesis, we examined Insulin expression in 72 hpf dnIRS2; ela:cre 
embryos after heat shock induction, but did not detect any dnIRS2-GFP+ cells that co-
expressed Insulin protein (Figure 5-11A). Next, to address whether acinar to β cell 
trandifferentiation could be induced by combining the conditions of insulin signaling 
deficiency and β cell loss, we ablated β cells in ela:cre; dnIRS2; ins:Flag-NTR transgenic 
embryos. However, we found that following metronidazole-induced β cell ablation (271), 
regenerating β cells were only observed in the islet region, and that no ectopic dnIRS2-
GFP+ Insulin+ cells were detected at 1 day post ablation (Figure 5-11B). These results 
indicate that derepression of Pdx1 in acinar cells it is not sufficient to promote their 
transformation into β cells. These data indicate that blockade of insulin signaling in 
acinar cells activates Pdx1 expression, and suggest that insulin normally serves to 
suppress acinar cell expression of Pdx1. 
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Diminished insulin signaling during pancreatogenesis permanently alters exocrine 
pancreas morphology 
In order to explore the long term effects of insulin signaling blockade on exocrine 
pancreas development, we aged control and insaMO-injected embryos to 2 months post 
fertilization (mpf), and then analyzed the morphology of the exocrine pancreas. For this 
we used fish bearing the transgene Tg(fabp10:dsRed;ela3l:GFP), in which hepatocytes 
are marked with red and acinar cells with green fluorescence.  Morpholinos become 
diluted as cells divide and this diminishes their capacity for genetic knockdown (261). 
We therefore questioned whether restortation of insulin expression would stimulate 
exocrine pancreas regeneration. Externally, insaMO-injected adult fish were 
indistinguishable from controls (Figure 5-5A). Internally, in control fish, the head of the 
pancreas is positioned on the right side (as seen from the dorsal aspect) and the principal 
islet is located at the anterior of the pancreatic head, which is usually covered by liver 
(Figure 5-5B, D).  The zebrafish pancreas continues to grow throughout adult stages 
(384), and multiple pancreatic tails extend along the intestinal loops (Figure 5-5B,D, J). 
A distribution of smaller secondary islets is found along each of these tail lobes (Figure 
5-5D).  Surprisingly, we found that pancreas morphology was greatly disrupted in 
insaMO-injected fish. In insaMO-injected fish, we observed that the exocrine pancreas 
near the principal islet was severely diminished (Figure 5-5C,G,H,K).  In addition, we 
found that the endocrine morphology was also strongly influenced by insaMO. While in 
control pancreas the secondary islets were scattered throughout the exocrine tissues 
(Figure 5-5D-F), in 2 mpf insaMO-injected pancreata we observed “naked” secondary 
islets that were not surrounded by acinar cells (Figure 5-5G,I; Figure 5-12A).  
Furthermore, in control pancreas, both principal islet and secondary islets were 
comprised of β cells and α cells (Figure 5-5E-F). However, in insaMO-injected pancreata, 
the α cell population was severely decreased in the principal islet and was absent from 
naked  secondary islets (Figure 5-5H). This was consistent with our earlier findings 
(Chapter Four), which showed that Insulin deficiency could promote biased, 
compensatory β cell differentiation at the expense of α cell fate.  
Interestingly, in insaMO-injected fish, we observed discrete segments of pancreas that 
are not contiguous along the intestine (Figure 5-5C,G,K). We occasionally observed 
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secondary islets that were surrounded by acinar cells in these segments (Figure 5-12B,C), 
and the alpha cell content in these islets also appeared to be similar to control (Figure 5-
12B,C). We speculate that this is due to pancreas regeneration that occurs after relieving 
the insulin signal blockade (more discussion below). Nevertheless, the existence of these 
extra-pancreatic segments may rescue the general development and glucose metabolism 
of insaMO-injected zebrafish.  
 
V.D. Discussion 
In this study, we used different genetic approaches to demonstrate that insulin 
signaling is critical for exocrine pancreas formation and maturation, as well as 
maintaining the differentiated acinar cell fate. Our data demonstrate that loss of insulin 
signaling, using either insulin knockdown or dnIRS2 over-expression, resulted in the 
impairment of exocrine development. This included a decrease in exocrine pancreas size 
and in expression of genes encoding digestive enzymes. Moreover, insufficient insulin 
signaling resulted in decreased progenitor cell differentiation into exocrine lineages, 
which subsequently resulted in permanent diminution of the exocrine pancreas in adult 
fish. Finally, our results showed that specifically blocking insulin signaling in acinar cells 
induced Pdx1 activation and altered acinar cell morphology. These results indicate that 
insulin signaling not only acts as a development signal to promote acinar cell formation 
but also plays an important role in sustaining acinar cell fate. 
From the studies in Chapter Four, we have revealed an important role for insulin in 
regulating pancreatic progenitor cell differentiation. Loss of insulin signaling was found 
to induce precocious differentiation of progenitor cells into β cells, which then depleted 
the pancreatic progenitor cell pool. Here, in consistent with our previous findings, our 
results demonstrated that after insulin knockdown, the initiation of ptf1a expression cells 
in the ventral endoderm requires insulin signaling. In the absence of insulin signaling, the 
induction of ventral ptf1a expressing cells was delayed and the quantity of ptf1a 
expressing cells was decreased.  Therefore, the simplest interpretation of these data is that 
the impairment of exocrine pancreas development resulting from insulin insufficiency 
was due to the loss of pancreatic progenitors. This is consistent with previous studies that 
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showed that loss of Notch signaling, which is crucial for regulation of pancreatic 
progenitor differentiation, induces premature differentiation of progenitors and depletes 
the pool of pancreatic precursor cells; this results in a shortage of progenitor cells that can 
differentiate into exocrine cells (106,107). Here, we have also demonstrated that 
insufficient insulin signaling during embryogenesis affects the adult pancreas.  We 
observed a severe defect in exocrine pancreas adjacent to the principal islet, and found 
that the relative quantity of α cells in the islet near the pancreatic head was strongly 
reduced. This is consistent with the observation that the adult pancreatic organ size is 
determined by the mass of early pancreatic progenitors (115). Interestingly, in our model, 
we observed the formation of discontinuous segments of pancreas which exhibited 
normal morphology. Although it is unclear in mammals whether pancreatic progenitors 
persist in adult pancreas (176,179,275), it is clear in zebrafish that pancreatic progenitors 
persist and retain their differentiation capacity until adulthood (2,223,385). Genetic 
lineage tracing results have demonstrated that zebrafish duct-associated progenitors can 
differentiate into all the pancreatic lineages (2), and this is consistent with observations 
that adult zebrafish exhibit a high capacity for regeneration following injury (247). 
Therefore, it is feasible and likely that the formation of complete, discrete pancreatic 
segments results from the differentiation of pancreas progenitors that had escaped long 
term effects of insulin deficiency during embryogenesis. This compensatory mechanism 
may resolve the exocrine pancreas insufficiency that would otherwise result from insulin 
deficiency during pancreas formation.  
In addition to an the influence on the pancreatic progenitor pool, our resultshave  also 
demonstrated that insulin signaling promotes pancreatic progenitor differentiation into 
exocrine lineages. Burlison et al. have shown that Pdx1 and Ptf1a co-expressing cells 
exist only transiently in early pancreatic progenitor population (68). During 
differentiation, each these two transcription factors is selectively repressed in different 
cellular lineages: Ptf1a is repressed in endocrine and duct, while Pdx1 is repressed in 
acinar cells (386). Here we have shown that insulin mediates acinar repression of Pdx1, 
and suggests that these insulin-deficient acinar cells may be trapped in a partially 
dedifferentiated state. Furthermore, we have revealed that knockdown of insulin results in 
formation of cells which retain both acinar and duct cell characteristics. All this 
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evidences supports the assertion that the exocrine pancreas differentiation program is 
highly dependent upon insulin signaling.  
Besides early progenitor programming, our studies have also revealed a critical role 
for insulin signaling in distinguishing duct and acinar cell lineages during progenitor cell 
differentiation. Knockdown of insulin appears to produce cells in a confused meta-state, 
whereby they express both acinar and duct cell markers. It is likely that insulin regulates 
cell fate determination via key transcription factors. Previous studies have shown that 
specification of the pancreas relies on two key transcriptional factors, Pdx1 and Ptf1a 
(68). The Ptf1a transcriptional complex binds many acinar cell-specific gene promoters 
and acts as a master regulatory factor for acinar cell formation and function (387). Pdx1 
is also expressed in the early pancreatic progenitor cells, and deletion of Pdx1 in mice 
results in pancreatic agenesis (62). However, in the adult mammalian pancreas, Pdx1 is 
only strongly expressed in β cells; outside the islet, Pdx1 expression is weak in small 
pancreatic ducts and centroacinar cells, and acinar expression of Pdx1 is minimal 
(381,388). In our studies we found that the dynamic expression pattern of Pdx1 is 
conserved between mammalian and zebrafish adult pancreata. The repression of Pdx1 in 
mature acinar cells is necessary for acinar cell functions (389), and persistent expression 
of Pdx1 induce exocrine hypoplasia and a dramatic reduction in digestive enzyme 
expression (389). Nonetheless, although Pdx1 is not expressed in mature acinar cells, it is 
required for the formation of acinar cells during late pancreatic organogenesis (390). 
Using a Tet-off regulatory system, it is shown that deletion of Pdx1 in later gestational 
stages blocked acinar cell formation and inhibited Ptf1a expression in acinar cells (390).  
Furthermore, activation of Pdx1 is observed in human and animal models pancreatitis, 
where it may be important for acinar cell regeneration (42,391). These findings contribute 
to a model in which Pdx1 is not completely silenced but rather dampened in mature 
acinar cells (392).  Furthermore, these findings clearly demonstrate that the dynamic 
regulation of Ptf1a and Pdx1 expression in acinar cells is crucial for acinar cell formation 
and regeneration.  
The extracellular signals that regulate expression of these two key transcription 
factors in acinar cells are unknown.  In this study, we have determined that insulin 
signaling may be an important extracellular cue that regulates Pdx1 and Ptf1a expression 
160 
 
in pancreatic progenitor cells and acinar cells. The studies from Chapter Four showed that 
insulin deficiency during embryogenesis promotes Pdx1 expression in the ventral 
endoderm progenitors. Moreover, our results here show that insulin signaling drives an 
increase in the quantity of Ptf1a-expressing cells.  Altogether these data support the 
hypothesis that insulin represses Pdx1, but activates Ptf1a expression to promote acinar 
cell formation. It is well recognized from human clinical studies that T1DM is correlated 
with reduced exocrine pancreas size and function (393). In addition, insulin plays an 
important role as a trophic agent for acinar cells, which further supports the existence of 
an islet-acinar axis (137,394). In this study, we have determined that insulin signaling 
regulates both acinar cell formation and maturation, likely via the regulation of Pdx1 and 
Ptf1a expression. Further understanding the molecular links between insulin signaling 
and the regulation of these key genes may spark new therapeutic strategies to confrong 
T1DM-induced exocrine pancreas insufficiency. 
This study also provides evidence that insulin signaling may contribute to the 
maintenance of acinar cell fate stability. The plasticity of acinar cells has been reported in 
many previous studies. In particular, it is reported that rat acinar cells can 
transdifferentiate into duct cells and re-activate Pdx1 when cultured in vitro; this 
underscores the importance of the in-vivo mircro-environment in maintaining acinar cell 
fate and Pdx1 repression (395). Moreover, persistent expression of Pdx1 in vivo, induces 
acinar to duct transition (389), and duct-like cells or tubular complexes appear in both 
pancreatitis and pancreatic neoplasia in humans; this acinar to ductal metastasis underlies 
the initiation of acinar cell carcinoma (381,396,397). In this study, we demonstrate that 
insulin signaling plays an essential role in regulating the acinar and duct cell fates: 
knockdown of insulin results in abnormal duct-like acinar cell morphology, and 
inhibition of insulin signaling in acinar cells reactivates Pdx1 expression, and results in 
the loss of acinar cell polarity. 
Obesity and adult onset Type 2 diabetes re highly associated with development of 
acinar cell carcinoma (398,399), which suggests a link between insulin signaling and 
pancreatic cancer. In contrast to type 1 diabetes, type 2 results from relative insulin-
deficiency due to unresponsiveness of target tissues to insulin, or “insulin resistance.”  
Although it was long held that insulin resistance was restricted to metabolically active 
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tissues like liver, skeletal muscle and adipocytes, recent work has broadend this view that 
“insulin resistance” in T2DM is a whole body physiological state associated with 
neurons, blood vessels, pancreatic endocrine cells and others (400-402). Although there is 
currently no evidence for acinar cell insulin resistance in T2DM, our studies suggest that 
reduced insulin signaling outputs in T2DM will promote the expression of Pdx1 in acinar 
cells and induce acinar to duct transdifferentiation, and this may then contribute to cancer 
development. 
Besides acinar to duct transformation, acinar cells can be transformed into β cells 
under some experimental conditions. Zhou et al. showed that the transfection of three 
transcription factors: Pdx1, Ngn3, and Mafa, is sufficient to drive acinar cell conversion 
into β cells (182). In addition, acinar to duct cell conversion can be achieved via 
repressing Ptf1a activity (183).  However, in this study, we did not detect acinar 
conversion after loss of insulin signaling. This indicates that Pdx1 misexpression alone is 
not sufficient to surmount the epigenetic barriers between acinar cells and endocrine 
cells, and is consistent with the findings of Zhou et al. (180), and that Ngn3 is required to 
initiate the pancreatic endocrine program (403). Moreover, Ngn3 is ectopically expressed 
in exocrine pancreas following partial duct ligation (PDL), an inflammation-associated 
pancreatic injury model (176,404). Furthermore, acinar to endocrine/β-cell conversion is 
triggered by PDL combined with pharmacological elimination of pre-existing β-cells 
(405). In accord with all these studies, our results have shown that insulin signaling also 
plays a critical role in acinar cell fate regulation. Therefore, it may be productive to 
investigate combinations of insulin suppression and Ngn3 induction in driving the 
transformation of acinar cells into β cell for the treatment of both T1DM and T2DM. 
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 Figure 5-1. Blocking insulin signaling impairs exocrine pancreas development. (A) 4 dpf 
Tg(ptf1a:GFP) control embryos and embryos injected with insaMO at one cell stage. 
ey:eye; hb: hindbrain; xp: exocrine pancreas. (B) In situ hybridization of trypsin 
expression in 3dpf and 4dpf control and insaMO embryos. (C) real time PCR of trypsin 
mRNA expression in 4dpf control and insaMO embryos, n=3.  (D) Illustration of c-
terminal deletion form of dnIRS2-GFP constract. (E) Illustration of blocking insulin 
signaling using Tg(hs:CSdnIRS2) and Tg(hs:cre) system. (F-G) Confocal projection of 
84hpf Tg(hs:CSdnIRS2-GFP) and Tg(hs:CSdnIRS2-GFP); Tg(hs:cre) pancreas stained 
for Alcam(red), GFP(green) and Insulin (white). Embryos were heat shock in 10hpf, 
24hpf, 36hpf, 48hpf, 56hpf and 72hpf to induce dnIRS2-GFP expression. Student t-test 
was used in C for statistical analysis.  
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 Figure 5-2. Knockdown insulin does not decrease proliferation of exocrine pancreas. (A-
B) Confocal projection of 48 hpf Tg(ptf1a:GFP) control and insaMO injected exocrine 
pancreas stained for GFP (green), Insulin (white) and PHH3 (red). (C) Quantification of 
PHH3+ ptf1α+ cell percentage in 48hpf and 74hpf control and insaMo embryos. (D-E) 
Confocal plane of 74 hpf Tg(ptf1a:GFP) control and insaMO injected exocrine pancreas 
stained for GFP(green), Insulin(white) and EDU(red). EDU solution was infused into 
embryos by injecting into pericardia sac 1 hour before fixation. (F) Quantification of 
EDU+ptf1a+ cell percentage in 74 hpf control and insaMO embryos. Two way Anova 
was used in C and student t-test used in F for statistical analysis.  
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 Figure 5-3. Insulin knockdown delays ptf1α initiation and impairs acinar and duct cell 
specification. (A-M) Confocal projections and planes of Tg(ptf1α:GFP) in control and 
insaMO pancreatic endoderm stained for Pdx1(red) and GFP(green). White arrow head 
indicates the principal islet. White arrow indicates ptf1α+ Pdx1- cells. Yellow arrow 
indicates remaining of ptf1α+Pdx1+ cells in 61hpf insaMO embryos. (N-O) Confocal 
planes of Tg(ptf1a:GFP) in control and insaMO pancreatic tail stained with duct marker 
2F11(red). Noted that in control pancreas, 2F11+ cells are ptf1a: GFP- but in insaMO 
pancreas 2F11+ cells are ptf1a: GFP+. (P) Quantification of total ptf1α+ cell number in 
control and insaMO injected embryos. (Q) Quantification of Pdx1+ ptf1α+cell percentage 
in control and insaMO injected embryos. (R) Illustration of the model of insulin regulates 
exocrine pancreas differentiation. Insulin signal is required for Pdx1+Ptf1a+ pancreatic 
progenitors differentiate into both Pdx1+Ptf1- duct progenitor lineage and Pdx1-Ptf1a+ 
acinar progenitor linage. Knockdown of insulin signal interrupts the progenitor cell 
differentiate appropriately into acinar and duct cell lineage and induces the formation of 
cells have mixed acinar and duct cellular characters.  
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 Figure 5-4. Inhibition of insulin signal in acinar cells re-activates Pdx1 expression. (A) 
Confocal plane of 84hpf pancreatic tail stained for Alcam (green) and Pdx1 (red). It is 
noted that Pdx1+ duct cells exhibit distinct cell morphology compared with Pdx1- acinar 
cells. (B) Confocal plane of 84hpf pancreatic tips stained for 2F11 (green) and Pdx1 (red) 
showing Pdx1 was limited in 2F11+ pancreatic duct cells. (C) Confocal plane of 84hpf 
Tg(hs:CSH2B-GFP); Tg(ela:cre) pancreas stained for GFP(green) and Pdx1(red). 
Embryos were heat shocked in 48hpf, 56hpf and 72hpf to induce H2B-GFP expression in 
acinar cells. (D) Zoom in of pancreatic tips in E showing Pdx1 expression was limited in 
pancreatic ducts and no H2B-GFP+ cells express Pdx1. (E) Confocal plane of 84hpf 
Tg(hs:CSdnIRS2-GFP); Tg(ela:cre) pancreas stained for GFP(green) and Pdx1(red). 
embryos were heat shocked in 48hpf, 56hpf and 72hpf to induce dnIRS2-GFP expression 
in acinar cells. (F) Zoom in image of pancreatic tips in C showing the expression of Pdx1 
in dnIRS2-GFP expression acinar cells.  
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Figure 5-5. Embryonic exocrine pancreas deficiency influences adult exocrine pancreas. 
(A) 2 month old control and insaMO injected fish. (B-C) Endoderm of 2 month old 
control and insaMO injected fish marked by Tg(fabp10:dsRed); Tg(ela3l:GFP).  Pi: 
principal islet; ib: intestine bulb; p: pancreas; li: liver. (D, G) Confocal projections of 2 
month old control and insaMO injected endoderm marked by Tg(ela3l:GFP) stained for 
Insulin(red) and Glucagon(white). Pi: principal islet; si: secondary islet; ib: intestine bulb; 
p: pancreas. Arrow heads showing the principal islet and arrow showing the secondary 
islet. (E-H) Confocal projections of 2 month old control and insaMO injected principal 
islet stained for Insulin (red) and Glucagon (white). (F-I) Confocal projections of 2 month 
old control and insaMO injected secondary islet indicated by arrows in D and G which is 
stained for Insulin (red) and Glucagon (white). It is noted that there is no Glucagon+ cells 
in insaMO injected secondary islet. (J-K) Illustration of adult pancreas in control and 
insaMO injected fish. (L) Illustration of the model for insulin regulates pancreatic 
development. Without receiving feedback insulin signal from β cells, pancreatic 
progenitor cells differentiate early into β cells. The reduced progenitor pool and impaired 
exocrine pancreas differentiation program will result in the reduced exocrine mass. 
 
 
 
168 
 
 Figure 5-6. Inhibition of Insulin signal impairs exocrine pancreas development. (A-B) 
Confocal projection of both control and insaMO injected endoderm in 3 dpf 
Tg(fabp10:dsRed); Tg(ptf1a:GFP); Tg(ins:dsRed) embryos. White arrows indicate the 
principal islet. li:liver; p: pancreas. (C-D) In Situ Hybridization showing the expression 
of trypsin in both control and dnIRS2-GFP mRNA injected embryos at 54 hpf.  (E-F) 
Confocal projections of control and β cell ablation endoderm stained with Alcam(green) 
and Insulin(red) at 72 hpf. Control: Tg(ins:cre)+Tg(gata5:loxp-mcherry-loxp-DTA)- ; β 
cell ablation: Tg(ins:cre)+ Tg(gata5:loxp-mcherry-loxp-DTA)+. (G) Quantification of β 
cell number in both 72 hpf control and β cell ablating embryos. (H) Quantification of 
pancreatic length marked by Alcam in both 72 hpf control and β cell ablating embryos. 
Student T-tests were used in I, L, M for statistical analysis. 
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 Figure 5-7. Knockdown of insulin does not increases exocrine pancreas apoptosis. (A) 
Confocal plane image of 3 dpf islet in Tg(ins:CFP-NTR) treated with MTZ for 4.5 hours 
stained with CFP(green) and Cleaved-Caspase 3(red). (B-C) Confocal plane of 54 hpf 
pancreas in Tg(ptf1a:GFP) control and insaMO injected embryos stained with 
Insulin(white) and Cleaved-Caspase3(red).   
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 Figure 5-8. Pdx1 expression is limited to adult zebrafish islet β cells and duct cells. (A-B) 
Confocal plane of 2 month old adult zebrafish principal islet (A) and secondary islet (B) 
stained with Insulin (green), Pdx1 (red) and 2F11 (white).  It is noted that Pdx1 
expression is limited to Insulin+ or 2F11+ cells in the pancreas.  
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 Figure 5-9. Knockdown of insulin induces the formation cells co-express both acinar and 
duct cell markers. (A-B) Confocal plane of 72 hpf Tg(tp1:nls-Red); Tg(ptf1a:GFP) 
control (A) and insaMO-injected zebrafish embryos. Yellow arrows in B indicate tp1: 
nls-Red+ ptf1a: GFP+ cells. It is noted that no double positive cells can be detected in A.  
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 Figure 5-10. Expression of insulin receptors in acinar cells. (A) The expression of insulin 
receptor a (insra, A) and insulin receptor b (insrb, B) at 3 dpf embryonic endoderm 
regions using In Situ Hybridization. p: pancreas, ib: intestine bulb. (B) Fluorescence In 
Situ Hybridization detecting the expression insulin receptors (red) in 3 dpf 
Tg(ptf1a:GFP)  embryos. (C) Fluorescence In Situ Hybridization detecting the 
expression insulin receptors (red) in 3 dpf Tg(nkx2.2:GFP)  embryos. In both B and C, 
insr probe was designed to bind at homologous region of both insra and insrb. It is noted 
that insulin receptor is strongly expressed in ptf1a: GFP+ acinar cells but week or not 
expressed in nkx2.2: GFP+ pancreatic duct cells.  
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 Figure 5-11. Block insulin signaling in acinar cells does not convert acinar cell into β 
cells. (A) Confocal image of 4 dpf Tg(ela3l:cre) Tg(hs:loxp-mcherry-loxp-dnIRS2-GFP) 
embryos stained with GFP(green) and Insulin(red). (B) Confocal image of 4 dpf 
Tg(ela3l:cre) Tg(hs:loxp-mcherry-loxp-dnIRS2-GFP)Tg(ins:Flag-NTR) embryos with 
MTZ treatment from 2 dpf to 3 dpf to ablate β cells stained with GFP(green) and 
Insulin(red). It is noted that no dnIRS2-GFP+ Insulin+ cells were detected in A or B.  
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 Figure 5-12. Secondary islets in extra-pancreatic segments exhibit normal morphology in 
2 month old insaMO injected fish. (A) Confocal plane of 2 month old insaMO injected 
Tg(ela3l:GFP) stained for Insulin(Red). Arrow head indicate the location of principal 
islet and arrows indicate the “naked” secondary islet. (B) Confocal projection of 2 month 
old insaMO injected Tg(ela3l:GFP) stained for Insulin(red) and Glucagon(white). (C) 
Confocal plane of secondary islet located in Tg(ela3l:GFP) extra-pancreas segments 
stained for Insulin(red) and Glucagon(white). It is noted that there is normal glucagon 
expression in these islets.  
 
 
 
 
 
 
 
 
 
 
175 
 
CHAPTER SIX: Summary and future directions 
 
VI.A. Summary and Implications 
Although the roles of pancreatic hormones in regulating metabolic homeostasis are 
well understood, the influence of pancreatic hormone on pancreatic endocrine cell 
formation during both developmental  and tissue regeneration phases are poorly 
investigated. In this dissertation, I have used various genetic and pharmaceutical 
approaches to identify the novel roles of pancreatic hormones in regulating pancreatic 
endocrine homeostasis. Interestingly, I also showed that the exocrine pancreas component 
is strongly influenced by insulin signaling during development. In particular, we have 
shown for the first time that the balance between insulin and glucagon signaling is 
required to maintain endocrine cell fate stability and pancreatic progenitor self-renewal 
and differentiation. Therefore, fully understanding the roles of pancreatic hormones in 
regulating the development and differentiation of the pancreas not only will shine light on 
understanding the integrative roles of pancreatic cells types in the development process 
but also brings insight into the pathology of diseases like Diabetes. Moreover, 
understanding the roles of pancreatic hormones in pancreatic endocrine homeostasis will 
lead to the development of new therapeutic targets to promote regeneration of new β 
cells, which will ultimately bring hope to the cure of Diabetes. 
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 Figure 6-1. Summary for the role of pancreatic hormones in regulating pancreas 
development and β cell neogenesis. Following β cell ablation, new β cells can be derived 
from either α cell transdifferentiation or ventral pancreatic progenitor differentiation. 
Increased Glucagon/GLP-1 signaling can directly or indirectly stimulate liver 
gluconeogenesis to promote β cell regeneration from these two cellular sources. On the 
other hand, Insulin signal secreted from β cells can feed inhibit ventral pancreatic 
progenitor different into β cells via manipulating two key transcription factors Pdx1 and 
Ptf1a. Moreover, insulin signal is require for acinar cell development and maintain acinar 
cell fate stability.  
 
Embryonic pancreas development   
In the past several decades, the innate genetic control of critical steps for pancreas 
development have been well clarified; however, the extracellular signals required for 
regulating the pancreas development process is less clear. Earlier studies have shown that 
signals secreted from the nearby mesoderm like notochord or dorsal aorta plays critical 
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roles in pancreatic progenitor domain initiation (92,93). The mass of this progenitor pool 
was shown by previous studies to determine the whole pancreatic organ size (115). 
However, the regulation of pancreatic progenitor self-renewal and differentiation is 
unclear. Moreover, through the development process, the pancreatic progenitor pool will 
ultimately differentiate into different endocrine and exocrine cell lineages. Although a 
variety of growth factors and cytokines secreted from surrounding mesenchyme and 
pancreatic ductal epithelium have been proposed to play roles in regulating pancreatic 
progenitor differentiation (94,98,99,406,407), it is wholly unknown how the organism 
achieves the balance between endocrine and exocrine ratio as well as cell quantity control 
for different endocrine cell types through the development process. In this dissertation, 
through investigating the complicated roles of insulin and glucagon genes in pancreas 
endocrine and exocrine formation, I have revealed a feedback regulatory system that 
functions during pancreas development at different levels: from islet cells to pancreatic 
progenitors; from pancreatic endocrine cells to exocrine cells; interaction between α cells 
and β cells. Moreover, the pancreatic hormones can influence the pancreas development 
process via integrating the metabolic cues such as glucose regulation. The stem cell 
transplantation I have developed here can contribute to the understanding of circulating 
factors derived from of pancreatic hormones’ effects during embryonic development. 
Moreover, understanding the extracellular signaling control of pancreas development 
regulating pancreatic progenitor differentiation and cell fate specification can help 
determine the targets which can stimulate in vitro β cell differentiation from stem cells or 
neogenesis from adult pancreatic progenitor cells.  
It is well appreciated that gestational diabetes is strongly associated with the 
development of diabetes in offspring in later life (408,409). Interestingly, another set of 
studies have shown that maternal starvation during pregnancy is also strongly associated 
with the development of diabetes in offspring in later lifer (410-412). During 
development, the embryo exchanges nutrients with the mother and embryonic pancreas 
hormone secretion is tightly associated with the environmental nutrient (413,414). The 
conclusions from this dissertation indicate that inappropriate pancreatic hormone 
secretion resulting from the abnormal nutrient state will alter the embryonic pancreas 
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development program, which could ultimately contribute development of diabetes later in 
life. Future studies using mammalian models are required for testing such hypothesis.  
 
β Cell regeneration for Diabetes treatment 
From the systemic view, there are two driving forces to create the need for β cell 
formation: impaired β cell mass and insufficient β cell function. The latter can be mainly 
characterized by insufficient insulin signaling.  Considering the cellular origins, β cells 
can regenerate from self-replication and neogenesis from non-β cells. Although the 
mechanisms involved in the regulation of β cell self-replication induced regeneration is 
highly investigated (22,162,200,290,415), the cell signaling that regulates β cell 
regeneration from neogenesis is relatively unknown. In this dissertation, I have 
investigated the process of β cell neogenesis following β cell injury and insulin signaling 
blockage. Specifically, I have revealed in zebrafish models that β cells mainly regenerate 
from two cellular sources: pancreatic progenitor differentiation and α cell 
transdifferentiation.  Importantly, I have found that the insulin and glucagon hormones 
play critical roles in controlling β cell regeneration from both cellular sources. 
Interestingly, similar to metabolic regulation, insulin and glucagon hormones also appear 
to play counter-balancing roles in directing β cell formation and endocrine cell fate 
specification. Revealed by this dissertation, glucagon signaling can promote β cell 
formation via increasing progenitor cell differentiation and destabilizing α cell fates to 
induce α to β cell transdifferentiation. On the other hand, insulin signaling can inhibit the 
early differentiation of pancreatic progenitors and stabilize α cell fate. This indicates that 
under normal conditions, an imbalanced glucagon and insulin ratio can be corrected by 
the feedback mechanisms via adjusting α and β cell ratios.  
Therefore, it will be interesting to understand whether these feedback correction 
mechanisms are impaired under pathological conditions like diabetes. Moreover, further 
understanding the downstream effectors which control the pancreatic hormonal feedback 
mechanisms will help with the design of novel drug targets for promoting in vivo β cell 
regeneration from either α cell transdifferentiation or pancreatic progenitor cell 
differentiation. Furthermore, understanding the effects of pancreatic hormone in β cell 
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formation will also contribute to the design of a rationale protocol to achieve a higher 
yield for in vitro differentiation from stem cells toward β cells within shorter time. 
However, compared with in vitro β cell regeneration approaches, in situ regeneration of β 
cells from endogenous sources would circumvent many of the obstacles encountered by 
surgical restoration of β cell mass via transplantation.  The studies presented here have 
defined tunable endogenous cellular sources for β cell regenerating which can be 
regulated by physiological hormones. Therefore, it provides valuable directions for future 
studies in the field of in vivo β cell regeneration based diabetes therapeutic design.  
 
Exocrine pancreas insufficiency and mutagenesis 
 As an integrated organ, the endocrine and exocrine pancreas serves different but 
highly connected functions to achieve the homeostasis for metabolism. Although it has 
long been appreciated that the function of the exocrine pancreas is highly influenced by 
hormones secreted from islet cells (137), it is not known whether this islet-exocrine axis 
exists during embryonic development. The studies in this dissertation have revealed the 
unique developmental roles of insulin signaling in regulating the differentiation and 
maturation of exocrine acinar cells. Moreover, we also found that insulin signaling plays 
important roles in stabilizing acinar cell fate. These findings contribute to the 
understanding of research areas, such as diabetes associated exocrine pancreatic disease. 
For example, it is well known that early on-set T1DM often results in exocrine pancreatic 
insufficiency (373,416,417). Meanwhile T2DM is found to be strongly associated with 
pancreatic cancer (399). Although the mechanisms underlying pancreatic cancer are not 
completely understood, more and more evidence indicates that acinar to duct metaplasia 
is highly involved in the early pancreatic cancer progression (396,397). Therefore, it will 
be interesting to test whether the “insulin resistant” stage in acinar cells will induce the 
acinar cell fate changes, which will ultimately promote the cancer development process 
in T2DM and reveal novel drug targets for pancreatic cancer treatments.  
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VI.B. Future Directions 
The mechanisms of pancreatic hormone regulated pancreas development 
 I have demonstrated in this dissertation that insulin and glucagon signaling will 
influence the cell fate decisions during early pancreatic progenitor differentiation. This 
feedback regulation mechanism is critical to regulate α and β cell number during 
development. Although glucagon increased progenitor cell differentiation may be 
indirectly mediated via glucose, the insulin signaling appears to directly act on early 
pancreatic progenitors. Therefore, it is necessary to further dissect the complicated 
interactions between glucagon, glucose and insulin in regulating pancreatic progenitor 
differentiation.  
(1) Examine the genetic profile during the differentiation process from pancreatic 
progenitor into α and β cell linages. We will first use transgenic zebrafish embryos 
Tg(gcga:GFP); Tg(ins:dsRed); Tg(sst2:mKate2); Tg(neurod:BFP) and perform cell 
sorting  to isolate neurod:BFP+ (undifferentiated endocrine progenitor cells), 
neurod:BFP+ins:dsRed+ (β cells), neurod:BFP+ gcga:GFP+ (α cells) and 
neurod:BFP+sst2:mKate2+(δ cells). Genetic sequencing will then be performed on these 
cell populations. These data will be further used to specifically analyze the signals 
associated with the glucagon, insulin and glucose metabolism pathways. The signaling 
pathway activation can then be analyzed together with the innate genetic transcription 
factors to give the link between the signal and gene transcription. This approach can also 
be used to define signal targets involved in progenitor differentiation and those that 
discern the various endocrine cell lineages.  
(2) In vitro cell culture system to analyze the downstream signaling involved in 
pancreatic hormone regulated pancreas progenitor differentiation. Primary zebrafish 
endocrine progenitor cells can be obtained by cell sorting (as indicated above) and then 
cultured in vitro. Following treatment with glucagon/insulin/glucose signaling activators 
and inhibitors, real-time RT-PCR can be used to analyze the transcription factors 
involved in downstream cell signaling and cell fate determination. For example, from the 
studies in this thesis, insulin signaling can regulate pancreatic progenitor differentiation 
via manipulating the expression of two key transcription factors pdx1 and ptf1a. 
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Furthermore, the differentiation of progenitor cell is highly depended on Notch signaling 
pathways. Using this approach, we can identify tested the following hypothesis that 
insulin regulates the expression of pdx1 and ptf1a via manipulate downstream Notch 
target genes such as hes1. Similarly, we can test how pancreatic hormones influence the 
expression of key transcriptions factors involved in α and β cell fate determination such 
as arx and mafa. Besides zebrafish primary endocrine cell culture, the mammalian 
endoderm progenitors, which can be differentiated from embryonic stem cells, can also 
be used to further verify the signals in mammalian systems. 
In addition to analyzing the target genes, we can also use the large chemical screening 
approach to identify the chemical compounds which can stimulate progenitor 
differentiation. The undifferentiated pancreatic progenitor cells (neurod:BFP+, ins:dsRed-
; gcga:GFP-; sst2:mKate2-) can be isolated from Tg(gcga:GFP); Tg(ins:dsRed); 
Tg(sst2:mKate2); Tg(neurod:BFP) as indicated above. If these progenitor cells 
differentiate into β cells, it will turn on the insulin promoter and start to express red 
fluorescent protein. If α cell fate is activated under certain stimulations, the glucagon 
promoter will be turned on and these cells will express green fluoresent protein. This 
system can then be used to screen chemical compounds from a compound library which 
contains the chemicals involved in pancreatic hormones and cell metabolism pathways. 
Using this high-throughput screening can help identify novel targets to stimulate 
pancreatic progenitor differentiation.  
(3) In vivo genetic approach to analyze the effects of glucagon/glucose/insulin on 
pancreatic progenitor differentiation. In addition to providing valuable insight into the 
control of pancreas development and regeneration, my dissertation research has generated 
multiple genetic tools which can be used to further investigate downstream signaling 
pathways involved in pancreatic hormone regulated cell differentiation in vivo. For 
example, we can use this approach to selectively activate the glucagon downstream 
signaling in progenitors to investigate the direct effects of glucagon stimulation on 
pancreatic progenitors. One signaling pathway involved in glucagon regulation is via 
stimulation of cAMP dependent-protein kinase A (PKA) (118). Binding of cAMP by the 
regulatory subunits of PKA results in their dissociation from the catalytic subunits and 
activation of the enzyme (418). Previous studies have shown that constitutive activation 
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of PKA can be achieved via overexpression of catalytic subunit of PKA (419,420). 
Therefore, we can investigate whether over expression constitutive activated PKA 
(aPKA) in endocrine progenitor can mimic glucagon effect and drive progenitor 
differentiation into β cells. For doing this, we can create the following transgenic fish 
Tg(sox17: loxp-mcherry-loxp-aPKA); Tg(neurod1:cre). The caveat here is that neurod is 
not only expressed in pancreatic endocrine progenitors, but is also found in differentiated 
pancreatic endocrine cells as well as enteroendocrine cells. However, the genetic 
sequencing experiments proposed above may provide new targets to define the zebrafish 
pancreas endocrine progenitor specific genes. Besides the traditional transgenic approach, 
the current advance in Cas9-mediated genomic editing also makes it possible to create 
tissue specific knockout in zebrafish in a short time period and this knockout approach 
can also be used to verify the results obtained from the in vitro findings (421).  
(4) Exploring pancreatic hormone-mediated progenitor cell differentiation using a cell 
transplantation system. In this dissertation, I have developed a novel model in which 
blastula stem cells are transplanted into zebrafish host larvae in order to investigate the 
effects of insulin signaling on pancreas progenitor differentiation. Using this approach, 
we have shown that there are complicated interactions between transplanted stem cells 
and the host system. The relatively easy genetic manipulation in zebrafish donor and host 
embryos and the transparency of zebrafish makes it a powerful model to further explore 
the stem cell-host interactions. For example, increased glucagon signaling in the host 
larvae following β cell ablation may be a cue to influence transplanted stem cell 
differentiation. To test this hypothesis, future studies may include transplantation of 
dnIRS2-overexpression blastula stem cells into β cell ablated larvae in the background of 
gcgaMO or gcgr/glp1r mutants. Furthermore, our findings provide evidence that 
transplanted “insulin resistant” blastula stem cells can secrete certain factors that 
facilitate host β cell regeneration. In the future, we will isolate the differentiated blastula 
stem cell after transplantation into the host and perform a large scale genetic sequencing 
study to determine potential targets that stimulate β cell regeneration.  
(5) Exploring the mechanisms by which pancreatic hormones maintain acinar cell 
fate. In this dissertation, I showed that inhibition of insulin signaling in acinar cells can 
activate Pdx1 expression. The next question is whether these Pdx1+ acinar cells can be 
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further directed and differentiated into β cells. Previous studies show the potential of 
acinar cell transdifferentiation via repressing ptf1a or virus induced transfection of three 
key β cell transcription factor: Pdx1, Mafa and Ngn3. The expression of Ngn3 can be 
activated in partial duct ligation mouse models, which is proposed to be induced by 
immune factors. Thus, the following hypothesis that can be tested in the future is the 
following: reprograming of acinar cells can be achieved via combing insulin signaling 
suppression and immune factors stimulation. It will be also interesting to understand how 
inhibition of insulin signaling alleviates the suppression mechanism of Pdx1 in acinar 
cells. Although it is proposed that in differentiated β cells, insulin activates Pdx1 
expression via repressing Foxo activity, our studies indicate that in certain cell types, 
such as endoderm progenitor cell and acinar cells, insulin signaling can suppress Pdx1 
expression, indicating that a link other than Foxo may exist between insulin and Pdx1. 
Finding such a link will increase our understanding of the complex role that insulin plays 
in regulating pancreas development and cell fates. Besides acinar to β cell transformation, 
another attractive direction of investigation is to pursue the possibility that insulin 
signaling promotes pancreatic cancer metastasis. To test that idea, we can create a 
pancreatic cancer model by over-express the oncogene, k-ras, in acinar cells using the 
elastase promoter and examine how an insulin resistant state influences cancer progress.  
 
The mechanism by which pancreatic hormones regulate α cell fate and stability  
In this dissertation, I have shown that pancreatic hormones like insulin and glucagon 
not only play important roles in regulating pancreatic progenitor differentiation, but also 
govern α cell fate and stability. More importantly, we have shown that α cells can serve 
as a new cellular source to regenerate new β cells following extreme β cell loss. 
Therefore, further understanding the mechanism underlying these findings may unlock 
new doors for β cell regeneration in diabetes therapies.  
(1) Examine the adaption of α cells in response to β cell injury. Previous studies and 
the results in this dissertation indicate that α cells sense the injury of β cells, and facilitate 
β cell regeneration. The response of α cells to β cell injury includes increased glucagon 
gene activity and transdifferentiated into β cells. However, it is still unclear how α cells 
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sense the injury or loss of β cells. The following possibilities exist: direct cell-cell 
interaction, β cells release certain signals upon injury, imbalance of glucagon and insulin 
hormone ratio, indirect effects via altered metabolism upon lacking of insulin.  Because 
the zebrafish pancreas resides in the endoderm region, it is challenging to perform in vivo 
imaging tracing to determine the dynamic interaction between α and β cells under 
physiology condition as well as under β cell injury. Therefore, we can use in vitro 
endoderm culture to exploring this possibility. Using this approach, we can capture the 
complete process involved in α to β cell transdifferntiation. Furthermore, we can combine 
genetic modification and pharmaceutical treatments to determine how cell-cell 
connections and extracellular signals influence α cell response toward β cell injury. For 
example, the new regenerated pancreatic endocrine cells can form the long cellular 
membrane protrusions to connect with the existing islet cells (Chapter Three).  Recent 
studies have shown that cellular  protrusions not only help cell migration but also also 
involved in long-distance cell signal transduction (422,423). Therefore, it will be highly 
interesting to test whether α and β cells can communicate via dynamic cellular 
protrusions or whether this behaviors is required for islet regeneration. The in vivo time 
laps system developed here will thus be highly valuable. Besides the in vitro endoderm 
culture, the current advance of the light-sheet fluorescence microscopy may also make it 
possible to trace the behaviors of α cells in response to injury in in vivo zebrafish models 
(424).  
(2) Examine the genetic profile during α to β cell transdifferentiation. In order to 
further explore the signaling pathways that directs α to β cell transdifferentiation, large 
scale sequencing can be performed using the sorted α and β cells in the non-regeneration 
or regeneration groups using Tg(gcga:GFP); Tg(ins:dsRed) transgenic fish lines. An 
alternative approach is to sort the gcga:GFP+ins:dsRed+ cells in the regenerating islet, as 
these cells may represent the transdifferentiating stage of α/β cells. We will then compare 
the phenotype of these transdifferentiating cells with the gcga:GFP+ (α) cells and 
ins:dsRed+ (β) cells. Using this approach, we can define new genetic targets that are 
activated during the transdifferentiation process.  
(3) Understanding the mechanisms by which pancreatic hormones maintain α cell 
stability in mammalian systems. In order to verify whether, in mammalian systems, 
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pancreatic hormones play similar roles in governing α cell fate, the mammalian α cell line 
(αTC) together with pharmaceutical approaches using glucagon and insulin signaling 
activator/inhibitors will be performed. Further genetic modification in these cell lines can 
be achieved either via siRNA or CRISPR techniques. Moreover, following these 
experiments, we will move these findings into in vivo rodent models. For example, we 
can test the effects of glucagon signaling on α cell transdifferentiation using the 
Tg(ins:DTR) mice models which can induce extreme β cell ablation in the background of 
Gcgr-/- or GLP-1r-/-. Furthermore, this examination can be performed in human islets to 
test whether the plasticity of α cells is present in humans, and whether glucagon/insulin 
signaling can manipulate this process.   
 (4) Understanding the downstream signaling mechanisms by which pancreatic 
hormones regulate α cell fate.  Our results demonstrate that insulin and glucagon 
signaling play important roles in directing the α to β cell transforming process.  It is 
expected that these signals may act on the innate genetic program to alter the expression 
of key α and β transcription factors. Finding such a link between hormone signaling and 
transcription factor expression may be critical to provide a specific drug to promote α cell 
transdifferentiation into β cells. Previous studies have shown that certain transcription 
factors, including Arx and Pdx1, can push this transformation process.. Therefore, these 
transcription factors may provide initial targets, and the genetic profiling approach 
detailed above will generate new transdifferentiation targets. We can then use an in vivo 
transgenic approach to activate specific signaling pathways in α cells to verify that these 
processes play a role in β cell transdifferentiation. For example, we can over-express 
constitutional activated PKA in α cells using the glucagon promoter to verify whether 
glucagon-induced PKA activation play an essential role in directing the α cell fate switch. 
Furthermore, it is likely that insulin/glucagon hormones regulate α cell fate changes via 
epigenetic machinery. Therefore, it will be interesting to analyze DNA methylation and 
histone modifications in the key transcription factors that are involved in α and β cell 
fates, and examine whether alterations in the epigenetic profile in promote 
transdifferentiation.  
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The disease models to achieve the future research directions 
(1) Exploring the β cell regeneration mechanisms in partial β cell ablating models. 
Previous studies have shown that the mode of β cell regeneration is highly dependent 
upon injury models and the age of organisms. Previous studies in rodents indicate that α 
cell transdifferentiation only occurs following extreme β cell ablation. Nevertheless, it is 
unknown whether in the zebrafish model, transdifferentiation of α cells is also restricted 
to this extreme β cell ablation condition. Thus, it will be interesting to analyze whether α 
cell transdifferentiation can occur under partial β cell ablation. We have determined that 
Tg(gata5:loxp-mcherry-loxp-DTA); Tg(ins:cre) can induce partial β cell ablation. 
Therefore, we will investigate the question above via Tg(gata5:loxp-mcherry-loxp-DTA); 
Tg(ins:creER) tamoxifen inducible β cell specific ablation  system. If future studies 
reveal the restriction of α cell transdifferentiation to extreme β cell ablation condition in 
zebrafish models, it would suggest that β cells are critical for maintaining α cell fate 
stability. Other results in this dissertation indicate that insulin secreted from β cells may 
play such a role. Understanding the interaction between α and β cells in order to maintain 
cell fate maintenance could path the way for a cure to diabetes.  
(2) β cell regeneration under inducible inflammation models. This inflammation 
environment can be created by inducible pancreatic expression of immune factors such as 
IL-1β or IFN-γ. Previous studies also show that immune cells, such as macrophages, may 
act as a double-edged sword in islet reorganizing and β cell regeneration. Thus, it is will 
interesting to determine the specific role of immune cells in regulating the sources of β 
cell. Zebrafish containing hs:loxp-mcherry-loxp-IL-1β/IFN-γ; ins:cre can be designed to 
selectively activate an inflammatory response in a time controlled manner. Further 
studies regarding immune cell infiltration and remodeling in the islet in response to the 
secreted immune factors can be pursued.  
(3) β cell regeneration and compensation in adult zebrafish models. β cell 
regeneration in adult fish has been tested in previous published studies. Future β cell 
regeneration studies in adult fish can be carried on in STZ-induced β cell ablation model 
and MTZ-Tg(ins:CFP-NTR) β cell ablation models. Different from the embryonic fish, 
the adult fish pancreas is composed of secondary islets that arise from the ventral 
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pancreatic endocrine cells. Thus, it will be possible to dissect the potential different roles 
of dorsal and ventral derived α cells in contributing to β cell regeneration. In addition to β 
cell specific ablation, we can also determine whether obesity or genetically induced 
insulin resistance can stimulate β cell compensation in adult fish. Moreover, previous 
studies have shown that the ability of β cells to regenerate decreases with age. Because of 
the fast life cycle of zebrafish, it will be interesting to analyze how aging influences 
pancreatic progenitor self-renewal and β cell regeneration in zebrafish models.  
(4) Studies in mammalian diabetic systems. Although it is more expensive to perform 
experiments using mammalian systems such as rodent models, there are certain questions 
we cannot answer using a zebrafish model. For example, rodent models must be used to 
investigate the effects of insulin and glucagon on embryonic pancreas development 
during maternal gestational diabetes. Furthermore, it is also critical to verify whether the 
findings we observed in zebrafish models are conserved in mammalian systems as well. 
To do this, we can use rodent models that mimic human T1DM or T2DM to analyze the 
effects of pancreatic hormones on β cell development. Verifying such targets in rodent 
model will be a necessary step to move towards the cure for Diabetic patients. Besides 
using in-vivo rodent models, we can also perform in-vitro studies using human islet 
samples to test the roles of pancreatic hormones in islet endocrine cell fate specification. 
Furthermore, recent advances in human-stem cell research of in-vitro β cell 
differentiation also make it feasible to study the effects of the pancreatic hormones in 
regulating pancreatic progentior cell differentiation. All together, through studies using 
differnet model systems, it will bring better understanding for the roles of pancreatic 
hormone signaling pathways in regulating pancreas development and endocrine 
homeostasis, which will provide new therapeutic targets for β cell regeneration in 
Diabetic treatment.  
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APPENDICES 
 
Appendix one: Zebrafish de-novo dnmt3ab is required for pancreas development 
 
 
Figure 1. dnmt3ab knockdown induces small and duplicated pancreas.  
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 Figure 2. knockdown of dnmt3ab expand Pdx1 domain to anterior during development. 
li: liver  
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 Figure 3. Knockdown of dnmt3ab decreases pancreatic endocrine cell number. 
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 Figure 4. Knockdown of dnmt3ab blocks endocrine differentiation from ventral pancreas.  
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 Figure 5.  Treatment of Dnmts inhibitor ADC mimics dnmt3ab morphants phenotype. 
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 Figure 6. knockdown of dnmt3ab increase endoderm expression of retinoic acid effector 
hoxb5b during development.   
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 Figure 7. Model figure for dnmt3ab regulated pancreas development via retinoic acid 
signaling. 
 
 
 
 
 
 
 
 
 
 
 
 
 
195 
 
 Figure 8. Knockdown of dnmt3ab induce formation of duplicated pancreas. 
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 Figure 9. Knockdown of dnmt3ab reduce trypsin expression in pancreas. 
 
 
Figure 10. Knockdown of dnmt3ab induce extra-pancreas bud from Pdx1+ endoderm 
domain 
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 Figure 11. Knockdown of dnmt3ab reduces δ cell number. 
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 Figure 12. Knockdown of dnmt3ab increases Pdx1 expression in ventral endoderm and 
liver domain. 
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 Figure 13. Knockdown of dnmt3ab induces ectopic Pdx1 expression in liver cells. 
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 Figure 14. Reduced pancreatic duct and endocrine progenitor formation from dnmt3ab 
knockdown. 
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 Figure 15. Treatment of Dnmts inhibitor ADC reduces pancreas size 
 
 
Figure 16. Pre-treatment of Dnmts inhibitor ADC impairs β cell regeneration 
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 Figure 17. Knockdown of dnmt3ab altered retinoic signaling effector expression. 
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Appendix two: The role of maintenance dnmt1 is regulating α cell fate stability and 
β cell regeneration 
 
 
Figure1. Expression of Dnmt1 in α and β cells is co-related with endocrine cell 
proliferation.  
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 Figure2. dnmt1 depleting cells differentiated into pancreatic endocrine cells but not 
exocrine cells.  
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 Figure3. α cells increased proliferation but not Dnmt1 expression at 1 dpa β cell 
regenerating phase.  
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 Figure4. Loss of dnmt1 increases α cell transdifferentiate into β cells following β cell 
ablation.  
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 Figure5. Treatment of Dnmt1 inhibitor ADC increases β cell regeneration.  
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 Figure 6. Dnmt1 is not expressed in the dorsal pancreas derived β cells.  
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 Figure 7. Remaining of H2B-RFP+ and H2B-RFP- Pdx1 expression in dnmt1-/- principal 
islet and extra-pancreatic duct. 
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 Figure 8. dnmt1-/- does not influence endocrine cell number during development.  
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Honors and Awards 
2014-2015     T32 Diabetes and Obesity Training Fellowship 
2014               IUPUI Graduate Professional Education Grant 
2014               73th Annual SDB Travel grant 
2013               Aquaneering Arts of Science Photomicrography Contest, Third Prize 
2010-2011      Indian University Graduate Student Fellowship 
2008               Peking University First grade scholarship for excellent medical student 
2007               Peking University Wearnes medical education scholarship 
2006               Peking University General electric medical education scholarship 
2005               Peking University Second grade scholarship for excellent medical student 
 
 
Teaching 
2014 Indiana University School of Medicine, F503 Human  Physiology 
Lecture: “Growth hormone and thyroid hormone” and “The endocrine   
pancreas” 
2014               Indiana University Purdue University Indianapolis, BIOL55900      
                       Endocrinology 
            Lecture: “GI hormone” and “Pancreatic hormone”  
2014               Indiana University Purdue University Indianapolis, BIOL697 Epeigenetics 
 
 
            Lecture: “mammalian DNA methylation” and “DNA demethylation”  
2014-2015     Indianapolis Lighthouse Collage Preparatory Academy Program,  
                      Activity: zebrafish β cell regenerating demonstrating, diabetes lecturer 
2014-2015     Molecular Medicine in Action Program, 
           Lecture: “Using mouse & zebrafish models to find therapies for Diabetes” 
2011-2015     Molecular Medicine in Action Program, Team member 
           Activity: lab tour, experiment demonstration 
2008              Peking University School of Pharmaceutical Science 
           Lab instructor: General Chemistry 
 
 
Service and Professional Memberships 
2015              Science judge for 27th Annual Hoosier Science and Engineering Fair 
2014-2015     Indiana University Gateway Ph.D. Program, student mentor 
2012-2015     member of Society for Development Biology  
2013-2015     member of American Heart Association 
 
 
